

PRESIDENT'S COLUMN

Precision Medicine Is a Strategic Direction of ACCP

ACCP is my professional home, and the Hematology/Oncology PRN members are my professional family. ACCP PRNs are the College's lifeblood, serving as conduits for education, professional development, and collegiality, and represent the single greatest member benefit for many ACCP members. Given the importance and reach of the PRNs, I would like to update PRN members on several exciting ACCP initiatives in support of the College's strategic plan.

The ACCP Board of Regents recently revised and updated the College's strategic plan (https://www.accp.com/docs/about/ACCP_Strategic_Plan.pdf). ACCP's strategic plan is based on its core values and its mission to improve human health by extending the frontiers of clinical pharmacy, with three priorities defined within: to develop, advance, and position clinical pharmacists in practice, research, and education. As part of the strategic planning process, ACCP members were surveyed to identify emerging areas critical to clinical pharmacy. Through this member survey, precision medicine emerged as an important issue for clinical pharmacists.

Precision medicine was incorporated into the College's strategic plan as **Strategic Direction 1.2: Provide opportunities for developing knowledge and skills in precision medicine that advance clinical practice, education, and research.** ACCP is fortunate to count among its members many of the leaders in the science, practice, and implementation of precision medicine. Given that precision medicine is the standard of care in oncology and will soon be the standard of care in many therapeutic areas and that clinical pharmacists are the most qualified health care professionals to implement precision medicine, a need for more trained individuals was determined.

As such, a blue ribbon task force led by Vicki Ellingrod made up of leading pharmacogenomics researchers, practitioners, and educators is providing recommendations on how ACCP can advance knowledge and skill development in precision pharmacotherapy. On the basis of task force recommendations, ACCP members can expect several new training opportunities around precision medicine in the next few years. Clinical pharmacists interested in implementing pharmacogenomics-driven clinical practice may benefit from a clinical traineeship. Traineeships will likely be specialty based and provide both foundational knowledge and practical experience in developing and managing a genomics-based clinical practice.

For clinical pharmacists desiring to enhance their research skills, the FIT and MeRIT programs (<https://www.accpri.org/>) already offered by ACCP are being evaluated as mechanisms for delivering precision medicine training. FIT, which is designed for experienced researchers, is a 5-day in-person program focused on grant proposal development. Investigators with a draft grant proposal spend most of their time in the program revising their proposal to enhance its competitiveness. MeRIT, a 2-year longitudinal program designed for pharmacists with modest research experience, provides a mentored research experience through live programing and webinars that takes a research project from an idea to publication.

Consistent with its strategic plan, ACCP seeks to position clinical pharmacists by communicating their value, with two papers in development. First, led by Kelly Caudle, the PK/PD PRN is writing an opinion paper titled "What Is Precision Pharmacotherapy?" Second, the ACCP Clinical Practice Affairs Committee, led by Kevin Hicks and Kristine Aquilante, has been charged to develop a complementary ACCP white paper that articulates real-world clinical applications of precision medicine (specifically, "precision pharmacotherapy") to today's clinical pharmacist practice.

I thank the members who are taking on these important initiatives and invite all members to contact me at jill.kolesar@uky.edu with additional thoughts, suggestions, or plans for incorporating precision medicine into their research, teaching, and practice. Together, we can learn from ACCP members who are already leading important precision medicine initiatives and position ACCP as the leading organization in supporting precision medicine research and implementation.

PRNS PREPARE FOR ELECTIONS

PRNs Prepare for Elections

Introduction

It is time for the PRNs to determine who will serve as officers in the coming year. If you are interested in being a PRN officer or in nominating someone, please contact your PRN's chair.

Election Process

The Nominations Committee will consist of at least two individuals appointed by each PRN's chair. These individuals may be the PRN's current elected officers. Those who are on a PRN's Nominations Committee will be ineligible to run for office in that PRN's election that year. The Nominations Committee should prepare a slate of candidates and provide each candidate with information related to election procedures. The Nominations Committee should also provide a timeline and list of expected duties.

When possible, two or three candidates for each office shall be up for election. If only one candidate can be identified, an election will still be held, with voters given the option of identifying a write-in candidate. When there are more than three possible candidates, the PRN's Nominations Committee will be responsible for narrowing the slate to three candidates. The Nominations Committee will obtain a brief (250 words) biographical sketch or candidate statement from each candidate.

Voting

As in previous years, PRN elections will be held online, and PRN members will receive an e-mail from ACCP that outlines the voting procedure. Members will use their log-in and password to access the ACCP website. Each member will then be able to access the ballot for each PRN of which he or she is a current member.

As the election nears, members should review their e-mail and the ACCP website for further news about online voting.

2018 ELECTION TIMETABLE

PRN call for nominations	March 2018
Submission of slates and candidate biographies to ACCP	June 7, 2018
Electronic balloting opens	July 9, 2018
Committee contact notified of results	August 13, 2018
Nominations Committee notifies all candidates of election results	August 16, 2018 (within 10 days of the election)
ACCP staff notifies new officers of meeting date and time at the Annual Meeting	September 21, 2018

BOARD PREPARATORY AND RECERTIFICATION PRODUCTS FOR HOME STUDY

New in 2018 – Cardiology and Infectious Diseases Preparatory Courses

ACCP has expanded its Updates in Therapeutics® board certification preparatory review course offerings to include programs for the recently approved Board of Pharmacy Specialties (BPS) Cardiology Pharmacy and Infectious Diseases Pharmacy specialties. BPS plans to offer the initial certification exam for each specialty in the fall of 2018. Please visit the BPS website for additional testing information (www.bpsweb.org).

ACCP's [Cardiology Pharmacy](#) and [Infectious Diseases Pharmacy](#) preparatory review courses are designed for clinical pharmacists preparing for their respective BPS-administered specialty certification examinations. These courses address the knowledge and task statements contained in the BPS-approved outline.

Continued Excellence in Ambulatory Care, Critical Care, Oncology, Pediatrics, and Pharmacotherapy

ACCP continues to provide high-quality Board Preparatory Review and Recertification Products for the following BPS-approved specialties. Please click the links below for complete course information.

[Updates in Therapeutics®: Ambulatory Care Pharmacy Preparatory Review and Recertification Course](#)

[ACCP/SCCM Critical Care Pharmacy Preparatory Review and Recertification Course](#)

[ACCP/ASHP Oncology Pharmacy Preparatory Review and Recertification Course*](#)

[Updates in Therapeutics®: Pediatric Pharmacy Preparatory Review and Recertification Course](#)

[Updates in Therapeutics®: Pharmacotherapy Preparatory Review and Recertification Course](#)

*Live course held May 3–5, 2018, in San Diego, California. Home study products available on July 1.

PRN NEWS BRIEFS

Adult Medicine PRN

Promotions

- **Angela Miller:** Adjunct Assistant Clinical Professor, University of Kansas Department of Pharmacy Practice.

Awards

- **Nicole J. Asal:** 2017 Rhode Island Pharmacists Association Distinguished Young Pharmacist Award.
- **Julie A. Murphy:** 2017 American College of Clinical Pharmacy Education and Training PRN Best Poster Award.
- **Beth H. Resman-Targoff:** 2018 National Rho Chi Honor Society Faculty Advisor Award.
- **Diana Sobieraj:** 2017 American College of Clinical Pharmacy New Investigator Award.
- **Jennifer Twilla:** 2017 American College of Clinical Pharmacy Adult Medicine PRN Clinical Practice Award.

Grants

- **Diana Sobieraj:** Treatment of Depression in Older Adults. Role: Co-PI. Funding agency: AHRQ. Amount: \$380,000.

Publications

- **Anderson SL, Marrs JC.** The role of the pharmacist in heart failure transition of care. *Adv Ther* 2018. [Epub ahead of print]
- **Anderson SL, Marrs JC.** Direct oral anticoagulant (DOAC) use in valvular heart disease. *Clin Med Insights* 2018;10:1-6.
- **Anderson SL, Trujillo JM, Anderson JE, Tanenberg R.** Switching basal insulins – practical recommendations for health care providers. *Postgrad Med* 2017;1-10. [Epub ahead of print]
- **Asal NJ, Poyant J.** Role and impact of student pharmacists and a pharmacist on an international interprofessional medical brigade. *Curr Pharm Teach Learn* 2018. In press.
- **Boylan P, Trinh K, Helms J, Ghoubril-Waibel R, Mege J.** Integration of transitions of care pharmacist services within an accredited pulmonary rehabilitation clinic. *Pharmacotherapy* 2017;37:e214.
- **Boylan PM, Joseph T, Hale GM, Moreau C, Seamon M, Jones R.** Development of chronic obstructive pulmonary disease and heart failure self-management kits for outpatient transitions of care. *Consult Pharm* 2018;33:145-51.
- Luder H, Zavadsky A, Bukowitz A, Baumann A, **Boylan PM, Croley KS, Fu D, Kelling SE, Winder M, Register D.** Transitions of Care Case Examples Resource. Washington, DC: APhA, June 2017. Available at www.pharmacist.com/transitions-care.
- Clark KE, **Briand ME, Kapoor O, Pirasteh A.** Impact of a standardized beta-lactam allergy questionnaire on aztreonam use. *J Pharm Pract* 2018 Jan 1. [Epub ahead of print]
- Sowell AJ, Pherson EC, Almuete VI, Gillespie JV, **Gilmore V, Jensen M, Nehra R, Durand KM, Nesbit TW, Swarthout MD.** Expansion of inpatient clinical pharmacy services through reallocation of pharmacists. *Am J Health Syst Pharm* 2017;74:1806-13.
- **Murphy JA, Schroeder MN, Rarus RE, Yakubu I, McKee SOP, Martin SJ.** Implementation of a cardiac transitions of care pilot program: a prospective

study of inpatient and outpatient clinical pharmacy services for patients with heart failure exacerbation or acute myocardial infarction. *J Pharm Pract* 2018 Jan 1. [Epub ahead of print]

- **Murphy JA, Sheridan EA.** Evidence based review of pharmacotherapy for opioid-induced constipation in noncancer pain. *Ann Pharmacother* 2017. [Epub ahead of print]
- **Owens RE, Twilla JD, Self TH, Alshaya AI, Metra CJ, Cummings C, Oliphant CS.** β -Blockade in heart failure with reduced ejection fraction: does heart rate control influence readmissions? *J Pharm Pract* 2018;31:40-5.
- Roberts MZ, Farley TM, **Owens RE.** Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment: an alternative viewpoint. *Pharmacotherapy* 2017;37:e107-108.
- Shah SP, Self TH, Bradsher RW III, **Owens RE.** Clarithromycin-nifedipine-induced acute kidney injury. *Nurse Pract* 2017;42:49-51.
- Cutshall BT, **Twilla JD, Olinger AS, Oliphant CS.** A review on cardiovascular effects of newer hypoglycaemic medications. *Ann Med* 2017;49:603-12.
- **Wietholter JP, Grey C, Howard C, Johnson BN, Sween R, Rowlands AE.** Interprofessional collaborative practice through an adult medicine based simulation. *J Interprof Educ Pract* 2017;9:21-26.

Other Notable Achievements

- **Andrew Miesner:** Completed the SIDP Antimicrobial Stewardship Certificate Program.
- **Beth H. Resman-Targoff:** Elected to serve on the Association of Rheumatology Health Professionals Membership and Nominations Committee.

Ambulatory Care PRN

Promotions

- **Kajua Lor:** Chair of the Clinical Sciences Department.

Awards

- Daniel Wilk, Paul Bexk, **Julie Bartell:** 2017 Concordia Medication Management Accelerator Award for "Primary Care Initiative (PCI) – Collaborative Chronic Disease Management with Pharmacist-Led Visits."
- **Gregory Castelli:** George P. Heffner Award, Diabetes Camp of West Virginia, Inc.

- **Kelly Cochran:** University of Missouri-Kansas City School of Pharmacy Preceptor of the Year Award; Quality Improvement Champion, Department of Medicine, University of Missouri-Columbia School of Medicine.
- **Ruth Dapaah-Afriyie:** Best Practices Award 2017, ASHP.
- **Lucas Hill:** UTCOP Alumni Centennial Endowed Fellowship Preceptor Award.
- **Eric J. Ip:** Awarded one of Medscape's Rising Stars of Healthcare Research.
- **Kajua Lor:** 2016–2017 Outstanding Medical Student Teacher Award.
- **Maria Miller Thurston:** 2017 American College of Clinical Pharmacy New Educator Award.
- **Cheng Yuet:** New Faculty Scholar Award, Society of Teachers of Family Medicine.

Grants

- **Lucas Hill:** SAMHSA/TX HHSC – Operation Naloxone (\$2.2 million); (Co-I): SAMHSA/TX HHSC – Prescription Monitoring Program (\$642,000).
- **Kajua Lor:** Robert Wood Johnson Foundation Clinical Scholar 2017–2020.
- **Michelle T. Martin:** Martin MT, Koren D, Teply R, Zuckerman A. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model.

- **Paul Stranges:**

Cost-Effectiveness Analysis of Injectable Extended Release Naltrexone versus Buprenorphine/Naloxone for Treatment of Opioid Dependence in the United States: A Primary Care Perspective: American College of Clinical Pharmacy Ambulatory Care Seed Grant. Role: PI.

Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations (PREPARE). Patient-Centered Outcomes Research Institute (PCORI). Grant IP#00026071. Role: Site-PI.

Publications

- **Bucheit JD, Helsing H, Nadpara P, Virani SS, Dixon DL.** Clinical pharmacist understanding of the 2013 ACC/AHA cholesterol guideline. *J Clin Lipidol* 2017. [Epub ahead of print]
- **Bzowycykj AS, Dow A, Knab MS.** Evaluating the impact of educational interventions on patients and communities. *Acad Med* 2017;92:1531-5.

- **Bzowycyj AS, Stahnke AM.** Hypersensitivity reactions to human insulin analogs (HIAs) in insulin-naïve patients: a systematic review. *Ther Adv Endocrinol Metab* 2018;9:53-65.
- **Castelli G, Flaherty A, Jarrett JB.** PURLs: does azithromycin have a role in cesarean sections? *J Fam Pract* 2017;66:762-4.
- **Castelli G, Jarrett JB.** PURLs: when to “CAP” off treatment for pneumonia. *J Fam Pract* 2017;66:629-31.
- **Badowski M, Walker S, Bacchus S, Bartlett S, Chan J, Cochran KA, Coon S, Liedtke M, Phillips B, White T.** Meeting practice standards in comprehensive medication management (CMM) in telehealth. *Pharmacotherapy* 2018;38:e7-e16.
- **Lefebvre A, Zullo A, Dapaah-Afriyie R, Collins C, Elsaid K.** Outcomes of a pharmacist-managed clinic for underserved persons with unmanaged type 2 diabetes mellitus. *J Pharm Pract Res* 2018;48:65-71.
- **McAuliffe [Hunt] L, Zullo AR, Dapaah-Afriyie R, Berard-Collins C.** Development and validation of a transitions-of-care pharmacist tool to predict potentially avoidable 30-day readmissions. *AJHP* 2018;75:111-9.
- **Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Erdle CO, Abouzaki NA, Dixon D, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A.** Interleukin-1 blockade in recently decompensated systolic heart failure: results from the REcently Decompensated Heart failure Anakinra Response Trial (REDHART). *Circ Heart Fail* 2017;10:e004373.
- **Dixon DL.** The PREDIMED study: should the Mediterranean diet be recommended to prevent cardiovascular disease? *Lipid Spin* 2017;15:20-1.
- **Dixon DL, Salgado T, Abbate A.** Pharmacists as integral members of the cardiovascular team. *JAMA Cardiol* 2017;2:1279-80.
- **Dixon DL, Sisson EM, Parod ED, Van Tassell BW, Nadpara PA, Carl D, Dow A.** Pharmacist-physician collaborative care model and time to goal blood pressure in the uninsured population. *J Clin Hypertens* 2018;20:88-95.
- **Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW.** Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. *Diabetes Obes Metab* 2018 Feb 9. [Epub ahead of print]
- **Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW.** Comment on Buckley et al. Intensive versus standard blood pressure control in SPRINT-eligible participants of the ACCORD-BP trial. *Diabetes Care* 2018. In press.
- **Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW.** Intensive versus standard blood pressure control in SPRINT-eligible participants of the ACCORD BP trial. *Diabetes Care* 2017;40:1733-8.
- **Carbone S, Dixon DL, Abbate A.** Treatment of hypertension to prevent and treat heart failure in diabetic patients should include sodium glucose co-transporter 2 inhibitors. *JACC Heart Fail* 2018;6:85.
- **Hylton-Gravatt L, Flurie R, Lathjia E, Dixon DL.** Clinical guidance for managing statin and antimicrobial drug-drug interactions. *Curr Atheroscler Rep* 2017;19:46.
- **Littauer SL, Dixon DL, Mishra VK, Sisson EM, Salgado TM.** Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. *Pharm Pract* 2017;15:1134.
- **Zimmerman K, Salgado T, Dixon DL.** Medication review vs medication reconciliation. *JAMA* 2017;318:965-6.
- **Zimmerman KM, Salgado TM, Goode JV, Sisson EM, Dixon DL.** A prescription for prescribing: ensuring continued pharmacist preparedness. *Ann Pharmacother* 2018 Mar 1. [Epub ahead of print]
- **Hill LG.** Opioid harm reduction. The Prescription Drug Abuse Epidemic: Incidence, Treatment, Prevention, and Policy. Santa Barbara, CA: ABC-CLIO. In press.
- **Han JK, Hill LG, Koenig ME, Das N.** Naloxone counseling for harm reduction and patient engagement. *Fam Med* 2017;49:730-3.
- **Jordan RP, Bratberg J, Congdon HB, Cross LB, Hill LG, et al.** The report of the 2016-2017 advocacy standing committee. *Am J Pharm Educ* 2017;81:S10.
- **Ip EJ, Patel PB, Chi JJ, Shah-Manek B, Lau B.** What are pharmacists recommending for infant teething treatment? *J Am Pharm Assoc* (2003). 2018;58:79-83.e1.
- **Bergeron N, Al-Saiegh S, Ip EJ.** Do California pharmacy and medical students practice what they preach? An analysis of dietary and lifestyle practices. *Am J Pharm Educ* 2017;81:56.

- Ignoffo R, Chan L, Knapp K, Chan E, **Ip E**, Bandy J, Besinque K, Colbert J, Duby JJ, Galanto JS, Gloudeman M, Havard P, Lackey G, Lozano E, Scott J, Stewart TL. Efficient and effective precepting of pharmacy students in acute and ambulatory care rotations: a Delphi expert panel study. *Am J Health Syst Pharm* 2017;74:1570-8.
- **Kelly K**. On the Cutting Edge: The Gut Microbiome and Diabetes. 2018;38:4-34.
- **Leung AK**, Buckley K, Kurtz J. Sustainability of clinical benefits gained during a multidisciplinary diabetes shared medical appointment after patients return to usual care. *Clin Diabetes* 2018.
- **Martin MT**, Chen Y, Rosenfeld D, Lee TA, Koppe S. Evaluation of a diverse patient population's sustained virologic response rates after hepatitis C virus treatment at an urban academic medical center with an interdisciplinary team including a clinical pharmacist. Meeting Abstract 1550. *Hepatology* 2017;66:828A.
- **Martin MT**, Deming P. Closing the gap: the challenges of treating genotype 3 hepatitis C virus. *Pharmacotherapy* 2017;37:735-47.
- **Martin MT**, Koppe S. Elbasvir/grazoprevir use in post-liver transplantation patients on hemodialysis. *Transplantation* 2017;101:2088-91.
- **Martin MT**, Rosenfeld D, Lee TA. Comparison of sustained virologic response rates after hepatitis C virus treatment in patients with advanced fibrosis or cirrhosis at an urban academic medical center. Meeting Abstract 215. *Pharmacotherapy* 2017;37:E184-E185.
- Isho NY, Kachlic M, Marcelo J, **Martin MT**. Pharmacist-initiated hepatitis C virus screening in an outpatient pharmacy to increase awareness and link to care at the medical center. *J Am Pharm Assoc* 2017;57:S259-S264.
- Molino S, **Martin MT**. Hepatitis C virus resistance testing in genotype 1: the changing role in clinical utility. *Ann Pharmacother* 2017;51:811-6.
- Sapir T, Brau N, Mera J, Martinez AD, Litwin AH, **Martin MT**, Pardo CO, Simone L, Moreo K. Healthcare provider and payer perceptions of optimism, challenges, and strategies for achieving national goals for hepatitis C virus elimination. Meeting Abstract 590. *Hepatology* 2017;66:322A.
- Andrus MR, McDonough S, Kelley KW, Stamm PL, **McCoy EK**, Lisenby KM, Whitley HP, Slater N, Carroll DG, Hester EK, Helmer AM, Jackson CW, Byrd DC. Development and validation of a rubric to evaluate diabetes SOAP note writing in APPE. *Am J Pharm Ed* 2018 January. Available online ahead of print.
- Carroll DG, Bellone JS, Gaillard PR, Makki G, **McCoy EK**. Student perceptions and comfort with content in a women's health elective utilizing team based learning vs lecture delivery. *Pharm Educ* 2018;18:54-60.
- **McFarland MS**, Lamb K, Hughes J, Thomas A, et al. Perceptions of integration of the clinical pharmacist into the PCMH model by the PCMH team. *J Healthc Qual* 2017 Dec 22. [Epub ahead of print]
- Sisson EM, **Pamulapati L**, **Buchheit JD**, **Kelly M**, **Dixon DL**. The evolving role of non-statin therapy for the management of dyslipidemia and cardiovascular risk reduction: past, present, and future. *Pharmacotherapy* 2018;38:164-71.
- **Singh-Franco D**, Hale GM, Jacobs RJ. Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. *Hosp Pract* 2018;46:22-9.
- **Stranges PM**, Vouri SM. Impact of co-investigators on pharmacy resident research publication. *Pharm Pract* 2017;15:928.
- Kebodeaux CD, Peters GL, **Stranges PM**, Woodyard JL, Vouri SM. Faculty perception of team-based learning over multiple semesters. *Curr Pharm Teach Learn* 2017;9:1010-5.
- Moyer P, Chu PS, Pounds T, **Thurston MM**. Impact of a pharmacy team-led intervention program on the readmission rate of elderly patients with heart failure. *Am J Health Syst Pharm* 2018;75:183-90.
- **Turco NJ**, Kane-Gill SL, Hernandez I, Oleksiuk LM, D'Amico F, Pickering AJ. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. *Expert Opin Pharmacother* 2018;19:319-25.
- **Yuet WC**, Durman P, Sivoravong J. Diabetes injectables. *Core Content Rev Fam Med* 2017;48:25-8.

New ACCP Fellows

- **Michelle T. Martin**

Other Notable Achievements

- **Eric J. Ip**: Appointed Director of Clinical Therapeutics Curriculum for Stanford School of Medicine MSPA Program.
- **Kim Kelly**: Appointed by the AACE to be the Project Director for its new project "Innovating Decisions and Empowering Action."

- **Michelle T. Martin:** Editorial Board for the *Journal of the American College of Clinical Pharmacy (JACCP)*.

Poster Presentations

- Hale GM, **Singh-Franco D**, Joseph T, Hardigan P. An evaluation of practitioners' preference of stroke risk in nonvalvular atrial fibrillation: CHA₂DS₂VASc versus CHADS₂. American College of Cardiology 67th Annual Scientific Meeting; March 10, 2018; Orlando, FL.

New Certifications

- **Taryn Mondiello:** BCACP.
- **Seana Rozo:** BCACP.

Cardiology PRN

Promotions

- **Abir Kanaan:** Assistant Dean of Curriculum and New Programs.
- **Karen McConnell:** System Director of Clinical Pharmacy Service, Catholic Health Initiatives.
- **Nicholas Schwier:** PGY2 Cardiology Pharmacy Residency Program Director.

Awards

- Daniel Wilk, Paul Bexk, **Julie Bartell:** 2017 Concordia Medication Management Accelerator Award for "Primary Care Initiative (PCI) – Collaborative Chronic Disease Management with Pharmacist-Led Visits."
- **Shannon Finks:** Dr. Shannon Finks, Pharm.D., FCCP, BCPS-AQ Cardiology, ASH-CHC was awarded the 2017- 2018 SGAEC Excellence in Teaching Award for the University of Tennessee College of Pharmacy.
- **Abir Kanaan:** Academic of the Year, Department of Pharmacy Practice, School of Pharmacy – Worcester/Manchester, MCPHS University; Faculty Scholarship Award in Integration, MCPHS University.
- **Joel Marrs:** ASHP Section of Clinical Specialists and Scientists (SCCS) Distinguished Service Award, December 2017; American College of Clinical Pharmacy Adult Medicine PRN Mentor Award, October 2017.
- **Nicholas Schwier:** Honorary member of Phi Lambda Sigma (Pharmacy Leadership Fraternity).

- **James E. Tisdale:** 2017 American College of Clinical Pharmacy Russell R. Miller Award.

Grants

- **William L. Baker:** Treatment of Depression for Older Adults. AHRQ grant. Amount: \$380,000. Role: Co-PI.

Publications

- Tran RH, **Aldemerdash A**, Chang P, Sueta CA, Kaufman B, Asafu-Adjei J, **Vardeny O**, Daubert E, Alburikan KA, Kucharska-Newton AM, Stearns SC, **Rodgers JE**. Guideline-directed medical therapy and survival following hospitalization in patients with heart failure. *Pharmacotherapy* 2018 Feb 9. [Epub ahead of print]
- **Allender JE, Reed BN, Foster JL, Moretz JD, Oliphant CS, Jennings DL, DiDomenico RJ, Coons JC**. Pharmacologic considerations in the management of patients receiving left ventricular percutaneous mechanical circulatory support. *Pharmacotherapy* 2017;37:1272-83.
- **Baker WL**. NSAIDs and cardiovascular toxicity. In: McQueen CA, *Comprehensive Toxicology*, 3rd ed. Volume 13. Oxford: Elsevier, 2018:341-55.
- **Baker WL, DiDomenico RJ, Haines ST**. Improving peer review: what authors can do. *Am J Health Syst Pharm* 2017;74:2076-9. Invited review.
- Chou R, **Baker WL**, Banez L, Iyer S, Myers ER, Newberry S, Pincock L, Robinson KA, Sardenga L, Sathe N, Springs S, Wilt TJ. Agency for Healthcare Research and Quality evidence-based practice center methods for prioritization and selection of harms for inclusion in systematic reviews. *J Clin Epidemiol* 2018 Feb 2. [Epub ahead of print]
- Coleman CI, Turpie AGG, Bunz TJ, **Baker WL**, Beyer-Westendorf J. Effectiveness and safety of rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. *Thromb Res* 2018;163:132-7.
- Korol S, Mottet F, Perreault S, **Baker WL**, White M, de Denuis S. A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis. *Medicine* 2017;96:e8719.
- White CM, **Baker WL**. Cardiovascular medications and exercise. In: Thompson P, ed. *Exercise and Sports Cardiology*, 3rd ed. New York: McGraw-Hill, 2018.

- **Beavers CJ.** Transitions of care in ACS and HF. In: Dong BJ, Elliott DP, eds. Ambulatory Care Self-Assessment Program, 2018 Book 1. Cardiologic Care. Lenexa, KS: American College of Clinical Pharmacy, 2017:73-92.
- **Beavers CJ.** Editor for Cardiovascular drugs. In: Kolesar JM, Vermeulen LC. 2018/2019 Top 300 Pharmacy Drug Cards. New York: McGraw-Hill, 2017.
- Kelly MS, **Beavers CJ**, Bucheit JD, Sisson EM, Dixon DL. Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-44mg/dL). *J Clin Lipidol* 2017;11:872-9.
- Kuan W, **Beavers CJ**, Guglin M. Still sour about lactic acidosis years later: role of metformin in heart failure. *Heart Fail Rev* 2017 Sep 4.
- Smith KR, Hsu CC, **Berei TJ, Aldemerdash A, Hollis IB, Vardeny O, Rodgers JE.** PARADIGM-HF trial: secondary analyses address unanswered questions. *Pharmacotherapy* 2018;38:284-98.
- **Bucheit JD**, Helsing H, Nadpara P, Virani SS, Dixon DL. Clinical pharmacist understanding of the 2013 ACC/AHA cholesterol guideline. *J Clin Lipidol* 2017. [Epub ahead of print]
- Sisson EM, Pamulapati L, **Bucheit JD, Kelly M, Dixon DL.** The evolving role of non-statin therapy for the management of dyslipidemia and cardiovascular risk reduction: past, present, and future. *Pharmacotherapy* 2018;38:164-71.
- **Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW.** Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. *Diabetes Obes Metab* 2018 Feb 9. [Epub ahead of print]
- **Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW.** Comment on Buckley et al. intensive versus standard blood pressure control in SPRINT-eligible participants of the ACCORD-BP trial. *Diabetes Care* 2018. In press.
- **Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW.** Intensive versus standard blood pressure control in SPRINT-eligible participants of the ACCORD BP trial. *Diabetes Care* 2017;40:1733-8.
- **Cavallari LH, Lee CR,** Beitelshes AL, **Cooper-DeHoff RM,** Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, **Coons JC,** Denny JC, Dillon C, Elsey AR, Hamadeh I, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, **Nutescu EA,** Nwaba DC, Pakyz et al; on behalf of the IGNITE Network. Multisite investigation of outcomes with implementation of *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *JACC Cardiovasc Interv* 2018;11:181-91.
- **Cave B, Hough A, Dobesh P.** Extended venous thromboembolism prophylaxis in medically ill patients. *Pharmacotherapy* 2018. [Epub ahead of print]
- **Coons JC.** Pulmonary arterial hypertension. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:159-90.
- **Coons JC,** Bunner C, Ishizawar DC, Risbano MG, Rivera-Lebron B, Mathier MA, Chan SY, Simon MA. Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension. *Pulm Circ* 2018;8(10).
- Empey PE, Stevenson J, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, **Coons JC,** Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, **Cavallari LH, Lee CR;** on behalf of the IGNITE Network. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther* 2017. [Epub ahead of print]
- Whitman-Purves E, **Coons JC,** Miller T, DiNella JV, Althouse A, Schmidhofer M, Smith RE. Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. *Clin Appl Thromb Hemost* 2017 Jan 1.
- Fairman KA, **Davis LE,** Peckham AM, Sclar DA. Diagnoses of cardiovascular disease or addiction in U.S. adults treated for ADHD with stimulants or atomoxetine: is use consistent with product labeling? *Drugs Real World Outcomes* 2018. [Epub ahead of print]
- Fairman KA, **Davis LE,** Sclar DA. Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term

adherence in routine clinical practice. *Ther Clin Risk Manage* 2017;13:957-65.

- Hormann SM, **Davis LE**, Pogge EK. From theory to practice: the diuretic potential of sacubitril/valsartan – a tale of two patients. *J Cardiovasc Nurs* 2017. [Epub ahead of print]
- Pogge EK, **Davis LE**. Evaluating the safety and tolerability of sacubitril/valsartan for HFrEF managed within a pharmacist clinic. *Am J Cardiovasc Drugs* 2018. [Epub ahead of print]
- **DiDomenico RJ**. Residency application deadlines: can we all just agree on a date? *Am J Health Syst Pharm* 2018. In press.
- **DiDomenico RJ**. Digoxin remains a viable option to control heart rate in patients with atrial fibrillation. *Can J Hosp Pharm* 2017;70:391-2. Invited review.
- **DiDomenico RJ, Baker WL, Haines ST**. Improving peer review: what reviewers can do. *Am J Health Syst Pharm* 2017;74:2080-4. Invited review.
- **DiDomenico RJ, Page RL**. Chapter 12: Digoxin. In: Murphy J, ed. *Clinical Pharmacokinetics*, 6th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2017.
- Harrington R, Kumar VM, Zueger PM, Rigoni G, Atwood AM, **DiDomenico RJ**, Touchette DR. Cost-utility analysis of angiotensin receptor-neprilysin inhibitor sacubitril/valsartan compared with ACE inhibitors for the treatment of chronic heart failure in the United States. *Pharmacotherapy*. In press.
- Kim K, **DiDomenico RJ**, Touchette DR, Walton SM. Letter – the authors respond. *J Manag Care Spec Pharm* 2017;23:599-600.
- Kim K, Lee TA, Ardati AK, **DiDomenico RJ**, Touchette DR, Walton SM. Comparative effectiveness of oral antiplatelet agents in patients with acute coronary syndrome. *Pharmacotherapy* 2017;37:877-87.
- Kim K, Lee TA, **DiDomenico RJ**, Ardati AK, Touchette DR, Walton SM. Comparison of six-month costs between oral antiplatelet agents following acute coronary syndrome. *J Manag Care Spec Pharm*. In press.
- **Dixon DL**. The PREDIMED study: should the Mediterranean diet be recommended to prevent cardiovascular disease? *Lipid Spin* 2017;15:20-1.
- **Dixon DL**, Salgado T, Abbate A. Pharmacists as integral members of the cardiovascular team. *JAMA Cardiol* 2017;2:1279-80.
- **Dixon DL**, Sisson EM, Parod ED, **Van Tassell BW**, Nadpara PA, Carl D, Dow A. Pharmacist-physician

collaborative care model and time to goal blood pressure in the uninsured population. *J Clin Hypertens* 2018;20:88-95.

- Carbone S, **Dixon DL**, Abbate A. Treatment of hypertension to prevent and treat heart failure in diabetic patients should include sodium glucose co-transporter 2 inhibitors. *JACC Heart Fail* 2018;6:85.
- Hylton-Gravatt L, Flurie R, Lathjia E, **Dixon DL**. Clinical guidance for managing statin and antimicrobial drug-drug interactions. *Curr Atheroscler Rep* 2017;19:46.
- Littauer SL, **Dixon DL**, Mishra VK, Sisson EM, Salgado TM. Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. *Pharm Pract* 2017;15:1134.
- Zimmerman K, Salgado T, **Dixon DL**. Medication review vs medication reconciliation. *JAMA* 2017;318:965-6.
- Zimmerman KM, Salgado TM, Goode JV, Sisson EM, **Dixon DL**. A prescription for prescribing: ensuring continued pharmacist preparedness. *Ann Pharmacother* 2018 Mar 1. [Epub ahead of print]
- Cuker A, **Dobesh PP**, Doherty JU, Eikelboom J, Florido R, Hucker W, Mehran R, Messe S, Pollack CV, Rodriguez F, Sarode R, Siegal D, **Wiggins BS**. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulation. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 2017;70:3042-67.
- **Finks SW, Rogers KC**. Idarucizumab (Praxbind®): the first reversal agent for a direct oral anticoagulant. *Am J Med* 2017;130:e195-7.
- **Gibson CM**, Basto AN, Howard ML. Direct oral anticoagulants in cardioversion: a review of current evidence. *Ann Pharmacother* 2018;52:277-84.
- **Gibson CM**, Davis S, Bradford D. Examining the use of sodium nitroprusside in coronary artery bypass grafting: is the benefit worth the cost? *Hosp Pharm* 2017;52:502-7.
- **Gibson CM**, Elrod S. Student versus residency program perceptions of a high-quality PGY1 residency applicant. *Curr Pharm Teach Learn* 2017. [Epub ahead of print]
- **Gibson CM**, Smith CB, Scalese M. Assessment of apixaban prescribing patterns for non-valvular atrial fibrillation in hospitalized patients. *Ann Pharmacother* 2018;52:54-9.

- Bhat S, Kansal M, Kondos GT, **Groo V**. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. *Ann Pharmacother* 2018.
- **Haines ST, Baker WL, DiDomenico RJ**. Improving peer review: what journals can do. *Am J Health Syst Pharm* 2017;74:2086-9. Invited review.
- Gernant SA, **Hale G**, Jones R, Alameddine S, Maravent S, Joseph T, Eltaki S, Lucibella R, Seamon M. Building partnerships between a college of pharmacy and accountable care organizations: development of the ACORN SEED. *Am J Account Care* 2017;5:29-33.
- Singh-Franco D, **Hale G**, Jacobs RJ. Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. *Hosp Pract* 2018;46:22-9.
- Bensimon L, **Hale GM**. Acclimating to the increase in statin use in accountable care organizations based on changes in quality measures: a report from ACORN SEED. *J Manag Care Spec Pharm* 2017;23:943-4.
- Gonsai N, Amin V, Mendpara C, Speth R, **Hale GM**. Effects of dopamine receptor antagonist anti-psychotic therapy on blood pressure. *J Clin Pharm Ther* 2018;43:1-7.
- Choi YC, Saw S, Soliman D, Bingham A, Pontiggia L, Hunter K, Chuang L, Siemianowski LA, Ereshefsky B, **Hollands JM**. Intravenous vancomycin is associated with the development of nephrotoxicity in patients with class III obesity. *Ann Pharmacother* 2017;51:937-44.
- **Jackevicius CA**. Elephant in the room. Cost of proprotein convertase subtilisin/kexin type 9 inhibitors [editorial]. *Circ Cardiovasc Qual Outcomes* 2018;11:e004425. Originally published January 11, 2018.
- Ozaki AF, Nakagawa S, **Jackevicius CA**. Cross-cultural comparison of pharmacy students' attitudes, knowledge, practice and barriers regarding evidence-based medicine. *Am J Pharm Ed* 2017; published online ahead of print Dec 12, 2017.
- Vira P, Nazer L, Phung OJ, Jackevicius CA. A longitudinal evidence-based medicine curriculum and its impact on the attitudes, knowledge and behavior of student pharmacists. *Am J Pharm Ed* 2018; published online ahead of print Jan 24, 2018.
- Wijeyundera HC, Koh M, Alter DA, Austin PC, **Jackevicius CA**, Tu JV, Ko DT. Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy. *Open Heart* 2017;4:e000731.
- Wright M, Takeda K, Mauro C, **Jennings D**, Kurlansky P, Han J, Truby L, Stein S, Topkara V, Garan AR, Yuzefpolskaya M, Colombo P, Naka Y, Farr M, Takayama H. Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. *J Heart Lung Transplant* 2017;36:1226-33.
- **Jennings DL, Ensor CR**. Cardiac transplantation and mechanical circulatory support for advanced heart failure. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:401-44.
- Lee CL, Colombo PC, Eisenberger A, Diuguid D, **Jennings DL**, Han J, Salna MP, Takeda K, Kurlansky PA, Yuzefpolskaya M, Garan AR, Naka Y, Takayama H. Abciximab/heparin therapy for left ventricular assist device implantation in patients with heparin-induced thrombocytopenia. *Ann Thorac Surg* 2018;105:122-8.
- Lee CL, Eisenberger AB, **Jennings DL**, Takayama H. Abciximab/heparin during acute heparin-induced thrombocytopenia: a word of caution [reply]. *Ann Thorac Surg* 2018.
- Martinez BK, Yik B, Tran R, Ilham S, Coleman CI, **Jennings DL, Baker WL**. Meta-analysis of time in therapeutic range in continuous-flow left ventricular assist device patients receiving warfarin. *Artif Organs* 2018 Mar 6. [Epub ahead of print]
- Al Yami MS, Silva MA, Donovan JL, **Kanaan AO**. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis. *J Thromb Thrombolysis* 2018;45:36-47.
- Dietrich JN, **Kazmi H**. Bleeding risks in patients on percutaneous ventricular assist devices receiving two different dextrose concentrations of heparinized purge solution: a case series. *J Pharm Pract* 2018. [Epub ahead of print]
- **Khazan E, Hough A**. A modern method to monitor office blood pressure. *Inov Pharm* 2017;8:Article 10.
- Wang N, Vendrov KC, Simmons BP, Schuck RN, Stouffer GA, **Lee CR**. Urinary 11-dehydrothromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. *Prostaglandins Other Lipid Mediat* 2018;134:24-31.
- Anderson SL, **Marrs JC**. Antihyperglycemic medications and cardiovascular disease reduction. *Eur Endocrinol* 2017;13:86-90.

- Anderson SL, **Marrs JC**. The role of the pharmacist in heart failure transition of care. *Adv Ther* 2018;35:311-23.
- Leavitt IM, Luoma KA, **Marrs JC**, Nederveld AL, Regensteiner JG, Dunn AL, Glasgow RE, Huebschmann AG. How can clinical practices pragmatically increase physical activity for patients with type 2 diabetes? A systematic review. *Transl Behav Med* 2017;7:751-72.
- **McConnell KJ**. Blood pressure management in adult patients. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:707-53.
- Westberg SM, Beatty SJ, Corona AR, Deines S, Gunning KM, Gurgle HE, Holtan HS, Marciniak MW, **McConnell KJ**, McGivney MA, Patel RJ. Residency pathways to ambulatory care practice: essential insights for students, residents, and educators. *J Am Pharm Assoc* 2017. Available at <https://doi.org/10.1016/j.japh.2017.08.013>.
- Sabato LA, Salerno DM, **Moretz JD, Jennings DL**. Inhaled pulmonary vasodilator therapy for management of right-ventricular dysfunction after left ventricular assist device placement and cardiac transplantation. *Pharmacotherapy* 2017;37:944-55.
- **Oliphant CS, Finks SW, Rogers KC**. Ischemic heart disease and acute coronary syndrome. In: Chyka PA, Franks AS, Waddell JA, Boucher BA, eds. *APhA's Complete Review for Pharmacy*, 12th ed. Washington, DC: APhA, 2017:289-320.
- Wang N, Giblin E, **Rodgers JE**. Drug interactions with non-vitamin K oral anticoagulants. *JAMA* 2018;319:830.
- **Rogers KC**. Stable atherosclerotic disease. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:127-58.
- **Rogers KC**, de Denus S, **Finks SW, Spinler SA**. Acute coronary syndromes. In: DiPiro J, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2017:165-92.
- **Rogers KC, Parker RB**. Acute myocardial infarction. In: Schwinghammer TL, Koehler JM, Borchert JS, Park S, Slain DS, eds. *Pharmacotherapy Casebook: A Patient-Focused Approach*, 10th ed. New York: McGraw-Hill, 2017:67-70.
- Shah R, Matin K, **Rogers KC**, Rao SV. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: a comprehensive pairwise and network meta-analysis of randomized controlled trials. *Catheter Cardiovasc Interv* 2017;90:196-204.
- Short MR, **Schwier NC**, Hawkins WA. Acute coronary syndromes. In: Sutton SS, ed. *NAPLEX® Review Guide*, 3rd ed. New York: McGraw-Hill. In press.
- **Sieg A, Moretz JD, Horn E, Jennings DL**. Pharmacotherapeutic management of gastrointestinal bleeding in patients with continuous-flow left-ventricular assist devices. *Pharmacotherapy* 2017;37:1432-48.
- **Sikora Newsome A**, Sultan S, Murray B, Schmidt K, Pappas A, Filteau G, Laux J, Wolfe A, Williams F, Jones S, Cairns B. The effect of inhaled prostacyclins on oxygenation in inhalational injury. *Burns Open* 2017;1:49-53.
- **Sikora Newsome A**, Watkins P, Chastain D, Hawkins A. Complications and pharmacologic interventions of invasive positive pressure ventilation during critical illness. *J Pharm Technol*. Accepted for publication.
- Fouda A, **Sikora Newsome A**, Spellicy S, Waller J, Zhi W, Hess D, Ergul A, Edwards D, Fagan SC, Switzer JA. Minocycline in acute cerebral hemorrhage: an early phase randomized trial. *Stroke* 2017;48:2885-7.
- Gwynn M, Oates M, **Sikora Newsome A**. Development of a medication regimen complexity scoring tool (MRC-ICU) for critically ill patients. *AJHP Residents Edition*. Accepted for publication, December 2017.
- Smith SE, **Sikora Newsome A**, Hawkins AH. An argument for the protocolized screening and management of post-extubation stridor. Published online. *Am J Respir Crit Care Med*. January 16, 2018.
- **Tisdale JE**. Editorial commentary: optimization of dose selection for non-vitamin K antagonist oral anticoagulants. *Trends Cardiovasc Med* 2017;27:573-4.
- **Tisdale JE**. Arrhythmias. In: *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:445-524.
- **Tisdale JE**. Commentary on: Andrews J et al. Warfarin use is associated with progressive coronary arterial calcification: insights from serial

intravascular ultrasound. JACC Cardiovasc Imag 2017. Practice Update website, 2017. Available at www.practiceupdate.com/content/warfarin-use-is-associated-with-progressive-coronary-arterial-calcification/56095/65/2/1.

- Alburikan KA, Aldemerdash A, Savitz ST, **Tisdale JE**, Whitsel EA, Soliman EZ, Thudium EM, Sueta CA, Kucharska-Newton AM, Stearns SC, **Rodgers JE**. Contributions of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study. J Eval Clin Pract 2017;23:1274-80.
- **Trujillo TC**. Chapter 16: Lidocaine. In: Murphy JE, ed. Clinical Pharmacokinetics. Pocket Reference, 6th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2017.
- Thompson A, **Trujillo TC**. Ischemic heart disease. In: Applied Therapeutics: The Clinical Use of Drugs, 11th ed. Wolters Kluwer, 2017.
- **Van Tassell BW**, Canada J, Carbone S, Trankle C, **Buckley L**, Erdle CO, Abouzaki NA, **Dixon D**, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A. Interleukin-1 blockade in recently decompensated systolic heart failure: results from the recently decompensated heart failure anakinra response trial (REDHART). Circ Heart Fail 2017;10:e004373.
- **Walker EA**, Roberts AJ, Louie EL, **Dager WE**. Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy. ASAIO J 2018 Mar 13.
- **Wiggins BS**, Lamprecht DG, **Page RL**, **Saseen JJ**. Recommendations for managing drug-drug interactions with statins and HIV medications. Am J Cardiovasc Drugs 2017;17:375-89.
- **Wiggins BS**, Morris PB. Dyslipidemias, atherosclerosis, and coronary heart disease. In: Applied Therapeutics, 11th ed. 2018.
- Gee M, Watkins A, Brown J, **Young E**. Ivabradine for the treatment of postural orthostatic tachycardia syndrome: a systematic review. Am J Cardiovasc Drugs 2018 Jan 12. [Epub ahead of print]

New ACCP Fellows

- **James C. Coons**
- **Mike Moranville**
- **Maria Pruchnicki**
- **Andrew Smith**

Other Notable Achievements

- **Anastasia L. Armbruster**: Selected for participation in the American College of Cardiology Emerging Faculty Program.
- **Robert J. DiDomenico**: Fellow, American College of Cardiology.
- **Joel Marrs**: Fellow, American Heart Association (FAHA), Council on Clinical Cardiology.
- **Kelly C. Rogers**: Fellow, American College of Cardiology.
- **James E. Tisdale**: Appointed to the Editorial Board of *Trends in Cardiovascular Medicine*; Appointed as a peer reviewer for the 2017 American College of Cardiology/American Heart Association/Heart Rhythm Society Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death; Appointed as peer reviewer for the 2018 American College of Cardiology/American Heart Association/Heart Rhythm Society Focused Update of the 2014 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society Guideline for the Management of Patients with Atrial Fibrillation.
- **Toby Trujillo**: Appointed to the CV Team Executive Council for the Colorado State Chapter of the American College of Clinical Pharmacy.

Presentations

- **Valencia D**, Stoppi J, Kibert J II, **Parra D**, Allen A, Spoutz P, **Hough A**. Impact of a direct oral anticoagulant population management tool on anticoagulation therapy monitoring in clinical practice. American College of Cardiology 67th Annual Scientific Meeting; Cardiovascular Team Session; March 11, 2018; Orlando, FL.

Central Nervous System PRN

Introduction

The CNS PRN completed a survey of possible topics for the ACCP Annual Meeting. Given the survey results from members, the PRN is focused on developing programming involving a debate of medical cannabis for CNS conditions. In addition, the PRN is working with student members who have expressed interest in creating content and activities that may foster relationships between trainees with possible mentors. A survey of all members that focuses on the interests and needs of students and residents is being discussed.

The CNS PRN would like to congratulate the following members on their awards, activities, and accomplishments.

Promotions

- **Jack J. Chen:** Senior Associate Dean of Academic Affairs, School of Pharmacy, American University of Health Sciences.

Awards

- **Stephanie Phan:** New Investigator Award from American Society of Clinical Psychopharmacology.

Grants

- **Jeffrey Bishop:** Epigenetics of PTSD Treatment Response. R21AT009475.
- **Stephanie Nichols:** Community Pharmacist Integration into Contingency Management and Education for Opioid Exposed Patients.
- **Mark Schneiderhan:**

12-Month Retrospective Review of Clinical Outcome Measures in Patients Receiving Comprehensive Medication Management Pharmacist Services in a Community Mental Health Setting. Role: PI. IRB Pre-submission #STUDY00002090.

Enhance Comprehensive Pharmacist Services to Improve Patient Health Clinical Research Award. Amount: \$6000. Grant period: 11/1/17 – 10/31/18.

Publications

- **Bishop JR,** Ellingrod VL. Precision pharmacotherapy enables precision medicine. *Pharmacotherapy* 2017;37:985-7.
- Brown JT, Schneiderhan M, Eum S, **Bishop JR.** Serum clomipramine and desmethylclomipramine levels in a *CYP2C19* and *CYP2D6* intermediate metabolizer. *Pharmacogenomics* 2017;18:601-5.
- Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Gershon ES, Keshavan MS, Keefe RSE, Sweeney JA, **Bishop JR.** Cognitive burden of anticholinergic medications in psychotic disorders. *Schizophr Res* 2017;190:129-35.
- Eum S, Schneiderhan ME, Brown JT, Lee AM, **Bishop JR.** Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. *BMC Psychiatry* 2017;17:238.
- Lencer R, Mills LJ, Alliey-Rodriguez N, Shafee R, Lee AM, Reilly JL, Sprenger A, McDowell JE, McCarroll SA, Keshavan MS, Pearlson GD, Tamminga CA, Clementz BA, Gershon ES, Sweeney JA, **Bishop JR.** Genome-wide association studies of smooth pursuit and antisaccade eye

movements in psychotic disorders: findings from the B-SNIP study. *Transl Psychiatry* 2017;7:e1249.

- Zierhut HA, Campbell CA, Mitchell AG, Lemke AA, Mills R, **Bishop JR.** Collaborative counseling considerations for pharmacogenomic tests. *Pharmacotherapy* 2017;37:990-9.
- **Chen JJ.** Treatment of psychotic symptoms in patients with Parkinson disease. *Ment Health Clin* 2017:262-70.
- **Chen JJ.** Pharmacotherapeutic management of pseudobulbar affect. *Am J Manag Care* 2017;23(18 suppl):S345-S350.
- **Chen JJ,** Hewitt LA. Comparison of the pharmacokinetics of droxidopa after dosing in the fed versus fasted state and with 3-times-daily dosing in healthy elderly subjects. *Drugs R D* 2018. <https://doi.org/10.1007/s40268-018-0226-z>.
- **Faulkner MA.** Use of $\alpha 2\delta$ ligands for restless legs syndrome/Willis Ekbom disease. *CNS Drugs* 2018 Feb 26. [Epub ahead of print]
- **Faulkner MA.** Spotlight on perampanel in the management of seizures: design, development and place in therapy. *Drug Design Dev Ther* 2017;11:2921-30.
- **King PK,** Stump TA, Walkama AM, Ash BM, Bowling SM. Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke. *Ann Pharmacother* 2018. [Epub ahead of print]
- Martin SL, Baker RP, Kerr J, Dubovik T, **Nichols S.** Expanding the role of collaborative practice in primary care to include clinical pharmacists. *J Med Pract Manage* 2017;33:99-103.
- Holt T, McCall KL, Cattabriga G, Tu C, Smalley EK, **Nichols SD.** Using controlled substance receipt patterns to predict prescription overdose death. *Pharmacology* 2017;101:140-7.
- Piper BJ, Desrociars C, McCall KL, **Nichols SD.** Illicit and prescription drug misuse as reported to the Maine Diversion Alert Program. *Forensic Sci Int* 2018;285:65-71.
- Piper BJ, Shaw DT, Simoyan OM, McCall KM, **Nichols SD.** Trends in medical use of opioids in the United States: 2006–2016. *Am J Prev Med* 2018.
- **Peckham AM,** Evoy KE, Covvey JR, et al. Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured US population. *Pharmacotherapy* 2018 Feb 27. [Epub ahead of print]

- **Peckham AM**, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. *BMJ* 2017;359:j5456.
- **Peckham AM**, Fairman KA, Sclar DA. Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed? *Expert Opin Drug Saf* 2017 Oct 6. [Epub ahead of print]
- **Peckham AM**, Nicewonder JA. VMAT2 inhibitors for tardive dyskinesia – Practice implications. *J Pharm Pract* 2018 Feb 18. [Epub ahead of print]
- **Peckham AM**, Niculete ME, Steinberg H, et al. A survey of prescribers' attitudes, knowledge, comfort, and fear of consequences related to an opioid overdose education and naloxone distribution program. *J Public Health Manag Pract* 2017 Oct 27. [Epub ahead of print]
- Early NK, **Peckham AM**, Fairman KA, et al. Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson's disease: a national assessment of U.S. office-based physician visits. *J Parkinsonism Restless Legs Syndr* 2017;7:79-84.
- Fairman KA, Davis LE, **Peckham AM**, et al. Diagnoses of cardiovascular disease or substance addiction/abuse in US adults treated for ADHD with stimulants or atomoxetine: is use consistent with product labeling? *Drugs Real World Outcomes* 2018;5:69-79.
- Hawkins WA, **Phan SV**, Campbell SL. Effective of various antipsychotic regimens on incidence of delirium in critically ill adults. *J Crit Care* 2018;44:289-93.
- Phillips ME, Gilmore RA, Sheffield MC, **Phan SV**. Pain assessment documentation after opioid administration at a community teaching hospital. *J Pharm Pract* 2018 Jan. [Epub ahead of print]
- Stratton T, Palombi L, Blue H, **Schneiderhan M**. Ethical dimensions of the prescription opioid abuse crisis: how we got to where we are. Manuscript 2017AJHP0704R. Accepted as a commentary by *AJHP* on 12/8/17.
- **Schneiderhan ME**, Eum S, Brown JT, Bishop JR. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. *BMC Psychiatry* 2017;17:238.
- **Schneiderhan ME**, Nelson LA, Bauer S. Assessment of psychiatric disorders. In: DiPiro J, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2017:eChapter62.

A Pathophysiologic Approach, 10th ed. New York: McGraw-Hill, 2017:eChapter62.

- Brown JT, **Schneiderhan ME**, Eum S, Bishop JR. Serum clomipramine and desmethylclomipramine levels in a *CYP2C19* and *CYP2D6* intermediate metabolizer. *Pharmacogenomics* 2017;18:601-5.
- Okoro ON, Bastianelli KM, Wen Y, Bilden E, Konowalchuk BK, **Schneiderhan ME**. Awareness of state legislation on naloxone accessibility associated with willingness to prescribe naloxone. *Subst Abuse* 2017; online;1-7. <https://www.ncbi.nlm.nih.gov/pubmed/28727957>.

Other Notable Achievements

- **Edward M. Bednarczyk**: Last year, President-Elect of APhA-APRS. After the most recent APhA meeting, took over as President of APRS from Rob DiCenzo.

Clinical Administration PRN

Publications

- **Dong J**, Covington E, Sholar S, Galdo J. A proposed cost-benefit model for procalcitonin monitoring in a health system. *J Am Pharm Assoc*. In press.
- **Gazda NP**, Griffin E, Hamrick K, Baskett J, Mellon MM, Eckel SF, Granko RP. Development and implementation of a combined master of science and PGY1/PGY2 health-system pharmacy administration residency program at a large community teaching hospital. *Hosp Pharm* 2018;53:96-100.
- **Michalets EL**, Williams C, Park I. Ten year experience with student pharmacist research within a health system and education center. *Curr Pharm Teach Learn* 2018. Published online December 19, 2017.

Awards

- **Charles Summerlin**: 2018 APhA Student Leadership Award – one of four national recipients (with four recipients nationally every year). Presented with a \$500 scholarship and plaque during the APhA-ASP awards ceremony at the APhA annual meeting. Established in 1983, the APhA Student Leadership Award recognizes outstanding academic achievement and leadership ability in APhA-ASP at the local, regional, and national levels of students who are currently in their next-to-last year of pharmacy school.

Other Notable Achievements

- **Rasha Abdelsalam Elshinaway:** Reviewer in PSAP Infectious Disease Book Series 2018. January 2018; author of an Arabic book *Stories of Pharmacy and Medicine*, published in Cairo International Book Fair. January 2018.

Critical Care PRN

Introduction

The CRIT PRN Recognition Committee has been completing its charges for the year. Several CRIT PRN members were nominated for ACCP offices and awards. The CRIT PRN honors its members by presenting its own awards every year. PRN members will be recognized for their achievements throughout the past year at the PRN business meeting at the 2018 ACCP Annual Meeting. If you are interested in joining the Recognition Committee, please e-mail Nick Peters (npeters.butler@gmail.com).

Promotions

- **Chris Droege:** Adjunct Associate Professor of Pharmacy Practice at University of Cincinnati James L. Winkle College of Pharmacy.
- **Deena Horner:** Senior Clinical Pharmacist.

Awards

- **Mitchell Buckley:** SCCM Barry A. Shapiro Memorial Award for Excellence in Critical Care Management.
- **Alexis Crawford:** Virginia Commonwealth University School of Pharmacy 2017 Preceptor of the Year.
- **Joe Dasta:** Shubin-Weil Master Clinician/Teacher Award at SCCM Congress.
- **Chris Droege:** Presidential Citation, SCCM; Critical Care PRN Clinical Practitioner Award, American College of Clinical Pharmacy; Distinguished Alumni Award, Graduate of the Last Decade, University of Cincinnati James L. Winkle College of Pharmacy.
- **Alexander Flannery:** SCCM Star Research Achievement Award.
- **Drayton Hammond:** SCCM Star Research Award for Co-Investigator, awarded twice.
- **Abir Kanaan:** Academic of the Year, Department of Pharmacy Practice, School of Pharmacy Worcester/Manchester, MCPHS University; Faculty Scholarship Award in Integration, MCPHS University.
- **Kimberly E. Levasseur-Franklin:** 2017 Presidential Citation Award from Neurocritical Care Society.

- **Carolyn Magee:** Young Pharmacy Investigator Award, SCCM; Star Research Award, SCCM.
- **Janise Phillips:** Cleveland Clinic Abu Dhabi Safety Champion.
- **Megan Rech:** Star Research Award, SCCM; Presidential Citation Award, SCCM.
- **Pamela Smithburger:** AACP Rufus A. Lyman Award presented for the best paper published in the *American Journal of Pharmaceutical Education*; American College of Clinical Pharmacy Critical Care PRN Research Award for recognition of outstanding and sustained research contributions in critical care pharmacotherapy; AACP Award for Excellence in Assessment: Blended Simulation Progress Testing for Assessment of Practice Readiness.
- **Edward Van Matre:** American College of Clinical Pharmacy Travel Award; Skaggs School of Pharmacy and Pharmaceutical Sciences Top Postdoctoral Research Presentation.
- **Matthew Wanat:** Presidential Citation from SCCM; Rho Chi Teaching Excellence Award.

Grants

- **Gretchen Brophy:** Probabilistic Pharmacokinetic Models for Diagnosis, Prognosis, and Personalized Treatment. DHA 17B-003 STTR H17B-003-0041. Defense Health Agency Small Business Technology Transfer (STTR) Program.
- **Chris Droege:** En Route Care Research Division Pharmaceutical Degradation in Emergency Medical Service Deployment and in Extreme Temperature Simulation. U.S. Air Force School of Aerospace Medicine (2017). Foertsch MJ; Droege CA (PI). Grant No. FA8650-17-2-6G27UC Health-University of Cincinnati Medical Center, Cincinnati, Ohio.
- **Andrew Jarrell:** Grant from the Living Legacy Foundation to study valganciclovir/ganciclovir levels in CVVHD.
- **Yoonsun Mo:** Utilizing Online Case-Based Patient-Simulation to Improve Critical Thinking Skills in a Clinical Pharmacokinetics Course. LIU internal research grant.
- **Andrea Sikora Newsome:** Intramural grant from UGA COP.

Publications

- **Beckman EJ.** Analgesia and sedation in hospitalized children. In: Buck ML, Manasco KB, eds. Pediatric Self-Assessment Program, 2017 Book 3. Pediatric Critical Care. Lenexa, KS: American College of Clinical Pharmacy, 2017:7-30.

- **Bolesta S.** Specialized topics in cardiovascular disease. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:231-70.
- **Brophy GM,** Human T. Emergency neurological life support: pharmacotherapy. *Neurocrit Care* 2017;27(suppl 1):51.
- Human T, Cook AM, Anger B, Bledsoe K, Castle A, Deen D, Gibbs H, Lesch C, Liang N, McAllen K, Morrison C, Parker D Jr, Rowe AS, Rhoney D, Sangha K, Santayana E, Taylor S, Tesoro E, **Brophy GM.** Treatment of hyponatremia in patients with acute neurological injury. *Neurocrit Care* 2017;27:242-8.
- Papa L, Robicsek SA, **Brophy GM,** Wang KKW, Hannay HJ, Heaton SC, Schmalfluss I, Gabrielli A, Hayes RL, Robertson CS. Temporal profile of microtubule associated protein (MAP-2) – a novel indicator of diffuse brain injury severity and early mortality after brain trauma. *J Neurotrauma* 2018;35:32-40.
- **Carothers C.** Activated prothrombin complex concentrate for warfarin reversal in traumatic intracranial hemorrhage. *J Surg Res* 2018;223:183-7.
- Kramer A, **Dasta J,** Kane-Gill S. The impact of mortality on total costs within the intensive care unit. *Crit Care Med* 2017;45:1457-63.
- Dunlap ME, Hauptman PJ, Amin S, Chase SL, Chiodo J, Chiong JR, **Dasta JF.** Current management of hyponatremia in acute heart failure: a report from the Hyponatremia Registry for Patients with Euvolemic and Hypervolemic Hyponatremia (HN Registry). *J Am Heart Assoc* 2017;6:e005261.
- Kane-Gill S, **Dasta JF,** Buckley MS, Devabhakthuni S, Liu M, Cohen H, George EL, Pohlman AS, Agarwal S, Henneman EA, Bejian SM, Berenholtz SM, Pepin JL, Scanlon MC, Smith BS. Executive summary: clinical practice guideline: safe medication usage. *Crit Care Med* 2017;45:1546-51.
- Kane-Gill S, **Dasta JF,** et al. Clinical practice guideline: safe medication use in the ICU. *Crit Care Med* 2017;45:e877-e915.
- **DeMott JM,** Hebert CL, Novak M, Mahmood S, Peksa GD. Characteristics and resource utilization of patients presenting to the emergency department from mass gathering events. *Am J Emerg Med* 2017 Nov 6.
- **Droege CA,** Ernst NE. Commentary: impact of norepinephrine weight-based dosing compared to non-weight based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. *Ann Pharmacother* 2017;51:614-6.
- Horner D, Altshuler D, **Droege CA,** Feih J, Ferguson K, Fiorenza M, Greathouse K, Hamilton L, Pfaff C, Roller L, Stollings J, Wong A. Major publications in the critical care pharmacotherapy literature: January-December 2016. *J Crit Care* 2018;43:327-39.
- **Duprey MS,** Zekery-Saad SA, Devlin JW. The evidence clash between statins and delirium: should they stay, should they go, or should they be started? *Crit Care Med* 2017;45:1574-6.
- Skrobik Y, **Duprey MS,** Hill NS, Devlin JW. Low-dose nocturnal dexmedetomidine prevents ICU delirium: a randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 2018 Mar 2. [Epub ahead of print]
- Fox MA, **Elefritz JL,** Huang BM, Hunley C. Comparison of lurasidone versus quetiapine for the treatment of delirium in critically ill patients. *J Intensive Care Med* 2018 Jan. [Epub ahead of print]
- Juhl RC, Roddy JVF, Wang T, **Elefritz JL.** Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. *Leuk Lymphoma* 2018 Feb 9:1-6. [Epub ahead of print]
- **Flannery AH,** Thompson Bastin ML, Magee CA, Bensadoun ES. Vitamin C in sepsis: when it seems too sweet, it might (literally) be [letter]. *Chest* 2017;152:450-1.
- Bissell BD, Davis JE, **Flannery AH,** Adkins DA, Thompson Bastin ML. Aggressive treatment of life-threatening hypophosphatemia during recovery from fulminant hepatic failure: a case report. *J Intensive Care Med* 2017. [Online ahead of print]
- Bissell BD, Thompson Bastin ML, Magee CA, Moran PR, **Flannery AH.** Hemodynamic instability secondary to vasopressin withdrawal in septic shock. *J Intensive Care Med* 2017. [online ahead of print]
- La MK, Thompson Bastin ML, Gisewhite JT, Johnson CA, **Flannery AH.** Impact of restarting home neuropsychiatric medications on sedation outcomes in medical ICU patients. *J Crit Care* 2017. [Online ahead of print]
- Wong PJ, Pandya KA, **Flannery AH.** Evaluating the impact of obesity on safety and efficacy of weight-based norepinephrine dosing in septic shock: a single-center, retrospective study. *Intensive Crit Care Nurs* 2017;41:104-8.

- Allender JE, Reed BN, **Foster JL**, Moretz JD, Oliphant CS, Jennings DL, DiDomenico RJ, Coons JC. Pharmacologic considerations in patients receiving left ventricular percutaneous mechanical circulatory support. *Pharmacotherapy* 2017;37:1272-83.
- **Groth CM**, Acquistio NM, Khadem T. Current practices and safety of medication use during rapid sequence intubation (RSI). *J Crit Care* 2018;45:65-70.
- Treu CN, **Groth CM**, Patel JH. The use of continuous ketamine for analgesia and sedation in critically ill patients with opioid abuse: a case series. *J Crit Care Med* 2017;3(4).
- **Hammond DA**, Cullen J, Painter JT, McCain K, Clem OA, Brotherton AL, Chopra D, Meena N. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. *J Intensive Care Med*.
- **Hammond DA**, Rowe JM, Wong A, Wiley TL, Lee KC, Kane-Gill S. Patient outcomes associated with phenobarbital use with or without benzodiazepines for alcohol withdrawal syndrome: a systematic review. *Hosp Pharm* 2017;52:607-16.
- Personett HA, **Hammond DA**, Schramm GE, Skrupky L, Johnson T, Barreto E. Roadmap for research training in the residency learning experience. *J Pharm Pract*.
- **Hawkins WA**, Phan SV, Campbell SL. Effect of various antipsychotic regimens on incidence of delirium in critically ill adults. *J Crit Care* 2018;44:289-93.
- Bach QN, Gilmore RA, Sheffield MC, **Hawkins WA**. Evaluation of insulin use and hypoglycemia in hospitalized elderly patients. *Hosp Pharm* 2017;52:761-5.
- Chastain DB, Wheeler S, Franco-Paredes C, Olubajo B, **Hawkins WA**. Evaluating guideline adherence regarding empirical vancomycin use in patients with neutropenic fever. *Int J Infect Dis* 2018 Feb 22. [Epub ahead of print]
- **Hecht JP**, Richards PG. Continuous-infusion labetalol vs. nicardipine for hypertension management in acute stroke patients. *J Stroke Cerebrovasc Dis* 2017 Oct 30.
- **Hecht JP**, Wahl WL. Pharmacy issues in elderly trauma patients. In: Luchette F, Yelon J, eds. *Geriatric Trauma and Critical Care*, 2nd ed. New York: Springer, 2017.
- Kemmer HR, **Hecht JP**, Brozik MJ, Anderson HL. Prothrombin complex concentrates for abdominal trauma. In: Firstenberg MS, ed. *Prothrombin Complex Concentrates: Advances in Research and Clinical Applications*. New York: Nova Science, 2017.
- **Jarrell AS**, Krueger RM, Berescu LD, Pronovost PJ, Trivedi JB. Factors associated with in-hospital mortality among critically ill surgical patients with multidrug-resistant gram-negative infections. *J Crit Care* 2018;43:321-6.
- Banoub M, Curless MS, Smith JM, **Jarrell AS**, Cosgrove SE, Rock C, Avdic E. Higher (3 gram) versus lower (2 gram) dose of cefotetan or cefoxitin for surgical prophylaxis in patients >120 kg. *Surg Infect*. In press.
- Rozycki A, **Jarrell AS**, Krueger RM, Young S, Mendez-Tellez PA. Feasibility of a nurse-managed pain, agitation, and delirium protocol in the surgical intensive care unit. *Crit Care Nurse* 2017;37:24-35.
- Sugrue D, **Jarrell AS**, Krueger RM, Davis S, Johnson D, Tsui E, Snyder S, Crow J. Appropriateness of peripheral parenteral nutrition use in adult patients at an academic medical center. *Clin Nutr ESPEN* 2018;23:117-21.
- Al Yami MS, Silva MA, Donovan JL, **Kanaan AO**. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis. *J Thromb Thrombolysis* 2018;45:36-47.
- Hensler DM, McConnell DP, **Levasseur-Franklin KE**, Greathouse KM. Pentobarbital removal during continuous venovenous hemofiltration: case report and review of the literature. *J Pharm Pract* 2017 Jan 1.
- **Mo Y**, Thomas MC, Miano TA, et al. Effect of modafinil on cognitive function in intensive care unit patients: a retrospective cohort study. *J Clin Pharmacol* 2018;58:152-7.
- Chaijamorn W, Shaw AR, Lewis SJ, **Mueller BA**. Ex vivo ceftolozane/tazobactam clearance during continuous renal replacement therapy. *Blood Purif* 2017;44:16-23.
- Gharibian KN, Murthy V, **Mueller BA**. Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. *J Nucl Cardiol* 2018;25:234-9.
- Heung M, **Mueller BA**. Prevention of hypophosphatemia during continuous renal replacement therapy: an overlooked problem. *Semin Dial* 2018 Feb 5.
- Scoville BA, Vulaj V, **Mueller BA**, Annich GM, Wagner DS. Acetaminophen clearance during ex vivo continuous renal replacement therapies. *J Artif Organs* 2017.

- **Mullins BP**, Kramer CJ, Bartel BJ, et al. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam: a prospective, multicenter study. *Ann Pharmacother* 2018. [Epub ahead of print]
- **Poyant JO**, Albright R, Clain J, Pandompatam G, Barreto EF. Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with codeine) poisoning. *Clin Toxicol (Phila)* 2017 Nov 10:1-3.
- Asal NJ, **Poyant JO**. Role and impact of student pharmacists and a pharmacist on an international interprofessional medical brigade. *Curr Pharm Teach Learn* 2018 Feb. [Epub ahead of print]
- **Quidley AM**, Bookstaver PB. Central nervous system infections. In: Chisholm-Burns M, Wells BG, Schwinghammer TL, et al., eds. *Pharmacotherapy Principles and Practice*, 5th ed. New York: McGraw-Hill, 2018.
- Xiong L, Lu ZK, **Quidley AM**, Alford BS, Bookstaver PB. Evaluation of renal dosing methods specific to dynamic renal function in critically ill patients with acute kidney injury. *South Med J* 2018;111(5).
- Feldman JP, Habib N, **Radosevich JJ**, et al. Oral tadalafil in the treatment of pulmonary arterial hypertension. *Expert Opin Pharmacother* 2017;15:1661-7.
- **Rech MA**, Barbas B, Chaney W, Greenhalgh E, Turck C. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. *Ann Emerg Med* 2017;70:203-11.
- **Rech MA**, Bennett S, Donahey E. Pharmacist participation in acute ischemic stroke decreases door-to-needle time to tissue plasminogen activator. *Ann Pharmacother* 2017;51:1084-9.
- **Rech MA**, Mosier MJ, Zelisko S, Netzer G, Kovacs EJ, Afshar M. Comparison of a novel coding algorithm versus the American Burn Association sepsis definition to examine the epidemiology of sepsis in burn-injured adults. *J Burn Care Res* 2017;38:312-8.
- **Rech MA**, Von Roenn N, Durazo-Arvizu R, Cotler SJ, Kramer H. Vitamin D levels are associated with liver disease severity in patients with cirrhosis. *J Ren Hepat Disord* 2017;1:1-9.
- Kattub H, Sterk E, **Rech MA**, Bukar B, Khan S. Early recognition and treatment of sepsis after the addition of lactate to critical laboratory call list. *J Intensive Care Med* 2018;33:111-5.
- Patel GP, **Rech MA**. Anaphylaxis, allergies, angioedema, and acute CNS disorders. In: *Medical Problems in the ICU. Critical Care Self-Assessment Program*. Lenexa, KS: American College of Clinical Pharmacy, 2018.
- Shah T, Sterk E, **Rech MA**. Emergency department sepsis screening tool decreases time to antibiotics in patients with sepsis. *Am J Emerg Med* 2018 Jan 28. [Epub ahead of print]
- Wexler A, **Rech MA**. Case report: reversal of warfarin-associated life-threatening bleed with an attenuated dose of 4-factor prothrombin complex concentrate. *Ann Pharmacother* 2018;52:212-3.
- **Sikora Newsome A**, Sultan S, Murray B, Schmidt K, Pappas A, Filteau G, Laux J, Wolfe A, Williams F, Jones S, Cairns B. The effect of inhaled prostacyclins on oxygenation in inhalational injury. *Burns Open* 2017;1:49-53.
- **Sikora Newsome A**, Watkins P, Chastain D, Hawkins A. Complications and pharmacologic interventions of invasive positive pressure ventilation during critical illness. *J Pharm Technol*. Accepted for publication.
- Fouda A*, **Sikora Newsome A***, Spellicy S, Waller J, Zhi W, Hess D, Ergul A, Edwards D, Fagan SC, Switzer JA. Minocycline in acute cerebral hemorrhage: an early phase randomized trial. *Stroke* 2017;48:2885-7.
- Gwynn M, Oates M, **Sikora Newsome A**. Development of a medication regimen complexity scoring tool (MRC-ICU) for critically ill patients. *AJHP Residents Edition*. Accepted for publication, December 2017.
- **Smith SE**, Rumbaugh KA. False prolongation of international normalized ratio with daptomycin. *Am J Health Syst Pharm* 2018;75:269-74.
- **Smith SE**, Rumbaugh KA, May AK. Evaluation of a short course of antimicrobial therapy for complicated intra-abdominal infections in critically ill surgical patients. *Surg Infect* 2017;18:742-50.
- **Smith SE, Sikora Newsome A, Hawkins AH**. An argument for the protocolized screening and management of post-extubation stridor. *Am J Respir Crit Care Med*. Published online.
- Hamblin SE, **Smith SE**. Inhaled antibiotics: do as we say not as we study. *Crit Care Med* 2018;46:159-61.
- **Smithburger PL**, Korenoski AS, Alexander SA, Kane-Gill SL. Perceptions of families of intensive care unit patients regarding involvement in delirium prevention activities: a qualitative study. *Crit Care Nurse* 2017;37:e1-e9.

- **Smithburger PL**, Korenoski AS, Kane-Gill SL, Alexander SA. Perceptions of family members, nurses, and physicians on involving patients' families in delirium prevention. *Crit Care Nurse* 2017;37:48-57.
- Kane-Gill SL, **Smithburger PL**, Kashani K, Kellum, Frazee E. Clinical relevance and predicative value of damage biomarkers of drug-induced kidney injury. *Drug Saf* 2017;40:1049-74.
- **Van Matre ET**, Ho K, Lyda C, Fullmer BA, Oldland AR, Kiser TH. Extended stability of epinephrine hydrochloride injection in polyvinyl chloride bags stored in amber ultraviolet light-blocking bags. *Hosp Pharm* 2017;52:570-3.
- **Van Matre ET**, Satyanarayana G, Page RL II, Levi ME, Lindenfeld J, **Mueller SW**. Pharmacokinetic drug-drug interactions between immunosuppressant and anti-infective agents: antimetabolites and corticosteroids. *Ann Transplant* 2018;23:66-74.

New Fellows

- **Scott Mueller**: FCCM – Society of Critical Care Medicine.
- **Matthew Wanat**: FCCM – Society of Critical Care Medicine.

Other Notable Achievements

- **Basant Mohammed Abdelaziz**: BCCCP certification.
- **Elizabeth Beckman**: Selected as Specialty Council Member for BPS Specialty Council for Pediatric Pharmacy.
- **Scott Bolesta**: Chair-Elect, SCCM Research Section.
- **Gretchen Brophy**: President, Neurocritical Care Society.
- **Chris Droege**: BCCCP certification; resigned with ASHP for ASHP's BCCCP recertification course, PK-PD in critical illness; 2017 Chair-Elect, SCCM CPP Section Communications Committee.
- **Bethany Crouse**: BCCCP certification.
- **Jessica Elefritz**: PGY2 Critical Care Residency Director, Ohio State University.
- **Alexander Flannery**: Vice Chair, American College of Clinical Pharmacy Annual Meeting Program Committee; Chair, American College of Clinical Pharmacy Critical Care PRN Social Media Committee.
- **Jolie Gallagher**: BCCCP certification.

- **Christine Groth**: BCCCP certification; PGY2 Critical Care Residency Director, UPMC; Improving the management of pain, agitation, and delirium (PAD) in the intensive care unit: translating evidence into practice. E-learning course for NYS Partnership for Patients, together with Ely W and Girard T; Improving the management of pain, agitation, and delirium (PAD) in the intensive care unit: translating evidence into practice. Platform presentation for NYS Partnership for Patients at the Operationalizing Ventilator-Associated Events/Delirium Prevention Strategies in the ICU Symposium together with Ely W and Girard T, Syracuse and New York City.
- **Drayton Hammond**: Chair, American College of Clinical Pharmacy Critical Care PRN; Vice Chair, 2019 American College of Clinical Pharmacy Programming Committee; Chair-Elect, SCCM CPP Section Education Committee.
- **W. Anthony Hawkins**: Board of Directors, Georgia Society of Health-System Pharmacists.
- **Jason Hecht**: BCCCP certification.
- **Deena Horner**: JCI team.
- **Justin Kinney**: BCCCP certification; Speaker at CSHP Seminar.
- **Michael Liu**: Chair, YNHHS Pharmacist Career Ladder.
- **Carolyn Magee**: New Practitioners Forum Career Development Advisory Group Work Group Lead, ASHP.
- **Scott Mueller**: PGY2 Critical Care Residency Director, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.
- **Janelle Poyant**: BCCCP certification; Student Resident Fellow Committee Vice Chair, American College of Clinical Pharmacy Critical Care PRN.
- **John Radosevich**: Communications Committee Chair, American College of Clinical Pharmacy Critical Care PRN.
- **Megan Rech**: Research and Scholarship Committee Chair, SCCM CPP.
- **Andrea Sikora Newsome**: Communications Committee Chair, SCCM Southeast Chapter.
- **Susan Smith**: BCCCP certification.
- **Edward Van Matre**: Resident/Fellow Steering Committee Member, American College of Clinical Pharmacy Critical Care PRN.
- **Johnathan Voss**: BCNSP; Chair, American College of Clinical Pharmacy GI/Liver/Nutrition PRN.
- **Matthew Wanat**: President, SCCM Texas Chapter.

Drug Information PRN

Introduction

The DINF PRN has been providing live and recorded webinars on drug information topics to its members. The PRN's most recent webinar was presented by DINF PRN Membership Committee Chair Steven T. Johnson. The topic was "Copyright Basics for U.S. Drug Information Professionals."

The DINF PRN also hosts student and resident journal club presentations on a variety of topics. Journal clubs are presented live and recorded. The most recent journal club was "Simvastatin for Delirium" from *Lancet Respiratory Medicine*, presented by Lindsey Sellers, Pharm.D.

Promotions

- **Radha Manian:** Appointed as Instructor, University of Arizona – College of Pharmacy.

Awards

- **Ryan Rodriguez:** University of Illinois Chicago Teaching Recognition Program Award. It is awarded to selected faculty with demonstrated long-term teaching commitment.
- The University of Virginia Health System's Postgraduate Year One pharmacy residency program, directed by **Michelle W. McCarthy**, was selected as the 2017 ASHP Foundation Residency Excellence Program Award.

Publications

- **Boylan PM**, Joseph T, Hale G, Moreau C, Seamon M, Jones R. Chronic obstructive pulmonary disease and heart failure self-management kits for outpatient transitions of care. *Consult Pharm* 2018;33:152-8.
- **Boylan PM**, Trinh KV, Helms J, Ghoubrial-Waibel G, Mege J. Integration of transitions of care pharmacist services within an accredited pulmonary rehabilitation clinic. *Pharmacotherapy* 2017;37:e214.
- Luder H, Zavadsky A, Bukowitz A, Baumann A, **Boylan PM**, Croley KS, Fu D, Kelling SE, Winder M, Register D. Transitions of Care Case Examples Resource. Washington, DC: APhA, June 2017. Available at www.pharmacist.com/transitions-care. Bosworth HB, **Brown JN**, Danus S, Sanders LL, McCant F, Zullig LL, Olsen M. Evaluation of a packaging approach to improve cholesterol medication adherence. *Am J Manag Care* 2017;23:e280-6.

- Britnell SR, Chillari KA, **Brown JN**. The role of xanthine oxidase inhibitors in patients with history of stroke: a systematic review. *Curr Vasc Pharmacol* 2017 Sep 19. [Epub ahead of print]
- Britnell SR, Jackson AD, **Brown JN**, Capehart BP. Aripiprazole for post-traumatic stress disorder: a systematic review. *Clin Neuropharmacol* 2017;40:273-8.
- Britt RB, **Brown JN**. Characterizing the severe reactions of parenteral vitamin K1. *Clin Appl Thromb Hemost* 2018;24:5-12.
- Gee ME, Watkins AK, **Brown JN**, Anastasia EJ. Ivabradine for the treatment of postural orthostatic tachycardia syndrome: a systematic review. *Am J Cardiovasc Drugs* 2018 Jan 12. [Epub ahead of print]
- **May JR**, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. *Clin Ther* 2017;39:2410-9.
- **May JR, May DW**. Introduction to the concept of drug information. In: Malone PM, ed. *Drug Information – A Guide for Pharmacists*, 6th ed. New York: McGraw-Hill, January 2018:1-31.
- **Rodriguez R**, Moody ML, Kelly BJ. A survey evaluating the training, responsibilities, and practices of pharmacy & therapeutics committee member and non-member contributors. *J Manag Care Pharm* 2017;23:868-74.
- Spencer S, Ipema H, Hartke P, Krueger C, **Rodriguez R**, Gross AE, **Gabay MP**. Intravenous push administration of antibiotics. *Hosp Pharm* 2018. In press.

New ACCP Fellows

- **Mike P. Gabay**

Education and Training PRN

Awards

- **Elias Chahine:** 2018: Healthcare Educator Hero in Medicine Award, Palm Beach County Medical Society; 2017: Token of Appreciation, Indian Association of Colleges of Pharmacy/Devaki Amma Memorial College of Pharmacy.
- **Lucas Hill:** UTCOP Alumni Centennial Endowed Fellowship Preceptor Award.
- **Ryan Rodriguez:** UIC Teaching Recognition Program Award: Awarded to selected faculty with demonstrated long-term teaching commitment.

Grants

- **Elias Chahine:** (PI): Assessment of Supplemental Infectious Diseases Instruction Through Social Media. Funding: American College of Clinical Pharmacy Education and Training PRN Teaching Enhancement Grant \$500.
- **Lucas Hill:** (PI): SAMHSA/TX HHSC – Operation Naloxone (\$2.2 million); (Co-I): SAMHSA/TX HHSC – Prescription Monitoring Program (\$642,000).

Publications

- **Boylan P,** Joseph T, Hale GM, Moreau C, Seamon M, Jones R. Development of chronic obstructive pulmonary disease and heart failure self-management kits for outpatient transitions of care. *Consult Pharm* 2018;33:145-51.
- **Boylan P,** Trinh K, Helms J, Ghoubril-Waibel R, Mege J. Integration of transitions of care pharmacist services within an accredited pulmonary rehabilitation clinic. *Pharmacotherapy* 2017;37:e214.
- **Boylan PM,** Eltaki SM. Post-graduate year two transitions of care pharmacy residencies no longer accredited. *Curr Pharm Teach Learn* 2018. [Epub ahead of print]
- **Bzowickyj AS,** Dow A, Knab MS. Evaluating the impact of educational interventions on patients and communities. *Acad Med* 2017;92:1531-5.
- **Bzowickyj AS, Stahnke AM.** Hypersensitivity reactions to human insulin analogs (HIAs) in insulin-naïve patients: a systematic review. *Ther Adv Endocrinol Metab* 2018;9:53-65.
- **Chahine EB.** Diving into academic pharmacy. *Consult Pharm* 2017;32:488-9.
- **Chahine EB.** Sexually transmitted diseases, ambulatory care infections, and immunizations. In: Bland CM, Bookstaver PB, Chahine EB, et al., eds. *Updates in Therapeutics®: Infectious Diseases Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: ACCP, 2018:155-222 (ACPE approved for 1.5 hours of CE credit).
- **Chahine EB.** The rise and fall of metronidazole for *Clostridium difficile* infection. *Ann Pharmacother* 2018;52.
- **Chahine EB,** Cho JC, Worley MV. Bezlotoxumab for the prevention of *Clostridium difficile* recurrence. *Consult Pharm* 2018;33:89-97.
- **Chahine EB,** Karaoui LR. Lung Abscesses. In Murphy JE, Len MW, eds. *Pharmacotherapy Self-Assessment Program*, 2018 Book 1. Infectious Diseases. Lenexa, KS: ACCP, 2018:161-89 (ACPE

approved for 2.0 hours of CE credit and for BCPS recertification).

- **Chahine EB,** Kelley D, Childs-Kean LM. Sofosbuvir/velpatasvir/voxilaprevir: a pan-genotypic direct-acting antiviral combination for hepatitis C. *Ann Pharmacother* 2018;52:352-63.
- James SF, **Chahine EB,** Sucher AJ, Hanna C. Shingrix: the new adjuvanted recombinant herpes zoster vaccine. *Ann Pharmacother* 2018;52.
- Karaoui LR, Mansour H, **Chahine EB.** Elbasvir/grazoprevir: a new direct acting antiviral combination for hepatitis C. *Am J Health Syst Pharm* 2017;74:1533-40.
- **Dy-Boarman EA,** Bryant GA, Herring MS. Impact of debates on student perceptions and competency scores in the advanced pharmacy practice setting. *Curr Pharm Teach Learn* 2018;10:66-71.
- **Dy-Boarman EA, Nisly SA,** Costello TJ. It's no debate, debates are great. *Curr Pharm Teach Learn* 2018;10:10-3.
- Haack S, Fornoff A, Caligiuri F, **Dy-Boarman EA,** et al. Comparison of electronic versus paper rubrics to assess patient counseling experiences in a skills-based lab course. *Curr Pharm Teach Learn* 2017;9:1117-22.
- **Gibson CM,** Smith CB, Davis S, **Scalese MJ.** Assessment of apixaban prescribing patterns for nonvalvular atrial fibrillation in hospitalized patients. *Ann Pharmacother* 2018;52:54-9.
- **Hill LG.** Opioid harm reduction. *The Prescription Drug Abuse Epidemic: Incidence, Treatment, Prevention, and Policy.* Santa Barbara, CA: ABC-CLIO. In press.
- Han JK, **Hill LG,** Koenig ME, Das N. Naloxone counseling for harm reduction and patient engagement. *Fam Med* 2017;49:730-3.
- Jordan RP, Bratberg J, Congdon HB, Cross LB, **Hill LG,** et al. The report of the 2016-2017 advocacy standing committee. *Am J Pharm Educ* 2017;81:S10.
- **Nisly SA,** Kingdon LK, Janzen KM, Dy-Boarman EA. Using debates to mimic clinical discussion in experiential education. *Inov Pharm* 2017;8:9.
- **Rodriguez R,** Moody ML, Kelly BJ. A survey evaluating the training, responsibilities, and practices of pharmacy & therapeutics committee member and non-member contributors. *J Manag Care Pharm* 2017;23:868-74.

- Spencer S, Ipema H, Hartke P, Krueger C, **Rodriguez R**, Gross AE, Gabay MP. Intravenous push administration of antibiotics. *Hosp Pharm* 2018.
- Kido K, **Scalese MJ**. Management of oral anticoagulation therapy after gastrointestinal bleeding: whether to, when to, and how to restart an anticoagulation therapy. *Ann Pharmacother* 2017;51:1000-7.
- McGinn KA, Weigartz K, Lintner, **Scalese MJ**, Kahn SA. Nebulized heparin with N-acetylcysteine and albuterol reduces duration of mechanical ventilation in patients with inhalation injury. *J Pharm Pract* 2017.
- **Williams E**, Martin SL, Fabrikant A, Wang A, Pojasek M. Rates of depressive symptoms among pharmacy residents. *Am J Health Syst Pharm* 2018;75:292-7.

Other

- **Charles Seifert**: Promoted to Senior Executive Associate Dean.
- **Todd D. Sorensen**: Elected as American College of Clinical Pharmacy President-Elect.

Emergency Medicine PRN

Awards

- **Katelyn R. Dervay**: Pharmacist of the Year, Tampa General Hospital.
- **Megan A. Rech**: Star Research Award Certificate of Achievement, Society of Critical Care Medicine; Presidential Citation Award, Society of Critical Care Medicine.

Grants

- **Rachel Rafeq**: Grant from Camden County to develop a naloxone distribution program in the emergency department. This grant will allow for distribution of free naloxone kits and provide overdose education and information about resources straight in the ED for all patients who present with an overdose with or without family and friends who present with them.

Publications

- **Anderson PD**, Bokor G. Pharmacology. In: Ledford JK, Lens A, eds. *Principles and Practice in Ophthalmic Assisting: A Comprehensive Textbook*. Slack, Inc., 2017.
- **DeMott JM**, Hebert C, Novak M, Mahmood S, **Peksa GD**. Characteristics and resource utilization

of patients presenting to the emergency department from mass gathering events. *Am J Emerg Med* 2017. [Epub ahead of print]

- **DeMott JM**, Patel G, Lat I. Evaluating the effects of chronic antihypertensives on vasopressor dosing in septic shock. *Ann Pharmacother* 2018;52:40-7.
- **LaRue H**, **Peksa GD**, Shah S. A comparison of insulin doses for the treatment of hyperkalemia in patients with renal insufficiency. *Pharmacotherapy* 2017;37:1516-22.
- **Mah ND**, Birmingham AR, Bodkin RP, **Treu CN**, **Awad NI**, **Acquisto NM**. Sexually transmitted infection review for the acute care pharmacist. *J Pharm Pract* 2018. [Epub ahead of print]
- **Peksa GD**, Robbins MJ, Beyer AR, Weber EK, Johnson K. A calculation tool and process to preposition pharmaceuticals for anthrax post-exposure prophylaxis. *Health Secur* 2017;15:569-74.
- Gottlieb M, **Peksa GD**. Comparison of the loop technique with incision and drainage for soft tissue abscesses: a systematic review and meta-analysis. *Am J Emerg Med* 2018;36:128-33.
- Gottlieb M, **Peksa GD**, Pandurangadu AV, Nakitende D, Takhar S, Seethala R. Utilization of ultrasound for the evaluation of small bowel obstruction: a systematic review and meta-analysis. *Am J Emerg Med* 2018;36:234-42.
- **Rech MA**, Barbas B, Chaney W, Greenhalgh E, Turck C. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. *Ann Emerg Med* 2017;70:203-11.
- **Rech MA**, Bennett S, Donahey E. Pharmacist participation in acute ischemic stroke decreases door-to-needle time to tissue plasminogen activator. *Ann Pharmacother* 2017;51:1084-9.
- **Rech MA**, Mosier MJ, Zelisko S, Netzer G, Kovacs EJ, Afshar M. Comparison of a novel coding algorithm versus the American Burn Association sepsis definition to examine the epidemiology of sepsis in burn-injured adults. *J Burn Care Res* 2017;38:312-8.
- **Rech MA**, Von Roenn N, Durazo-Arvizu R, Cotler SJ, Kramer H. Vitamin D levels are associated with liver disease severity in patients with cirrhosis. *J Ren Hepat Disord* 2017;1:1-9.
- Kattub H, Sterk E, **Rech MA**, Bukar B, Khan S. Early recognition and treatment of sepsis after the addition of lactate to critical laboratory call list. *J Intensive Care Med* 2018;33:111-5.
- Patel GP, **Rech MA**. Anaphylaxis, allergies, angioedema, and acute CNS disorders. In: *Medical*

Problems in the ICU. Critical Care Self-Assessment Program. American College of Clinical Pharmacy, 2018.

- Shah T, Sterk E, **Rech MA**. Emergency department sepsis screening tool decreases time to antibiotics in patients with sepsis, *Am J Emerg Med* 2018. [Epub ahead of print]
- Wexler A, **Rech MA**. Case report: reversal of warfarin-associated life-threatening bleed with an attenuated dose of 4-factor prothrombin complex concentrate. *Ann Pharmacother* 2018;52:212-3.
- Wong A, Erdman M, Hammond D, Holt T, Holzhausen J, Horng M, Huang LL, Jarvis J, Kram B, Kram S, Lesch C, Mercer J, **Rech MA**, Rivosecchi R, Stump B, Teevan C, Day S. Major publications in the critical care pharmacotherapy literature: January 2015 – December 2015. *Am J Health Syst Pharm* 2017;74:295-311.
- Mo Y, **Thomas MC**, Antigua AD, Ebied AM, Karras GE. Continuous lidocaine infusion as adjunctive analgesia in intensive care unit patients. *J Clin Pharm* 2017;57:830-6.
- Mo Y, **Thomas MC**, Laskey CS, Scherbakova N, Bankert ML, Halloran RH. Current practice patterns in the management of alcohol withdrawal syndrome. *Pharm Ther* 2018;43:158-62.
- Mo Y, **Thomas MC**, Miano TA, Stemp LI, Bonacum JT, Hutchins K. Effect of modafinil on cognitive function in intensive care unit patients: a retrospective cohort study. *J Clin Pharm* 2018;58:152-7.
- Zimmermann AE, **Thomas MC**. Essential training, resources, and skills of 1st year and junior pharmacy practice faculty needed in the development of an individual research program. *J Pharm Pract* 2017. [Epub ahead of print]

Other Notable Achievements

- **Craig Cocchio**: Chair, Graduate Pharmacy Education Committee – CHRISTUS Health System; CHRISTUS Mother Frances Health System PGY2 expansion to two emergency medicine residents.
- **Joshua M. DeMott**: Completed M.Sc. degree at Rush University.
- **Donna M. Schuler**: Completed National Healthcare Disaster Professional Board Certification.
- **Michael C. Thomas**: Appointed to the Editorial Board for the *Journal of the American College of Clinical Pharmacy (JACCP)*.

Endocrine and Metabolism PRN

Introduction

The ENDO PRN's members are from a variety of practice settings. The PRN was formed to achieve the following goals and objectives: (1) provide an opportunity for pharmacists with an interest in endocrine and metabolism disorders to promote practice, research, and education in these areas; (2) provide a mechanism for members with similar interests to meet during ACCP meetings to network, problem solve, and discuss professional issues and opportunities; and (3) promote practice involvement; educational needs of health care professionals, students, and patients; and research activities in the areas of endocrinology and metabolism that may be favorably affected by this ACCP PRN effort. The PRN has kept its membership updated with the February newsletter and periodic posting to social media, including Facebook and Twitter. In addition, the PRN has maintained regular posts to the PRN blog (<https://endoprn.wordpress.com>).

Promotions

- **Andrew Bzowycykj**: Promoted to Clinical Associate Professor, Division of Pharmacy Practice & Administration
- **Lara C. Kerwin**: Assistant Professor of Pharmacy Practice, Division of Ambulatory Care – St. Louis College of Pharmacy

Awards

- **Maryam Fazell**: First-place poster for American College of Clinical Pharmacy Endocrine and Metabolism PRN Annual Meeting Walk-Rounds.
- **Jennifer Goldman**: Faculty Preceptor of the Year Award, MCPHS Biopharmaceutical Industry Fellowship Program.

Grants

- Infrastructural Support to Develop a Novel Vocational School for Street Youth. Amount: \$85,000. Source: Japanese Embassy. Project Team: Benjamin Link, **Sonak Pastakia**, Samuel Kimani, Benson Njuguna, Imran Manji, et al.
- Creation of Pharmacy Infrastructure in a Resource-Constrained Setting. Amount: \$165,000. Source: Celgene. Project Team: **Sonak Pastakia (PI)**, Imran Manji, Rakhi Karwa, et al.
- Strengthening Referral Networks for the Management of Hypertension Across the Health System (STRENGTHS) Trial. Amount: \$900,000.

Source: NIH. Investigators: Constantine Akwanalo (PI), Jemima Kamano (Co-I), **Sonak Pastakia (Co-I)**, et al.

- Community-Based Screening for Breast and Cervical Cancer in Rural Western Kenya. Amount: \$13,000. Source: Edmundsen Family Foundation Center. Investigators: **Sonak Pastakia (PI)**, Tina Tran, Daria Szkwarko, et al.

Presentations

- **Gupta V**, Viswesh V, Hincapie AL. Impact of supplemental experiential summits during advanced pharmacy practice experiences on student perceptions of preparedness to provide pharmaceutical care. Poster presented at: American Association of Colleges of Pharmacy Annual Meeting; July 16, 2017; Nashville TN.
- Hincapie AL, Penm J, Vargas C, Avila M, Rover M, Morales F, Villa L, Chinthammit C, **Gupta V**. Evaluating the evidence: a medication safety research: a Bibliometric Analysis of Latin America (LATAM) scientific research output (2000–2015). Poster presented at: International Pharmaceutical Federation (FIP) World Congress; August 28 – September 1, 2016; Buenos Aires.
- Hincapie AL, Penm J, Vargas C, Avila M, Rover M, Morales F, Villa L, Chinthammit C, **Gupta V**. Systematic review of medication errors in Latin America (LATAM). Poster presented at: International Pharmaceutical Federation (FIP) World Congress; August 28 – September 1, 2016; Buenos Aires.
- **Hanania R**, Reiter J. Diabetes management from hospital admission through post-discharge. Poster presented at: American Association of Diabetes Educators 2017 Conference; August 2017; Indianapolis, IN.
- Janke KK, **Kerwin LC**. An alternative to traditional student ratings of teaching for course CQI. Mini-session presented at: 2017 AACP Annual Meeting; July 2017; Nashville, TN.
- **Klinkebiel D**. You want me to start what? Tips & techniques to optimize education with today's diabetes medication choices. Presented at: Avera McKennan Diabetes Conference; Sioux Falls, SD.
- **Schumacher C**. Getting to goal: taking a patient-centered approach to diabetes management. Presented for continuing education credit at: 29th Annual Midwest ASCP Regional Conference; Oak Brook, IL.
- **Schumacher C**. Your P.O. plan: picking an oral agent after metformin in the treatment of diabetes.

Presented for continuing education credit to pharmacists, Midwestern University alumni, and preceptors at: Midwestern University's 6th Annual Updates in Diabetes Management and Chronic Care Topics; Downers Grove, IL.

- **Schumacher C, Bradley K, Van Dril L**. Don't miss a beat: an update on the cardiovascular outcomes trials (CVOTs) for newer antihyperglycemic agents. Presented for continuing education credit to pharmacists, Midwestern University alumni, and preceptors at: Midwestern University's 6th Annual Updates in Diabetes Management and Chronic Care Topics; Downers Grove, IL.
- **Schumacher C, Bradley K, Van Dril L**. Everything but the insulin workshop: non-insulin medications in the treatment of patients with diabetes. Presented for continuing education credit to pharmacists, Midwestern University alumni and preceptors at: Midwestern University's 6th Annual Updates in Diabetes Management and Chronic Care Topics; Downers Grove, IL.

Publications

- **Bzowyckyj AS**, Brommelsiek M, Lofgren M, Gotham HJ, Lindsey CC. Reflecting on care: using reflective journaling to evaluate interprofessional education and clinical practicum experiences in two urban primary care clinics. *J Interprof Educ Pract* 2017;8:6-9.
- Janke KK, **Bzowyckyj AS**, Traynor AP. Editors' perspectives on enhancing manuscript quality and editorial decisions through peer review and reviewer development. *Am J Pharm Educ* 2017;81:Article 73.
- Karter AJ, Kasia J, Lipska KJ, O'Connor PJ, Liu JY, Moffet HH, Schroeder EB, Lawrence JM, Nichols GA, Newton KN, Pathak RD, Desai J, Waitzfelder B, **Butler MG**, Thomas A, Steiner JF on behalf of the SUPREME-DM Study Group. High rates of severe hypoglycemia among African American diabetes patients: the Surveillance, Prevention, and Management of Diabetes Mellitus (SUPREME-DM) Network. *J Diabetes Complicat* 2017;31:869-73.
- Trivedi M, Li L, Fung V, Kharbanda EO, Larkin EK, **Butler MG**, Horan K, Lieu TA, Wu AC. Racial disparities in family-provider interactions for pediatric asthma care. *J Asthma* 2017;14:1-6. [Epub ahead of print]
- **Donihi AC**. Practical recommendations for transitioning patients with type 2 diabetes from hospital to home. *Curr Diab Rep* 2017;17:52.

- **Fazel MT**, Bagalagel A, Lee JK, Martin JR, Slack MK. Impact of diabetes care by pharmacists as part of health care team in ambulatory settings: a systematic review and meta-analysis. *Ann Pharmacother* 2017;51:890-907.
- **Fazel MT**, Fazel M, Bedrossian NL, Picazo F, Sobel JD, Fazel M, Te C, Pendergrass ML. Impact of supplemental training programs on improving medical students' confidence in providing diabetes self-management education and support. *Adv Med Educ Pract* 2017;8:675-80.
- **Fazel MT**, Jedlowski PM, Cravens RB Jr, Erstad BL. Evaluation and treatment of acute and subacute hearing loss: a review of pharmacotherapy. *Pharmacotherapy* 2017;37:1600-16.
- **Fazel MT**, Pendergrass ML. Individualizing treatment of hyperglycemia in type 2 diabetes – clinical review. *J Clin Outcomes Manage (JCOM)* 2017;24:23-38.
- Alfayez OM, Al Yami MS, **Fazel MT**. The impact of pharmacists providing direct patient care as members of interprofessional teams on diabetes management. *Saudi Pharm J* 2017;25:1019-21.
- **Goldman JD**, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. *Curr Med Res Opin* 2017. [Online ahead of print]
- **Goldman JD**, Trujillo J. iGlarLixi: a fixed-ratio combination of insulin glargine 100U/ml and lixisenatide for the treatment of type 2 diabetes. *Ann Pharmacother*. Published online ahead of print June 2017.
- Dvorkin Camiel L, Kostka-Rokosz M, Tataronis G, **Goldman JD**. Performance and perceptions of student teams created and stratified based on academic abilities. *AJPE* 2017;81:1-7. Article 47.
- Taglieri C, Schnee D, Dvorkin Camiel L, Zaiken K, Mistry A, Nigro S, Tataronis G, Patel D, Jacobson S, **Goldman JD**. Comparison of long-term knowledge retention in lecture-based versus flipped team-based learning course delivery. *Curr Pharm Teach Learn* 2017;9:391-7.
- Trujillo J, **Goldman JD**. Lixisenatide, a once daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes. *Pharmacotherapy* 2017. [Online ahead of print]
- Valentine V, **Goldman JD**, Shubrook J. Rationale for initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and iGlarLixi, for the management of type 2 diabetes. *Diabetes Ther*. Published online ahead of print July 2017.
- **Gupta V**. Hypertension. APhA Pharmacy Library. *Pharmacotherapy First: A Multimedia Learning Resource*. Published May 2017. (Online book chapter)
- Hincapie AL, Brown SA, **Gupta V**, Metzger A. Exploring perceived barriers to medication adherence and the use of mobile technology in underserved patients with chronic conditions. *J Pharm Pract* 2017.
- Viswesh V, Yang H, **Gupta V**. Evaluation of a modified debate exercise adapted to the pedagogy of team-based learning. *Am J Pharm Educ* 2017; ajpe6278.
- **Hurren KM**, Dunham MW. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. *Expert Opin Drug Metab Toxicol* 2017;13:891-6.
- **Minze M**, Dillinger K. Chapter 64: Vaccinations. In: Koda-Kimble MA, Young LY, eds. *Applied Therapeutics: The Clinical Use of Drugs*, 11th ed. Philadelphia: Lippincott, Williams & Wilkins, 2017.
- **Minze MG, Will K, Terrell BT, Black RK, Irons BK**. Benefits of SGLT2 inhibitors beyond glycemic control – a focus on metabolic, cardiovascular, and renal outcomes. *Curr Diabetes Rev* 2017. [Epub ahead of print]
- **Pastakia SD**, Njuguna BN, Onyango BA, Washington S, Christofferson-Deb A, Kosgei W, Saravanan P. Prevalence of gestational diabetes mellitus based on various screening strategies in western Kenya: a prospective comparison of point of care diagnostic methods. *BMC Pregnancy Childbirth*. In press.
- **Pastakia SD**, Pekny CR, Manyara SM, Fischer L. Review of diabetes in sub-Saharan Africa, from policy to practice to progress: targeting the existing gaps for future care for diabetes. *Diabetes Metab Syndr Obes* 2017;10:247-63.
- Atun R, Davies J, Gale EAM, **Pastakia SD**, et al. Diabetes in sub-Saharan Africa; from clinical care to health policy. *Lancet Diabetes Endocrinol*. [http://dx.doi.org/10.1016/S2213-8587\(17\)30181-X](http://dx.doi.org/10.1016/S2213-8587(17)30181-X).
- Vedanthan R, Kamano JH, Lee H, **Pastakia SD**, et al. Bridging income generation with group integrated care (BIGPIC) for cardiovascular risk reduction: rationale and design of the BIGPIC study. *Am Heart J* 2017;188:175-85.

- **Whitley HP**, Hanson C, Parton JM. Systematic diabetes screening using point-of-care HbA1c testing facilitates identification of prediabetes. *Ann Fam Med* 2017;15:162-4.

New ACCP Fellows

- **Jennifer Clements**
- **Sonak Pastakia**

Other Notable Achievements

- **Carol Bowden**: Completed the Merck Fellowship for Global Health at the Centro de Investigacao em Saude de Manhica (CISM) in Manhica, Mozambique.
- **Liz Van Dril**: BCPS certification.
- **Diana Isaacs**: Became a certified pump trainer for the Medtronic 670G, hybrid closed-loop system.
- **Drew Klinkebiel**: BCACP certification.
- **Anne Misher**: BCACP and BC-ADM certifications.
- **Sonak Pastakia**: Completed a Ph.D. degree from the University of Warwick, UK.
- **Sara (Mandy) Reece**: Fellow, AADE.
- **Megan Wesling**: BCPS certification.

Presentations

- Williams E, **Gupta V**. Clinical trial design and biostatistics: what do I really need to know? CSHP/ NVSHP Annual Seminar; October 2017; Las Vegas, NV.
- **Isaacs D, Bzowjckyj A**, Stamm P. The hyper in hyperglycemia: current considerations in drug selection. ASHP Midyear Clinical Meeting; December 2–6, 2017; Orlando, FL.
- **Karr S, Kelley K**, Hartzler M. Managing prediabetes: beyond the basics. ASHP Midyear Clinical Meeting; December 2–6, 2017; Orlando, FL.
- Janke KK, **Kerwin LC**. An alternative to traditional student ratings of teaching for course CQI. Mini-Session. 2017 AACP Annual Meeting; July 2017; Nashville, TN.
- **Klinkebiel D**. You want me to start what? Tips & techniques to optimize education with today's diabetes medication choices. Avera McKennan Diabetes Conference; Sioux Falls, SD.
- **Schumacher C**. Getting to goal: taking a patient-centered approach to diabetes management. 29th Annual Midwest ASCP Regional Conference; Oak Brook, IL.

- **Schumacher C**. Your P.O. plan: picking an oral agent after metformin in the treatment of diabetes. Midwestern University's 6th Annual Updates in Diabetes Management and Chronic Care Topics; Downers Grove, IL.
- **Schumacher C, Bradley K, Van Dril L**. Don't miss a beat: an update on the cardiovascular outcomes trials (CVOTs) for newer antihyperglycemic agents. Midwestern University's 6th Annual Updates in Diabetes Management and Chronic Care Topics; Downers Grove, IL.
- **Schumacher C, Bradley K, Van Dril L**. Everything but the insulin workshop: non-insulin medications in the treatment of patients with diabetes. Midwestern University's 6th Annual Updates in Diabetes Management and Chronic Care Topics; Downers Grove, IL.
- Seckel E, Riche D, **Schumacher C**, Vest K, Homsted F. Engage with your learners: it's time for pharmacy preceptors phamily pheud! ASHP Midyear Clinical Meeting; December 2–6, 2017; Orlando, FL.

Poster Presentations

- Alshehri AA, Slack M, Valencia J, **Fazel MT**. Joint pharmacist-physician visit billing model and its impact on charges for pharmacist services. 2017 American College of Clinical Pharmacy Annual Meeting; September 7–10, 2017; Phoenix, AZ.
- **Gupta V**, Viswesh V, Hincapie AL. Impact of supplemental experiential summits during advanced pharmacy practice experiences on student perceptions of preparedness to provide pharmaceutical care. AACP Annual Meeting; July 16, 2017; Nashville, TN.
- Hincapie AL, Penm J, Vargas C, Avila M, Rover M, Morales F, Villa L, Chinthammit C, **Gupta V**. Evaluating the evidence of a medication safety research: a bibliometric analysis of Latin America (LATAM) scientific research output (2000-2015). International Pharmaceutical Federation (FIP) World Congress; August 28 – September 1, 2016; Buenos Aires.
- Hincapie AL, Penm J, Vargas C, Avila M, Rover M, Morales F, Villa L, Chinthammit C, **Gupta V**. Systematic review of medication errors in Latin America (LATAM). International Pharmaceutical Federation (FIP) World Congress, August 28 – September 1, 2016, Buenos Aires.
- **Hanania R**, Reiter J. Diabetes management from hospital admission through post-discharge. AADE 2017 conference; August 2017; Indianapolis, IN.

- Sutton C, **Misher A**. Impact of pharmacy diabetes management service on patient outcomes. ASHP Midyear Clinical Meeting; December 2–6, 2017; Orlando, FL.
- **Van Dril E, Wesling M, Schumacher C, dela Pena L, Borchert J**. Advocating for the pharmacy profession through involvement in a type 1 diabetes day camp as a postgraduate year 2 pharmacy residency learning experience. ASHP Midyear Clinical Meeting; December 2–6, 2017; Orlando, FL.

Geriatrics PRN

Introduction

The Geriatrics PRN looks forward to a successful 2018 ACCP Annual Meeting and the installation of new officers. The PRN is proud of its members' recent accomplishments.

Promotions

- **Jack J. Chen**: Senior Associate Dean of Academic Affairs, School of Pharmacy, American University of Health Sciences.
- **Greg Hughes**: Secondary appointment as Assistant Professor, Department of Medicine with the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
- **Mary Beth O'Connell**: Full Professor at Wayne State University.

Awards

- **Heather Sakely**: Pennsylvania Geriatric Society – Western Division, Geriatric Teacher of the Year Award for Healthcare Professionals.
- **Anne Williams**: PQA-CVS Academic Scholar Award.

Grants

- **Emily Peron**: Promoting Art for Life Enrichment Through Transgenerational Engagement: PALETTE at VCU. Commonwealth of Virginia Geriatric Training and Education Initiative Award Fund. Amount awarded: \$23,998. Funding period: 12/5/2017 – 06/30/2018. Role: PI.

Publications

- **Askins Bailey T, Panjwani S**. Atypical antipsychotics in late-life and treatment resistant depression. *Consult Pharm* 2018;33:83-8.
- **Chen JJ**. Pharmacotherapeutic management of pseudobulbar affect. *Am J Manag Care* 2017;23(18 suppl):S345-S350.

- **Chen JJ**. Treatment of psychotic symptoms in patients with Parkinson disease. *Ment Health Clin* 2017;262-70.
- **Chen JJ, Hewitt LA**. Comparison of the pharmacokinetics of droxidopa after dosing in the fed versus fasted state and with 3-times-daily dosing in healthy elderly subjects. *Drugs R D* 2018. <https://doi.org/10.1007/s40268-018-0226-z>.
- Haines SL, Dy-Boarman EA, **Clifford KM**, Summa MA, Willson MN, Boyle JA, Peeters MJ. Methods used by US colleges/schools of pharmacy to prepare student pharmacists for careers in academia. *Am J Pharm Educ* 2017;81:6.
- Haines SL, Summa MA, Peeters MJ, Dy-Boarman EA, Boyle JA, **Clifford KM**, Willson MN. Toolkit for US colleges/schools of pharmacy to prepare student pharmacists for careers in academia. *Curr Pharm Teach Learn* 2017;9:750-62.
- Wagner JL, **Clifford KM**. Successful stewardship in long-term care facilities. *Contagion* 2018;3:20-1.
- **Hughes GJ**, Lee R, Sideras V. Delivering clinical pharmacokinetics – curriculum and content in colleges of Pharmacy. *Am J Pharm Educ* 2018. [Epub ahead of print]
- Goldin M, **Hughes GJ**, Choudhary Z, Tariq S, Shafeeq H, Cohen J. Reversal of anticoagulation: therapeutic advances and clinical guidelines. *Am J Ther* 2018;25:e44-52.
- Ma AH, **Hughes GJ**. Updates in management of complicated urinary tract infections: a focus on multidrug-resistant organisms. *Am J Ther* 2018;25:e53-66.
- **Kaufman MB**. Pharmaceutical Approval Update. *P T* 2018;43:141-2 (March). Approvals include: Zoster Vaccine Recombinant, Adjuvanted (Shingrix), Angiotensin II Injection (Giapreza), and Glycopyrrolate Inhalation Solution (Lonhala Magnair).
- **Kaufman MB**. Pharmaceutical Approval Update. *P T* 2018;43:83-4 (February). Approvals include: Benznidazole, Vestronidase Alfa-vjvk (Mepsevii), and Hepatitis B Vaccine (recombinant) adjuvanted (Heplisav-B).
- **Kaufman MB**. Pharmaceutical Approval Update. *P T* 2018;43:22, 23, 60 (January). Approvals include: Latanoprostene Bunod Ophthalmic Solution (Vyzulta), Letermovir (Prevymis), and Benralizumab (Fasenra).
- **Kaufman MB**. Pharmaceutical Approval Update. *P T* 2017;733-4, 755 (December). Approvals include: Secnidazole Oral Granules (Solosec),

Triamcinolone Acetonide Extended-Release Injection (Zilretta) and Insulin Aspart Injection (Fiasp).

- **Kaufman MB.** Pharmaceutical Approval Update. P T 2017;42:673-4, 683 (November). Approvals include: Aminolevulinic acid HCl (Gleolan), Delafloxacin (Baxdela), and Glecaprevir/Pibrentasvir (Mavyret).
- **Kaufman MB.** Pharmaceutical Approval Update. P T 2017;42:620-1 (October). Approvals include: Endari (L-glutamine oral powder), Radicava (edaravone), and Rydapt (midostaurin).
- **Kaufman MB.** Pharmaceutical Approval Update. P T 2017;42:562-3, 580 (September). Approvals include: Kevzara (sarilumab), Ingrezza (valbenazine tosylate), and Bineura (cerliponase alpha).
- **Kaufman MB.** Bimekizumab improves joint & skin symptoms in PsA Patients Plus EU approves certolizumab pegol for pregnant & nursing patients. Rheumatologist 2018;12:80.
- **Kaufman MB.** Bimekizumab improves joint & skin symptoms in PsA Patients Plus EU approves certolizumab pegol for pregnant & nursing patients. Rheumatologist 2018;12:80.
- **Kaufman MB.** Bisphosphonate Drug Holidays & Hip Fracture Risk Plus updates on golimumab & ustekinumab. Rheumatologist 2017;11:76.
- **Kaufman MB.** Efficacy studied following accelerated Drug Approvals Plus secukinumab meets 5-year benchmark for psoriasis. Rheumatologist 2017;11:56.
- **Kaufman MB.** Biosimilar to adalimumab receives FDA Approval Plus updates on baricitinib, tofacitinib & bimekizumab. Rheumatologist 2017;11:84
- **Kaufman MB.** Abatacept approved for active psoriatic arthritis in Adults Plus sirukumab approval stalls. Rheumatologist 2017;11:52.
- **Kaufman MB.** Opana ER Pulled from U.S. Market Plus upadacitinib, abatacept, topical diclofenac sodium & more. Rheumatologist 2017;11:56.
- **Lockman K, Haines ST, McPherson ML.** Improved learning outcomes after flipping a therapeutics module: results of a controlled trial. Acad Med 2017;92:1786-93.
- **Sunilkumar MM, Lockman K.** Practical pharmacology of methadone: a long-acting opioid. Indian J Palliat Care 2018;24:10-4.
- **Rubin SE, Peron EP, Gendron TL.** Making the case for transgenerational learning. JIR 2017;16:139-45.

- **Triantafylidis LK, Clemons JS, Peron EP, Roefaro J, Zimmerman K.** Brain over bladder: a systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging 2018;35:27-41.
- **Haver A, Sakely H, Somma McGivney M, Thorpe C, Corbo J, Cox-Vance L, Klatt P, Schleiden L, Balestrino V, Coley K.** Geriatrics care team perceptions of pharmacists caring for older adults across health care settings. Ann Long Term Care 2017;25:20-6.
- **Vouri SM, Reckenburg KA.** Drug-induced adverse events and prescribing cascades in older adults: pharmacy stakeholder survey. Inov Pharm 2017;8:Article 19.
- **Vouri SM, Schootman S, Strobe SA, Birge SJ.** Differential prescribing of antimuscarinic agents in older adults with cognitive impairment. Drugs Aging 2018. In press.
- **Kebodeaux CD, Peters GL, Stranges PM, Woodyard JL, Vouri SM.** Faculty percept of team-based learning over multiple semesters. Curr Pharm Teach Learn 2017;9:1010-5.
- **Somerville E, Massey K, Keglovits M, Vouri SM, Hu YL, Carr D, Stark S.** Scoring, clinical utility and psychometric properties of the In-Home Medication Management Evaluation. Am J Occup Ther 2017. In press.

Other Notable Achievements

- **Judy Beizer:** Elected to serve a second term as part of the AGS Nominations Committee.
- **Kalin Clifford:** Invited to serve on AMDA's Common Infections in Older Adults Guideline Writing Committee.
- **Christine Eisenhower:** Accepted into the JAGS Junior Reviewer Program (11/2017).
- **Andrea Leschak:** BCGP.
- **Emily Peron:** BCGP.
- **Anne Williams:** Matched for a 2-year Family Medicine/Ambulatory Care Residency and Faculty Development Fellowship at UPMC St. Margaret.

Poster Presentations

- **Eisenhower C.** MeRIT project: pharmacist-initiated optimization of inhalers in high-risk, older adults with COPD. 2017 American College of Clinical Pharmacy Annual Meeting.
- **Nardolillo J, Eisenhower C, Rumanowski A, Ingemi A, Charpentier M.** The importance of a pharmacist on interprofessional global medical brigades. ASHP Midyear Clinical Meeting and Exhibition; 2017.

- Wildes TM, Corder T, Hungerford J, Coyne T, Arnold C, Tymkew H, **Vouri SM**, Keglovits M, Somerville E, James A, Stark S, Clemson L. Adaption of the fall prevention intervention STEPPING ON for older adults with cancer. International Society of Geriatric Oncology 17th Annual Conference; Warsaw, Poland.

GI/Liver/Nutrition PRN

Introduction

The GILN PRN would like to congratulate its members on their exceptional accomplishments from September 2017 to February 2018. Way to go and keep up the good work! Keep updated on new articles, professional meeting highlights, and discussions on the PRN's Facebook page.

We hope to see you at the ACCP Annual Meeting if you plan to attend. Focus session planning is under way, and we are excited to bring new updates to the organization that cover all three therapeutic areas.

Publications

- **Al-Zeidaneen SA**. Medical-nutritional intervention in a Jordanian child with glycogen storage disease type IIIA. *EJBPS* 2017;4(8).
- **Al-Zeidaneen SA**, Ahmed MN, Al-Ebuose A, Hamad AR. Interactive role of obesity indices on breast cancer severity in Jordanian women. *EJBPS* 2017;4(6).
- Al-Zeidaneen SA, Al-Bayyari NS, Al-Zidaneen MA. The impact of maternal employment on infant weight, length and BMI based on WHO growth chart standard for age z-score. *Int J Child Health Nutr* 2017;6(3).
- **Al-Zeidaneen SA**, Al-Bayyari NS, Ismail Y. Effect of physical activity and gender on malnutrition risk among a group of elderly Jordanian people. *Pakistan J Nutr* 2017;16(9).
- Al-Bayyari N, Saadeh N, Hailat R, **Al-Zeidaneen SA**. Assessment of atorvastatin effect on body weight and blood glucose levels among diabetic and non-diabetic patients. *Romanian J Diabetes Nutr Metab Dis* 2017;24(3).
- **Andres J**, Lott S, Qureshi K. Eight-week outcomes of ledipasvir/sofosbuvir in noncirrhotic treatment-naive patients with hepatitis C: analysis of pharmacy-based data. *J Manag Care Spec Pharm* 2018;24:23-8.
- Calabrese MJ, **Hynicka LM**, de Bittner MR, Shaya FT. Future considerations for the evaluation of

hepatitis c virus treatments in pan-genotypic therapy for noncirrhotic treatment-naïve patients. *J Manag Care Spec Pharm* 2018;24:20-2.

- **Martin MT**, Chen Y, Rosenfeld D, Lee TA, Koppe S. Evaluation of a diverse patient population's sustained virologic response rates after hepatitis C virus treatment at an urban academic medical center with an interdisciplinary team including a clinical pharmacist. Meeting Abstract 1550. *Hepatology* 2017;66:828A.
- **Martin MT**, Deming P. Closing the gap: the challenges of treating genotype 3 hepatitis C virus. *Pharmacotherapy* 2017;37:735-47.
- **Martin MT**, Koppe S. Elbasvir/grazoprevir use in post-liver transplantation patients on hemodialysis. *Transplantation* 2017;101:2088-91.
- **Martin MT**, Rosenfeld D, Lee TA. Comparison of sustained virologic response rates after hepatitis C virus treatment in patients with advanced fibrosis or cirrhosis at an urban academic medical center. Meeting Abstract 215. *Pharmacotherapy* 2017;37:E184-E185.
- Isho NY, Kachlic M, Marcelo J, **Martin MT**. Pharmacist-initiated hepatitis C virus screening in an outpatient pharmacy to increase awareness and link to care at the medical center. *J Am Pharm Assoc* 2017;57:S259-S264.
- Molino S, **Martin MT**. Hepatitis C virus resistance testing in genotype 1: the changing role in clinical utility. *Ann Pharmacother* 2017;51:811-6.
- Sapir T, Brau N, Mera J, Martinez AD, Litwin AH, **Martin MT**, Pardo CO, Simone L, Moreo K. Healthcare provider and payer perceptions of optimism, challenges, and strategies for achieving national goals for hepatitis C virus elimination. Meeting Abstract 590. *Hepatology* 2017;66:322A.
- Holcombe B, Mattox TW, **Plogsted S**. Drug shortages: effect on parenteral nutrition therapy. *Nutr Clin Pract* 2018;33:53-61.

Grants

- Martin MT, Koren D, Teply R, Zuckerman A. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model. Funding period: 12/2017 – 11/2018.

New ACCP Fellows

- **Michelle T. Martin**
- **Emma Tillman**

Other Notable Achievements

- **Michelle T. Martin:** Editorial Board for the *Journal of the American College of Clinical Pharmacy (JACCP)*.

Awards

- **Katherine H. Chessman:** American College of Clinical Pharmacy Pediatrics PRN Outstanding Practitioner Award.

Global Health PRN

Awards

- **Gina M. Prescott:** Pharmacist of the Year, Tampa General Hospital.

Publications

- **Park P, Pastakia SD.** Access to hemoglobin A1c in rural Africa; a difficult reality with severe consequences. *J Diabetes Res* 2018. In press.
- **Prescott GM, Nobel A.** A multi-modal approach to teaching cultural competency in the doctor of pharmacy curriculum. *AJPE*. Published online (29 Nov 2017), ahead of print.
- **Prescott GM, Patzke CL, Brody PM Jr, Prescott WA Jr.** Comparison of prescribing patterns between United States and Dominican Republic prescribers on short-term medical mission trips. *Int Health* 2017 December 22. <https://doi.org/10.1093/inthealth/ihx045>.

Local Continuing Education

- Pharmaceutical considerations for culturally diverse patients. Primary Care Update Conference. Millennium Hotel Buffalo; January 2018; Buffalo, NY.
- **Sonak Pastakia:** Jefferson Science Fellow; USAID Africa Bureau Health Team for Sustainable Development, Eldoret, Kenya.

Grants

- **Melanie Nichol:** Evaluating Antiretroviral Pharmacology in the Female Genital Tract to Optimize HIV Prevention. NIH NIAID: K08 Mentored Clinical Scientist Research Career Development Award. Role: PI \$784,480 direct/\$62,531 indirect. Funding period: 2/2018 – 1/2023.

Publications

- **Nicol MR, Brewers LM, Kashuba ADM, Sykes DC.** Role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. *AIDS* 2018;32:11-5.

Presentations

- **Japs K.** Sources of drug information in neonatal guidelines of low- and middle-income countries. Western States Conference; May 22, 2018; San Diego, CA.
- **Japs K.** Sources of drug information in neonatal guidelines of low- and middle-income countries. University of California Collaborative Annual Pharmacy Leadership Forum; June 6, 2018.

Program Completions

- **Kelsey Japs:** UCSF Global Health Clinical Scholars Pathway in July.

Health Outcomes PRN

Publications

- **Nguyen E, Coleman CI, Nair S, Weeda ER.** Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. *J Diabetes Complicat* 2018;32:210-5.
- Coleman CI, Vaitiakhovich T, **Nguyen E, Weeda ER, Sood NA, Bunz TJ, et al.** Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. *Clin Cardiol* 2018;41:119-25.
- Smith N, Finn M, **Segars L, Burns E, Peterson J, Sutton A, Menser M.** Melanoma and medical education: knowledge and sun safety practices amongst medical students. *Our Dermatology Online* 2018;9:11-4.
- **Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake K, Lang JE.** Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control and other clinical outcomes in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. *JAMA* 2018.
- **Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, Blake K, Lang JE, Baker WL.** Association of combined use of inhaled corticosteroids and long-acting beta agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. *JAMA* 2018.
- **Weeda ER, Caranfa JT, Zeichner SB, Coleman CI, Nguyen E, Kohn CG.** External validation of generic and cancer-specific risk stratification tools in patients with pulmonary embolism and active cancer. *J Natl Compr Cancer Netw* 2017;15:1476-82.

- White CM, **Weeda ER**, **Nguyen E**. Should an LDL-cholesterol target-based approach be readopted? *Ann Pharmacother* 2018;52:175-84.

Hematology/Oncology PRN

Introduction

The HMON PRN continues to provide a forum for hematology/oncology pharmacists to network and collaborate on scientific, educational, and political issues affecting clinical practice, teaching, and research. The PRN has 792 members, with trainees (students and residents) making up almost 50% of its membership.

At the 2017 ACCP Annual Meeting in Phoenix, the PRN hosted resident and student travel awardees. Because of the increase in student membership and the desire for more opportunities to connect, the second half of the PRN meeting served as a networking session focused on clinical and research activities of the membership. One of the requests made to the PRN was to increase the amount of student involvement; therefore, the PRN has created new activities geared toward trainees. The PRN has also formed a committee within, which includes trainees, to help PRN officers complete their initiatives. The PRN has plans to donate to the Frontiers Fund, and nominations for 2018 awards have been submitted. Plans for PRN collaboration are under way for the 2018 PRN focus session.

Publications

- Seddon AN, Chaim J, Aking O, **Adel N**, et al. Similar incidence of typhilitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. *Leukemia Research*. 2018.
- **Afanasjeva J**. Administration of injectable vitamin K orally. *Hosp Pharm* 2017;52:645-9.
- Chair KW, **Aistrope DS**, Ausili J, et al. The report of the 2016-2017 professional affairs standing committee: formally embracing and engaging preceptors in the academy-the time has come. *Am J Pharm Educ* 2017;81:S16.
- **Avila JA**, Alliger AA, Carvajal B, et al. Estradiol rapidly increases GluA2-mushroom spines and decreases GluA2-filopodia spines in hippocampus CA1. *Hippocampus* 2017;12:1224-9.
- **Avila JA**, Zanca RM, Shor D, et al. Chronic voluntary oral methamphetamine induces deficits in spatial learning and hippocampal protein kinase Mzeta with enhanced astrogliosis and cyclooxygenase-2 levels. *Heliyon* 2018;4:e00509.
- **Barreto JN**, McCullough KB, Peskey CS, et al. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. *Leuk Lymphoma* 2017;58:2588-97.
- Leung JG, **Barreto JN**, Thompson CA. Lymphoma following clozapine exposure: more information needed. *Schizophr Res* 2018.
- Yemm KE, **Barreto JN**, Mara KC, Dierkhising RA, Gangat N, Tosh PK. A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia. *J Antimicrob Chemother* 2017;73:204-11.
- Weil AJ, Masters ET, Barsdorf AI, **Bass A**, et al. Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain. *Health Qual Life Outcomes* 2017;15(1).
- Hwang MF, **Beechinor RJ**, Wade KC, et al. External evaluation of two fluconazole infant population pharmacokinetic models. *Antimicrob Agents Chemother* 2017;61(12).
- Puri S, Hyland KA, Weiss KC, **Bell GC**, et al. Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. *Support Care Cancer* 2018. [Epub ahead of print]
- Vo TT, **Bell GC**, Obeng AO, Hicks JK, Dunnenberger HM. Pharmacogenomics implementation: considerations for selecting a reference laboratory. *Pharmacotherapy* 2017;37:1014-22.
- Sigler M, Leal JE, **Bliven K**, Cogdill B, Thompson A. Assessment of appropriate antibiotic prescribing for urinary tract infections in an internal medicine clinic. *South Med J* 2015;108:300-4.
- Bryk A, Koontz S, Mayor J, Betcher J, Tombleson R, **Bookout R**, Saunders IM. Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists. *J Oncol Pharm Pract*. May 2017.
- Chen L, **Brown J**, Marmaduke DQ, et al. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database. *Support Care Cancer* 2018.
- **Bubalo J**. Managing the mental distress of the hematopoietic stem cell transplant (HSCT) patient: a focus on delirium. *Curr Hematol Malig Rep* May 2018.

- **Bubalo J**, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz R. A randomized, placebo-controlled pilot trial of aprepitant combined with standard anti-emetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). *Bone Marrow Transplant* 2018.
- **Bubalo JS**, Herrington JD, Takemoto M, et al. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. *Support Care Cancer* 2017;26:1273-9.
- Horvat TZ, Seddon AN, Ogunniya A, King AC, **Buie LW**, Daley RJ. The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia. *Ann Pharmacother* 2018;52:268-76.
- **Cass AS**, Alese JT, Kim C, Curry MA, LaFollette JA, Chen Z, Alese OB. Analysis of opioid use following curative cancer treatment at a large urban safety-net hospital. *Clin J Pain* 2018 Mar 23. [Epub ahead of print]
- **Chan A**, Abdullah MM, Ishak WZBW, Ong-Cornel AB, Villalon AH, Kanessvaran R. Applicability of the National Comprehensive Cancer Network/ Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: a consensus statement. *J Glob Oncol* 2017;3:801-13.
- **Chan A**, Lew C, Wang XJ, Ng T, Chae JW, Yeo HL, Shwe M, Gan YX. Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory-Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. *Health Qual Life Outcomes* 2018;16:20.
- **Chan A**, Ngai GH, Chung WL, Yeo A, Ng T, Loh KW, Farid M, Lim SY, Fok R. Practitioners' perspectives on community-based breast cancer survivorship care in Singapore: a focus group study. *Health Soc Care Community* 2017 Dec 15. [Epub ahead of print]
- **Chan A**, Yo TE, Wang XJ, Ng T, Chae JW, Yeo HL, Shwe M, Gan YX. Minimal clinically important difference of the multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for fatigue worsening in Asian breast cancer patients. *J Pain Symptom Manage* 2018;55:992-997.e2.
- Chae JW, Chua PS, Ng T, Yeo AHL, Shwe M, Gan YX, Dorajoo S, Foo KM, Loh KW, Koo SL, Chay WY, Tan TJY, Beh SY, Lim EH, Lee GE, Dent R, Yap YS, Ng R, Ho HK, **Chan A**. Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. *Breast Cancer Res Treat* 2018;168:713-21.
- Chong MF, **Chan A**. Thalidomide for delayed chemotherapy-induced nausea and vomiting: where is its place in therapy? *J Clin Oncol* 2018;36:827-8.
- Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, **Chan A**. Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. *Psychooncology*. 2018 Jan 9. [Epub ahead of print]
- Ng T, Lee YY, Chae JW, Yeo AHL, Shwe M, Gan YX, Ng RCH, Chu PPY, Khor CC, Ho HK, **Chan A**. Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. *BMC Cancer* 2017;17:867.
- Tan SH, Kng KK, Lim SM, **Chan A**, Loh JKK, Lee JY. Long-term clinical and cost outcomes of a pharmacist-managed risk factor management clinic in Singapore: an observational study. *Clin Ther* 2017;39:2355-65.
- Wang XJ, Tan TT, Lim ST, Farid M, Tao M, Quek R, **Chan A**, Tang T. Role of procalcitonin in differentiating between infectious and noninfectious fevers among patients with lymphoma. *Pharmacotherapy* 2017;37:908-15.
- Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, **Chan A**. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: an observational study. *J Oncol Pharm Pract* 2018 Jan 1. [Epub ahead of print]
- Leyden J, Pavlakis N, **Chan D**, Michael M, Clarke S, Khasraw M, Price T. Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. *Asia Pac J Clin Oncol* 2017 Nov 6. [Epub ahead of print]
- Powell AGMT, Parkinson D, Patel N, **Chan D**, Christian A, Lewis WG. Prognostic significance of serum inflammatory markers in gastric cancer. *J Gastrointest Surg* 2018;22:595-605.
- **Chan DL**, Dixon M, Law CHL, Koujanian S, Beyfuss KA, Singh S, Myrehaug S, Hallet J. Outcomes of cytoreductive surgery for metastatic low-grade

neuroendocrine tumors in the setting of extrahepatic metastases. *Ann Surg Oncol* 2018 Mar 20. [Epub ahead of print]

- **Chan DL**, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): a practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS). *Neuroendocrinology* 2018 Mar 14. [Epub ahead of print]
- **Chan DL**, Singh S. Developments in the treatment of carcinoid syndrome – impact of telotristat. *Ther Clin Risk Manag* 2018;14:323-9.
- Chi W, Warner RRP, **Chan DL**, Singh S, Segelov E, Strosberg J, Wisnivesky J, Kim MK. Long-term outcomes of gastroenteropancreatic neuroendocrine tumors. *Pancreas* 2018;47:321-5.
- Singh S, **Chan DL**, Moody L, Liu N, Fischer HD, Austin PC, Segelov E. Recurrence in resected gastroenteropancreatic neuroendocrine tumors. *JAMA Oncol* 2018 Mar 15. [Epub ahead of print]
- Chio CC, Hsu CC, Tian YF, Wang CH, Lin MT, **Chang CP**, Lin HJ. Combined hemorrhagic shock and unilateral common carotid occlusion induces neurological injury in adult male rats. *Int J Med Sci* 2017;14:1327-34.
- Chou W, Liu YF, Lin CH, Lin MT, Chen CC, Liu WP, **Chang CP**, Chio CC. Exercise rehabilitation attenuates cognitive deficits in rats with traumatic brain injury by stimulating the cerebral HSP20/BDNF/TrkB signalling axis. *Mol Neurobiol* 2018 Mar 25. [Epub ahead of print]
- Lin HJ, Hsu CC, Chio CC, Tian YF, Lin MT, Lin TW, Chang CH, **Chang CP**. Gamma-secretase inhibitors attenuate neurotrauma and neurogenic acute lung injury in rats by rescuing the accumulation of hypertrophic microglia. *Cell Physiol Biochem* 2017;44:1726-40.
- Lin W, Hsuan YC, Lin MT, Kuo TW, Lin CH, Su YC, Niu KC, **Chang CP**, Lin HJ. Human umbilical cord mesenchymal stem cells preserve adult newborn neurons and reduce neurological injury after cerebral ischemia by reducing the number of hypertrophic microglia/macrophages. *Cell Transplant* 2017;26:1798-810.
- Lin W, Hsuan YC, Su YC, Lin CH, Lin MT, Chen ZH, **Chang CP**, Lin KC. CD34-human placenta-derived mesenchymal stem cells protect against heat stroke mortality in rats. *Oncotarget* 2017;9:1992-2001.
- Lin X, Zhao T, Lin CH, Zuo D, Ye Z, Lin S, Wen S, Liu L, Lin MT, **Chang CP**, Chao CM. Melatonin provides protection against heat stroke-induced myocardial injury in male rats. *J Pharm Pharmacol* 2018 Feb 27. [Epub ahead of print]
- Andrick B, Alwhaibi A, **DeRemer D**, Quershi S, Khan R, Bryan LJ, Somanath PR, Pantin J. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. *Br J Haematol* 2017 Jul 24. [Epub ahead of print]
- Gwynn ME, **DeRemer DL**. The emerging role of PD-1/PD-L1-targeting immunotherapy in the treatment of metastatic urothelial carcinoma. *Ann Pharmacother* 2018;52:60-8.
- Lemke AA, Hulick PJ, Wake DT, Wang C, Sereika AW, Yu KD, Glaser NS, **Dunnenberger HM**, Haidar C. Patient perspectives following pharmacogenomics results disclosure in an integrated health system. *Pharmacogenomics* 2018;19:321-31.
- **Fahrenbruch R**, Kintzel P, Bott AM, Gilmore S, Markham R. Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract* 2018;14(3).
- Hough S, Vulaj V, **Farris KB**, Mackler ER. Oncology pharmacist opportunities: closing the gap in quality care. *J Clin Oncol* 2017;35(8_suppl):174.
- Mensa-Wilmot Y, Bowen SA, Rutledge S, **Farris KB**, et al. Early results of states' efforts to support, scale, and sustain the National Diabetes Prevention Program. *Prev Chronic Dis* 2017;14.
- **Fernandez E**, Rosado JB, Perez DR, Santana SS, Aguilar MT, Bringas M. Effectiveness of a computer-based training program of attention and memory in patients with acquired brain damage. *Behav Sci* 2017;8:4.
- Weiss R, **Fernandez E**, Liu Y, Strong R, Salmon AB. Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. *Aging* 2018.
- Scardina TL, Martinez EK, Balasubramanian N, **Fox-Geiman M**, Smith SE, Parada JP. Evaluation of risk factors for *Clostridium difficile* infection in hematopoietic stem cell transplant recipients. *Pharmacotherapy* 2017;37:420-8.
- McFarlane IM, Ozeri DJ, Saperstein Y, Alvarez MR, Leon SZ, Koci K, **Francis S**, et al. Rheumatoid arthritis in sickle-cell population: pathophysiologic insights, clinical evaluation and management. *Rheumatology* 2017;7(3).

- **Gatwood KS**, Culos KA, Binari LA, Engelhardt BG, Kassim A, Byrne MT, Goodman SA, Chinratanalab W, Sengsayadeth SM, Greer JP, Jagasia M, Savani BN. Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia. *Bone Marrow Transplant* 2018 Mar 14. [Epub ahead of print]
- Gatwood J, **Gatwood K**, Gabre E, Alexander M. Impact of clinical pharmacists in outpatient oncology practices: a review. *Am J Health Syst Pharm* 2017;74:1549-57.
- Blackmer A, Thompson A, **Glode A**, Jeffres M, Mahyari N, Thompson M. Clinical pharmacy academic career transitions: viewpoints from the field – part 1: understanding feedback, evaluation, and advancement. *Curr Pharm Teach Learn* 2017. In press.
- Blackmer A, Thompson A, **Glode A**, Jeffres M, Mahyari N, Thompson M. Clinical pharmacy academic career transitions: viewpoints from the field. *Curr Pharm Teach Learn* 2017. In press.
- Jeffres M, Blackmer A, Thompson A, **Glode A**, Mahyari N, Thompson M. Clinical pharmacy academic career transitions: viewpoints from the field – part 3: learning when and how to say yes. *Curr Pharm Teach Learn* 2017. In press.
- Thompson A, **Glode A**, Jeffres M, Mahyari N, Thompson M. Clinical pharmacy academic career transitions: viewpoints from the field – part 2: understanding and balancing of distribution of effort. *Curr Pharm Teach Learn* 2017. In press.
- **Glode AE**, Babiker H. Emerging therapies in CLL: current trials. *J Adv Pract Oncol* 2017;8:71-86.
- **Glode AE**, Norskog S. Opioid management for patients with cancer. *Pharmacy Purchasing & Products Magazine*. 2018; S1-5.
- Bodge M, Culver M, **Glode AE**. Geriatric assessments and medication management in elderly oncology patients. *Consult Pharm* 2017;32 Suppl B:1-20.
- Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, **Goldspiel B**, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. *Clin Pharmacol Ther* 2018;103:574-81.
- Xu X, Wang AQ, Latham LL, Celeste F, Ciccone C, Malicdan MC, **Goldspiel B**, Terse P, Craddock J, Yang N, Yorke S, McKew JC, Gahl WA, Huizing M, Carrillo N. Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy. *Mol Genet Metab* 2017;122:126-34.
- Sissung TM, McKeeby JW, Patel J, Lertora JJ, Kumar P, Flegel WA, Adams SD, Eckes EJ, Mickey F, Plona TM, Mellot SD, Baugher RN, Wu X, Soppet DR, Barcus ME, Datta V, Pike KM, DiPatrizio G, Figg WD, **Goldspiel BR**. Pharmacogenomics implementation at the National Institutes of Health Clinical Center. *J Clin Pharmacol* 2017;57(suppl 10):S67-S77.
- Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, **Gregornik D**, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. *Pediatr Nephrol* 2017;32:1575-84.
- Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE, DeFilipp Z, Doan V, **Gulbis A**, Hicks L, Juckett M, Khera N, Krishnan A, Selby G, Shah NN, Stricherz M, Viswabandya A, Bredeson C, Seftel MD. Choosing wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's list of 5 tests and treatments to question in blood and marrow transplantation. *Biol Blood Marrow Transplant* 2018 Jan 31. [Epub ahead of print]
- Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, **Gulbis A**, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. *Blood* 2017;130:1857-68.
- Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, **Gulbis A**, Ciurea SO. Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation. *Biol Blood Marrow Transplant* 2018;24:353-8.
- Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, **Gulbis A**, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II trial of high-dose gemcitabine/busulfan/melphalan with autologous stem cell transplantation for primary refractory or poor-risk relapsed Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2018 Mar 2. [Epub ahead of print]

- Chahoud J, Sui D, Erwin WD, **Gulbis AM**, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad L, Bassett RL, Jabbour E, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated results of rituximab pre- and post-BEAM with or without 90Yttrium-ibritumomab tiuxetan during autologous transplant for diffuse large B-cell lymphoma. *Clin Cancer Res* 2018 Feb 23. [Epub ahead of print]
- Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, Vence LM, Allison JP, **Gulbis AM**, Sharma P. Ipilimumab plus lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies. *Clin Cancer Res* 2018;24:1011-8.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, **Gulbis AM**, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. *Nat Rev Clin Oncol* 2018;15:47-62.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, **Gulbis AM**, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit “ALL.” *Nat Rev Clin Oncol* 2018;15:218.
- Ragon BK, Mehta RS, **Gulbis AM**, Saliba RM, Chen J, Rondon G, Papat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. *Bone Marrow Transplant* 2018;53:315-25.
- Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, **Haidar CE**, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. *Genet Med* 2017 Oct 26. [Epub ahead of print]
- **Harvey RD**. Science of biosimilars. *J Oncol Pract* 2017;13(9_suppl):17s-23s.
- Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, **Harvey RD**, Venkatakrisnan K. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling. *Clin Pharmacokinet* 2017;56:1355-68.
- Lichtman SM, **Harvey RD**, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. *J Clin Oncol* 2017;35:3753-9.
- Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, **Harvey RD**, Schilsky RL. American Society of Clinical Oncology statement: biosimilars in oncology. *J Clin Oncol* 2018 Feb 14.
- Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, **Harvey RD**, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL. A phase 1 study of ARQ 087 an oral pan-FGFR inhibitors in patients with advanced solid tumors. *Br J Cancer* 2017;117:1592-9.
- Singh V, Gillespie TW, **Harvey RD**. Intranasal ketamine and its potential in cancer related pain. *Pharmacotherapy* 2018;38:390-401.
- Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, **Harvey RD**. The effect of itraconazole and rifampicin and the pharmacokinetics of osimertinib. *Br J Clin Pharmacol* 2018 Jan 30.
- Clement JM, **Holle LM**. Safe administration of intracerebral spinal fluid chemotherapy: time for guidelines. *J Oncol Pract* 2017;13:713-8.
- Puri S, **Holle LM**, Forouhar FA, Clement JA. Subcutaneous metastasis from recurrent basaxoid squamous cell carcinoma of the esophagus. *J Oncol Pharm Pract* 2017 Jan 1.
- Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkougou S, Le AD, Wood LM, Gabizon AA, **La-Beck NM**. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate. *J Control Release* 2018;271:139-48.
- Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkougou S, Le AD, Wood LM, Gabizon AA, **La-Beck NM**. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate. *J Control Release* 2018;271:139-48.
- **Lee BJ**, Go AS, Parikh R, Leong TK, Tan TC, Walia S, Hsu RK, Liu KD, Hsu CY. Pre-admission proteinuria impacts risk of non-recovery after dialysis-requiring acute kidney injury. *Kidney Int* 2018;93:968-76.

- **Lee BJ**, Rhodes NJ, Scheetz MH, McLaughlin MM. Engaging pharmacy students in research through near-peer training. *Am J Pharm Educ* 2017;81:6340.
- Jung SY, Lee SH, **Lee SY**, Yang S, Noh H, Chung EK, Lee JI. Antimicrobials for the treatment of drug-resistant *Acinetobacter baumannii* pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. *Crit Care* 2017;21:319.
- Kim JY, Yang S, **Lee JI**, Chang MJ. Correction: cardiovascular effect of incretin-based therapy in patients with type 2 diabetes mellitus: systematic review and meta-analysis. *PLoS One* 2018;13:e0191744.
- Noh H, Jung SY, Kwak JY, Kim SH, Oh SJ, Zang DY, Lee S, Park HL, Jo DJ, Shin JS, Do YR, Kim DW, **Lee JI**. Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. *Cancer Med* 2018 Mar 25. [Epub ahead of print]
- Chung C, Patel S, **Lee R**, Fu L, Reilly S, Ho T, Lionetti J, George MD, Taylor P. Implementation of an integrated computerized prescriber order-entry system for chemotherapy in a multisite safety-net health system. *Am J Health Syst Pharm* 2018;75:398-406.
- **Liewer S**, Huddleston A. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. *Expert Opin Investig Drugs* 2018;27:105-12.
- Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, **Liu J**. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. *MAbs* 2018;19:1-58. [Epub ahead of print]
- Rana JS, Karter AJ, **Liu JY**, Moffet HH, Jaffe MG. Improved cardiovascular risk factors control associated with a large-scale population management program among diabetes patients. *Am J Med* 2018 Mar 22. [Epub ahead of print]
- **Reiss SN**, Yerram P, Modelevsky L, Grommes C. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. *JITC* 2017;5:99.
- Gottlieb RL, **Sam T**, Wada SY, et al. Rational heart transplant from a hepatitis C donor: new antiviral weapons conquer the Trojan horse. *J Card Fail* 2017;23:765-7.
- **Seddon AN**, Chaim J, Akin O, et al. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. *Leuk Res* 2018.
- **Seddon AN**, Laul A, Yadav U, et al. Alternative conditioning regimens incorporating bortezomib or carmustine with high-dose melphalan are safe and effective for multiple myeloma patients receiving a second autologous stem cell transplant. *Biol Blood Marrow Transplant* 2018;24:S134.
- Click Z, Geswein L, **Seddon AN**, Nathan S. Lower steroid dosing with prednisone 40 mg daily or equivalent is an effective and well tolerated treatment for engraftment syndrome developing in patients following an autologous stem cell transplant. *Biol Blood Marrow Transplant* 2018;24:S133.
- Horvat TZ, **Seddon AN**, Ogunniyi A, et al. The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia. *Ann Pharmacother* 2018;52:268-76.
- **Siderov J**. Letters about published papers. *J Oncol Pharm Pract* 2017;23:557-8.
- Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, **Simmons B**, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol* 2018 Feb 21. [Epub ahead of print]
- Wang N, Vendrov KC, **Simmons BP**, et al. Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. *Prostaglandins Other Lipid Mediat* 2018;134:24-31.
- Burney M, Mathew L, Gaikwad A, Nugent EK, Gonzalez AO, **Smith JA**. Evaluation fucoidan extracts from *Undaria pinnatifida* and *Fucus vesiculosus* in combination with anticancer drugs in human cancer orthotopic mouse models. *Integr Cancer Ther* 2017 Nov 1. [Epub ahead of print]
- Cotton S, Brown RE, Nugent EK, Robazetti SC, Berens PD, **Smith JA**. Quality improvement to demonstrate the lack of reliability of the human papillomavirus mRNA assay to identify women with latent human papillomavirus infections. *Obstet Gynecol* 2018;131:681-7.
- Mathew L, Burney M, Gaikwad A, Nyshadham P, Nugent EK, Gonzalez A, **Smith JA**. Preclinical evaluation of safety of fucoidan extracts from *Undaria pinnatifida* and *Fucus vesiculosus* for use in cancer treatment. *Integr Cancer Ther* 2017;16:572-84.

- Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, **Smith JA**. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. *Gynecol Oncol Res Pract* 2017;4:16.
- Viteri OA, Sallman MA, Berens PM, Berens PD, Amro FH, Hutchinson MS, Ramin SM, Blackwell SC, Refuerzo JS, **Smith JA**. Potential of metformin to improve cardiac risk in postpartum women with gestational diabetes. *Front Med (Lausanne)* 2017;4:180.
- **Swiss K**, Anderson J, Wirth S, et al. A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. *Bone Marrow Transplant* 2018;53:300-6.
- Patel P, Oh AL, Koshy M, **Swiss K**, et al. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m² and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. *Leuk Lymphoma* 2017 Oct 25:1-6. [Epub ahead of print]
- **Thackray J**, Spatz K, Steinherz PG. Vincristine toxicity with co-administration of fluconazole: long-term concerns. *Pediatr Blood Cancer* 2017;64(12).
- Mathew S, Kussin ML, Liu D, Pozotrigio M, Seyboth B, **Thackray J**, Yan SQ, Hsu M, Cohen N, Seo S. Retrospective analysis of posaconazole suspension dosing strategies in a pediatric oncology population: single-center experience. *J Pediatric Infect Dis Soc* 2017;6:e149-e151.
- Patel P, Robinson PD, **Thackray J**, Flank J, Holdsworth MT, Gibson P, Orsey A, Portwine C, Freedman J, Madden JR, Phillips R, Sung L, Dupuis LL. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. *Pediatr Blood Cancer* 2017;64(10).
- Bhat R, Yadav P, Sahay D, Bhargava D, Creighton CJ, Yazdanfard S, Al-rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar V, Osborne CK, Schiff R, **Trivedi MV**. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. *Breast Cancer Res Treat* 2018.
- Ekinci E, Nathoo S, Korattiyil T, Vadhariya A, Zaghoul HA, Niravath PA, Abughosh SM, **Trivedi MV**. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? *J Cancer Surviv* 2018.
- Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, **Trivedi MV**. Perspective on circulating tumor cell clusters: why it takes a village to metastasize. *Cancer Res* 2018;78:1-8.
- Hwang GS, Bhat R, Crutchley RD, **Trivedi MV**. Impact of *CYP2D6* polymorphisms on endoxifen concentrations and breast cancer outcomes. *Pharmacogenomics J* 2018;18:201-8.
- Niravath P, Bhat R, Al-Ameri M, AlRawi A, Foreman C, **Trivedi MV**. Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy. *Pharmacol Res Perspect* 2017;5:e00330.
- Schettini F, Buono G, **Trivedi MV**, De Placido S, Arpino G, Giuliano M. PI3K/mTOR inhibitors in the treatment of luminal breast cancer. Why, when and to whom? *Breast Care* 2017;12:290-4.
- **Wahking RA**, Steele RL, Hanners RE, Lockwood SM, Davis KW. Outcomes from a pharmacist-led proton pump inhibitor stewardship program at a single institution. *Hosp Pharm* 2018;53:59-67.
- Gillis NK, Rotroff DM, Mesa TE, Yao J, Chen Z, Carulli MA, Yoder SJ, **Walko CM**, Teer JK, McLeod HL. Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. *Oncotarget* 2017;8:115114-27.
- Marcath LA, Deal AM, Van Wieren E, Danko W, **Walko CM**, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL. Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. *Pharmacogenet Genomics* 2017;27:402-9.
- Vela CM, Knepper TC, Gillis NK, **Walko CM**, McLeod HL, Hicks JK. Quantitation of targetable somatic mutations among patients evaluated by a personalized medicine clinical service: considerations for off-label drug use. *Pharmacotherapy* 2017;37:1043-51.
- Williams GR, Deal AM, Shachar SS, **Walko CM**, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. *Cancer Chemother Pharmacol* 2018;81:413-7.
- Milfred-LaForest SK, Gee JA, Pugacz AM, Piña IL, Hoover DM, **Wenzell RC**, Felton A, Guttenberg E, Ortizb J. Heart failure transitions of care: a

pharmacist-led post-discharge pilot experience. <http://dx.doi.org/10.1016/j.pcad.2017.08.005>.

- Gunasekaran K, **Winans ARM**, Murthi S, Ahmad MR, Kaatz S. Rectus sheath hematoma associated with apixaban. *Clin Pract* 2017;7:957.
- Paoletta GA, Boyd AD, **Wirth SM**, Cuellar S, Venepalli NK, Crawford SY. Adherence to oral anticancer medications: evolving interprofessional roles and pharmacist workforce considerations. *Pharmacy (Basel)* 2018;6(1).
- **Yee GC**, et al. StrengthsFinder® signature themes of talent in pharmacy residents at four midwestern pharmacy schools. *Curr Pharm Teach Learn* 2018;10:61-5.
- Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, **Yee GC**, Kyle RA. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2018;36:812-8.
- Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jaggi R, Jimenez R, Theriault RL, Vandenberg TA, **Yee GC**, Moy B. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. *J Clin Oncol* 2017;35:3978-86.
- Reiss SN, **Yerram P**, Modelevsky L, Grommes C. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. *J Immunother Cancer* 2017;5:99.
- Jerkins JH, Hamadani M, **Zook F**, et al. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. *Am J Hematol* 2017;92:E610-E611.

Presentations

- **Bell GC**. Speaker at the 2018 UF Precision Medicine Conference.
- **Seddon AN**. New drugs update. BCOP recertification education at: ASHP Midyear Clinical Meeting; December 2–6, 2017; Orlando, FL; Encore presentation; New drugs update. BCOP recertification education at: American College of Clinical Pharmacy Annual Meeting; October 2017; Phoenix, AZ.
- **Yerram P**. The clot thickens, direct oral anticoagulants in the cancer patient and their reversal. HOPA Annual Meeting; March 2018; Denver, CO.

Awards

- **Holle LM**. 2016 ASCO Advocacy Champion – President’s Circle Level.

HIV PRN

Publications

- **Bagwell A**, Kelley T, Carver A, Lee J, Newman B. Advancing patient care through specialty pharmacy services in an academic health-system. *J Managed Care Spec Pharm* 2017;23:815-20.
- **Bagwell A**, McFarland MS, Hulgan T. Novel approach to addressing the HIV care continuum: implementation of clinical pharmacy services in a Veterans Affairs HIV specialty clinic. *J Pharm Pract* 2017. [Epub June 22, 2017]
- Hammond DA, Cullen J, Painter JT, McCain K, Clem OA, **Brotherton AL**, Chopra D, Meena N. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. *J Intensive Care Med* 2017. [Epub ahead of print]
- Hammond DA, McCain K, Painter JT, Clem OA, Cullen J, **Brotherton AL**, Chopra D, Meena N. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. *J Intensive Care Med* 2017. [Epub ahead of print]
- **Chastain DB**, Franco-Paredes C, Stover KR. Addressing antiretroviral therapy-associated drug-drug interactions in patients requiring treatment for opportunistic infections in low-income and resource-limited settings. *J Clin Pharmacol* 2017;57:1387-99.
- **Chastain DB**, Guarner J, Franco-Paredes C. Cryptococcal antigen negative meningoencephalitis in HIV/AIDS. *Diagn Microbiol Infect Dis* 2017;89:143-5.
- **Chastain DB**, Henao-Martínez AF, Franco-Paredes C. Opportunistic invasive mycoses in AIDS: cryptococcosis, histoplasmosis, coccidioidomycosis, and talaromycosis. *Curr Infect Dis Rep* 2017;19:36.
- **Chastain DB**, Ngando IN, Bland CM, Franco-Paredes C, Hawkins WA. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital. *Ann Clin Microbiol Antimicrob* 2017;16:43.
- **Chastain DB**, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. *J Clin Transl Endocrinol* 2017;8:6-14.
- **Chastain DB**, White BP, Cretella DA, Bland CM. Is it time to rethink the notion of carbapenem-sparing therapy against extended-spectrum

β -lactamase-producing Enterobacteriaceae bloodstream infections? A critical review. *Ann Pharmacother* 2017. [Epub ahead of print]

- Franco-Paredes C, **Chastain DB**, Ezigbo C, Callins KR. Reducing transmission of HIV in southeastern USA. *Lancet HIV* 2017;4:e101-e102.
- Franco-Paredes C, **Chastain DB**, Rodriguez-Morales AJ, Marcos LA. Cryptococcal meningoen- cephalitis in HIV/AIDS: when to start antiretroviral therapy? *Ann Clin Microbiol Antimicrob* 2017;16:9.
- Franco-Paredes C, **Chastain DB**, Taylor P, Stocking S, Sellers B. Boar hunting and brucellosis caused by *Brucella suis*. *Travel Med Infect Dis* 2017;16:18-22.
- McCoy C, Badowski M, Sherman E, Crutchley R, Smith E, **Chastain DB**; Society of Infectious Diseases Pharmacists. Strength in amalgamation: newer combination agents for HIV and implications for practice. *Pharmacotherapy* 2018;38:86-107.
- Mandal S, Khandalavala K, Pham R, Bruck P, Varghese M, Kochvar A, Monaco A, Prathipati P, **Destache C**, Shibata A. Cellulose acetate phthalate and antiretroviral nanoparticle fabrications for HIV pre-exposure prophylaxis. *Polymer* 2017;9(423).
- Holec A, Mandal S, Prathipati PK, **Destache CJ**. Nucleoside reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. *Curr HIV Res* 2017. [Epub ahead of print]
- Mandal S, Prathipati PK, Kang G, Zhao Y, Zhe Y, Fan W, Li Q, **Destache CJ**. Tenofovir alafenamide and elvitegravir nanoparticles for long-acting prevention of HIV-1 vaginal transmission. *AIDS* 2017;31:469-76.
- Pattnaik A, Palermo N, Sahoo BR, Yuan Z, Hu D, Annamalai AS, Vu HLX, Correas I, Prathipati PK, **Destache CJ**, Li Q, Osorio FA, Pattnaik AK, Xiang S. Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening. *Antivir Res* 2017. [Epub ahead of print]
- Prathipati PK, Mandal S, Pon G, Vivekanandan R, Destache CJ. Pharmacokinetic and tissue distribution profile of long-acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model. *Pharm Res* 2017;34:2749-55.
- Patel UJ, **Mediwala KN**, Smith KM, Taylor S, Romanelli F. Carpe diem! Seizing the rise of co-curricular experiences. *Am J Pharm Educ* 2017;81(8).
- Badowski M, Mazur J, Lam SW, Miyares M, Schulz L, **Michienzi S**. Engaging in collaborative research:

focus on the pharmacy practitioner. *Hosp Pharm* 2017;52:33-43.

- Badowski M, **Michienzi S**, Robles M. Examining the implications of new healthcare technologies (analytical and remote monitoring) in clinical pharmacy practice. *Clin Pharm* 2017;9(6).
- **Nicol MR**, Brewers LM, Kashuba ADM, Sykes DC. Role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. *AIDS* 2018;32:11-5.
- Chappell CA, Lamorde M, Nakalema S, Chen BA, Mackline H, Riddler SA, Cohn SE, Darin KM, Achilles SL, **Scarsi KK**. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. *AIDS* 2017;31:1965-72.
- Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, **Scarsi KK**. The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine. *Clin Pharmacol Ther* 2017;102:529-36.
- Patel RC, Morroni C, **Scarsi KK**, Sripipatana T, Kiarie J, Cohen CR. Concomitant contraceptive implant and efavirenz use in HIV-positive women: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. *J Int AIDS Soc* 2017;20:1-6.
- Podany AT, Bares SH, Havens J, Shetty RD, O'Neill J, Lee S, Fletcher CV, Swindells S, **Scarsi KK**. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. *AIDS* 2018. [Epub ahead of print]
- Pizzi LT, Prioli KM, Harris LF, Cannon-Dang E, Marthol MM, Alcusky M, McCoy M, **Schafer JJ**. Knowledge, activation, and costs of the pharmacists' pneumonia prevention program (PPPP): a novel senior center model to promote vaccination. *Ann Pharmacother* 2017. [Epub ahead of print]

Poster Presentations

- **Bagwell A**, Douglas A, Farris K, Chastain C. Evaluation of the hepatitis C cascade of care in a multidisciplinary infectious diseases clinic. *ID Week*; 2017; San Diego, CA.
- **Boylan P**, Trinh K, Helms J, Ghoubril-Waibel R, Mege J. Integration of transitions of care pharmacist services within an accredited pulmonary rehabilitation clinic. *American College of Clinical Pharmacy Annual Meeting 2017*; October 2017; Phoenix, AZ.

- **Boylan PM**, Sedlacek JN, Santibañez M, Church AF, Lounsbury NF. Pharmacist-led gamification and active learning activities to teach pharmacotherapeutics to medical learners. American College of Clinical Pharmacy Updates in Therapeutics® 2018; February 2018; Jacksonville, FL.
- Carrizales P, Leszczynski J, Burgos R, Chiampas T, **Michienzi S**, Smith RO, Patel M, Young J, Badowski M. Real-world safety and efficacy of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). American College of Clinical Pharmacy Annual Meeting; October 2017; Phoenix, AZ.
- **Michienzi SM**, Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. American College of Clinical Pharmacy Annual Meeting; October 2017; Phoenix, AZ.
- **Michienzi SM**, Badowski ME, Smith RO. Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP): survey of student pharmacist knowledge, experiences, and attitudes. American College of Clinical Pharmacy Annual Meeting; October 2017; Phoenix, AZ.
- **Michienzi SM**, Stranges PM, Smith RO. Implementation of a pharmacist-led human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) clinic. American College of Clinical Pharmacy Updates in Therapeutics® 2018; February 2018; Jacksonville, FL.
- Borkowski J, **Polisetty RS**, Delacruz J, Lewis S, Manrique L. Impact of targeted fluoroquinolone restriction on antimicrobial usage in two community hospitals. ID Week; 2017; San Diego, CA.
- Asmuth DM, Chen An, Utay NS, Torok, **Poole PL**, Vongspanich J, Haight KR. Impact of occult HCV infection (OCV) on systemic immune activation after DAA therapy. Conference on Retroviruses and Opportunistic Infections (CROI); March 2018; Boston, MA.
- **Zuckerman A**, Douglas A, Farris K, Chastain C. MeRIT project: optimizing the hepatitis C cascade of care in the direct-acting antiviral era (final results). American College of Clinical Pharmacy; October 2017; Phoenix, AZ.
- Chinn M, Reynolds V, Jolly J, **Zuckerman A**, Kelley T. Impact of an integrated clinical and specialty pharmacy service model on access to PCSK9 inhibitor therapy. ASHP; December 2017; Orlando, FL.

- Douglas A, Chastain C, **Zuckerman A**. Changes to antiretroviral therapy regimens in co-infected human immunodeficiency virus and hepatitis C virus patients. ASHP; December 2017; Orlando, FL.
- Jolly J, Markley B, Holder G, Banks A, Zuckerman S, **Zuckerman A**. Improving adherence to multiple sclerosis disease modifying therapies through an integrated specialty pharmacy model. National Association of Specialty Pharmacy; Washington, DC.
- Mitchell R, Shah N, Terry S, Slack S, **Zuckerman A**, Jolly J. Improving medication adherence in pulmonary arterial hypertension: an integrated specialty pharmacy approach. National Association of Specialty Pharmacy; Washington, DC.
- Singleton E, Boils B, Litten K, Burkes S, **Zuckerman A**. Factors that impact treatment completion of teriparatide. ASHP; December 2017; Orlando, FL.
- Singleton E, Boils B, Litten K, Burkes S, **Zuckerman A**. Assessing the impact of high touch specialty pharmacy services in patients receiving teriparatide. National Association of Specialty Pharmacy; Washington, DC.

Internet Publications

- Luder H, Zavadsky A, Bukowitz A, Baumann A, **Boylan PM**, Croley KS, Fu D, Kelling SE, Winder M, Register D. Transitions of Care Case Examples Resource. Washington, DC: APhA, June 2017. Available at www.pharmacist.com/transitions-care.
- **Mediwala K**. An Overview of Outpatient Parenteral Antimicrobial Therapy Practices. IDStewardship.com. Published Aug 2017. Available at <https://www.idstewardship.com/overview-outpatient-parenteral-antimicrobial-therapy-practices/>.
- Gauthier TP, **Mediwala K**. A Comparison of Avycaz, Vabomere, and Zerbaxa. IDStewardship.com. Published Oct 2017. Available at <https://www.idstewardship.com/comparison-avycaz-vabomere-zerbaxa/>.
- Sandgren M, Fenn N, Nolt V, **Mediwala K**. Picking the Right Residency. ASHP Connect. Published August 2017. Available at <http://connect.ashp.org/blogs/norm-fenn/2017/08/09/picking-the-right-residency>.

Continuing Education

- **Boylan PM**. Scientific poster presentation session III: pulmonary. American College of Clinical Pharmacy Annual Meeting 2017; October 2017; Phoenix, AZ.

- **Boylan PM.** Cystic fibrosis: maximizing pharmacotherapy to improve patient outcomes. 34th Annual Southeastern Gathering. Florida Pharmacy Association. Destin, FL. Aug 2017.
- **Boylan PM.** A tough act to follow: 2017 healthcare legislation updates. Pharmacy Grand Rounds. Memorial Regional Hospital; Hollywood, FL. May 2017.
- **Boylan PM.** Pharmacists as providers to improve quality measures [Encore]. April CE Featurette. Interamerican Pharmacists Association; April 2017; Miami, FL.
- **Boylan PM.** Pharmacists as providers to improve quality measures. Annual Residency Program. Dade County Pharmacists Association; January 2017; Miami, FL.
- **Chastain DB.** 2 for 1: infected bones and the wide world of *Staphylococcus aureus*. Florida Society of Health-System Pharmacists District Meeting; November 2017; Tallahassee, FL.
- **Chastain DB.** It's no longer a death sentence: an update in HIV/AIDS. Georgia Society of Health-System Pharmacists Summer Meeting; July 2017; Amelia Island, FL.
- **Chastain DB.** I can't breathe!: an update of the HAP/VAP guidelines. Georgia Society of Health-System Pharmacists District Meeting; April 2017; Albany, GA.
- **Polisetty RS.** The new antimicrobial stewardship standards – is your institution ready? Illinois Council of Health-System Pharmacists – Champion Webinar in Pharmacy Education; March 2017; Loves Park, IL.
- **Polisetty RS.** Ready to launch: antimicrobial stewardship for all. Illinois Council of Health-System Pharmacists Annual Meeting; September 2017; Oakbrook Terrace, IL.
- **Scarsi K.** Common drug-drug interactions in HIV care that you need to know about. Continuing Education Webinar. North Carolina AIDS Education Training Center and Prime Therapeutics; December 2017; Chapel Hill, NC.
- **Scarsi K.** Medication management: HIV survivorship. American College of Clinical Pharmacy Annual Meeting; Phoenix, AZ. Oct 2017.
- **Zuckerman A.** Hepatitis C treatment in the DAA era: new challenges and opportunities. Vizient's Southeast Regional Pharmacy Meeting; Nashville, TN. Oct 2017.

Promotions

- **Paul M. Boylan:** Accepted position as Assistant Professor at Larkin University College of Pharmacy in August 2017.
- **Mark T. Sawkin:** Promoted from Assistant Clinical Professor to Associate Clinical Professor in September 2017.
- **Autumn Zuckerman:** Promoted to Program Director of Health Outcomes and Research at Vanderbilt Specialty Pharmacy.

Awards

- **Paul M. Boylan:** Completed an ASHP-accredited PGY2 Transitions of Care residency at Nova Southeastern University College of Pharmacy. Fort Lauderdale, FL. June 2017; BCPS certification BCPS in July 2017.
- **Robert Macky:** Received U.S. Public Health Service unit citation for "Recognition for Outstanding Accomplishments and Positive Impact While Serving as a Regional HIV Pharmacist Consultant" in August 2017.
- **Radhika Polisetty:** Promoted to Associate Professor in the Department of Pharmacy Practice at Midwestern University Chicago College of Pharmacy in July 2017.
- **Kimberly Scarsi:** Inducted as a Fellow of the American College of Clinical Pharmacy.
- **William R. Truong:** Achieved American Academy of HIV Medicine Pharmacist (AAHIVP) credential.
- **Autumn Zuckerman:** Received National Association of Specialty Pharmacy 2017 Abstract Poster Award – Third Place; September 2017.

Local/Regional/National Speakers

- **Daniel B. Chastain:**

Clinical pearls in infectious diseases. Phoebe Putney Memorial Hospital Family Medicine Residents. Phoebe Putney Memorial Hospital; June 2017; Albany, GA.

A rapid review of the updated HAP/VAP guidelines. Society of Hospital Medicine – Southwest Georgia Chapter; April 2017; Tifton, GA.

- **Mark T. Sawkin:** HIV pre-exposure prophylaxis (PrEP) in an urban community health center. American Pharmacists Association PharmTalk: Innovative Practices in Collaborating with Members of the Health Care Team Session. APhA Annual Meeting; March 2017; San Francisco, CA.

- **Kimberly Scarsi:**

Pharmacokinetic and pharmacodynamic considerations for contraception and antiretrovirals. NIH, NIAID Multipurpose Prevention Technology (MPT) Development: Strategies for Addressing the Biomedical, Behavioral, and Regulatory Challenges. Bethesda, MD.

Contraceptive options for women living with HIV: what's pharmacology got to do with it? NIH, NIAID Women's Health Research Working Group (WHRWG). Bethesda, MD.

Pharmacologic strategies to improve hormonal contraceptive implant effectiveness for HIV-positive women. University of Liverpool. Department of Molecular and Clinical Pharmacology. Liverpool, UK.

- **Autumn Zuckerman:**

From prescription to patient: navigating barriers to HCV treatment initiation. Southeast AIDS Education & Training Center Program: Nashville, Memphis, Knoxville, Johnson City, TN.

Pharmacologic considerations of HCV treatment. Southeast AIDS Education & Training Center Program: Nashville, Memphis, Knoxville, Johnson City, TN.

Published Abstracts

- Mandal S, Kang G, Prathipati P, Zhou Y, Yuan Z, Fan W, Li Q, **Destache C**. A comparison study of tenofovir alafenamide (TAF) plus emtricitabine (FTC) in solution and as nanoparticles (NPs) for pre-exposure prophylaxis (PrEP) in humanized BLT (hu-BLT) mice (Abstract WEPEA0194). 9th IAS Conference on HIV Science; July 23–26, 2017; Paris, France. Presented as a poster.
- Mandal S, **Destache CJ**. Combination antiretroviral (cARV) loaded nanoparticles: a potential alternative future for HIV patients. World Conference on STDs, STIs & HIV/AIDS; July 26–27, 2017; Vancouver, British Columbia, Canada.
- Broekhuis J, **Scarsi K**, Sayles H, Klepser D, Havens J, Swindells S, Bares SH. Midwest pharmacist's knowledge of & willingness to provide preexposure prophylaxis. APhA Annual Meeting & Exposition; March 2017; San Francisco, CA.
- Lee S, **Scarsi K**, Havens J, Sayles H, O'Neill J, Podany A, Swindells S, Bares S. A pharmacist-led protocol to transition HIV-infected patients taking tenofovir disoproxil to tenofovir alafenamide: assessment of patient knowledge and satisfaction. APhA Annual Meeting & Exposition; March 2017; San Francisco, CA.

- McLaughlin M, Blackshear C, Hernandez J, Ivanova G, Gerzenshtein L, **Scarsi K**. Safety and tolerability of high dose atazanavir/ritonavir and lopinavir/ritonavir in pregnant women living with human immunodeficiency virus; ID Week 2017. San Diego, CA; Oct 2017.
- Broekhuis J, **Scarsi KK**, Sayles H, Klepser D, Havens J, Swindells S, Bares SH. Midwest pharmacist's knowledge of & willingness to provide preexposure prophylaxis. Conference on Retroviruses and Opportunistic Infections; February 2017; Seattle, WA.
- Godfrey C, Barr L, Smeaton L, **Scarsi KK**, Mngquibisa R. Data needed to guide therapy post sexual assault for women living with HIV. 7th International Workshop on HIV & Women; February 2017; Seattle, WA.
- Podany A, Bares SH, Havens J, Dyavar Shetty R, O'Neill J, Lee S, Fletcher C, Swindells S, **Scarsi KK**. Plasma and intracellular PK of tenofovir in patients switched from TDF to TAF. Conference on Retroviruses and Opportunistic Infections; February 2017; Seattle, WA.
- Roberts O, Curley P, Reddy Rajoli RK, Moss DM, Lamorde M, Owen A, **Scarsi KK**, Siccardi M. An in vitro-in silico study of reduced-dose efavirenz interaction with levonorgestrel. Conference on Retroviruses and Opportunistic Infections; February 2017; Seattle, WA.

Grants

- **Chris J. Destache:** Combined Antiretroviral Drug and CCR5 Antibody Nanoparticle for HIV-1 Prevention. Nebraska cigarette tax LB629. 2017–2018. \$74,948. Funded.

Books

- **Schafer JJ**, Cocohoba J, Sherman E, Tseng A, eds. HIV Pharmacotherapy: The Pharmacist's Role in Care and Treatment. Bethesda, MD: American Society of Health-System Pharmacists.

Book Chapters

- **Schafer JJ**. HIV Testing and diagnosis. In: Schafer JJ, ed. HIV Pharmacotherapy: The Pharmacist's Role in Care and Treatment. Bethesda, MD: American Society of Health-System Pharmacists.
- **Schafer JJ**, Sherman EM, Gill TK, Birney J. Understanding and managing antineoplastic and antiretroviral therapy. In: Hardy WD, ed. The American Academy of HIV Medicine Fundamentals of HIV Medicine, 2017 edition. New York: Oxford University Press, 2017.

- Short WR, **Schafer JJ**. Antiretroviral therapy in pregnant women. In: Hardy WD, ed. *The American Academy of HIV Medicine Fundamentals of HIV Medicine*, 2017 edition. New York: Oxford University Press, 2017.

Published Abstracts

- **Bagwell A**, Douglas A, Chastain C. Evaluation of the hepatitis C cascade of care in a multidisciplinary infectious diseases clinic. *Open Forum Infect Dis* 2017;4(suppl_1):S200.

Immunology/Transplantation PRN

Introduction

The IMTR PRN, together with ASHP, has submitted a petition for the Board of Pharmacy Specialties to recognize solid organ transplantation as a specialty. In addition, the PRN has continued broadcasting monthly multi-PRN webinars and has submitted many worthy candidates for ACCP awards.

Promotions

- **Jennifer Trofe-Clark**: Reappointment – Adjunct Associate Professor of Medicine, Renal-Electrolyte and Hypertension Division, Associated Faculty of the Perelman School of Medicine, University of Pennsylvania, 2018–2022; Adjunct Clinical Professor, Department of Pharmacy Practice, Temple University School of Pharmacy, 2017–2018.

Awards

- **Rita R. Alloway**: University of Tennessee, College of Pharmacy, Distinguished Alumni, 2017.
- **Maya Campara**: University of Illinois at Chicago, Teaching Recognition Program Award.

Grants

- **James Fleming**: Opioid Use and Outcomes in Abdominal Transplant Recipients and Donors. Funded by American College of Clinical Pharmacy Immunology/Transplantation PRN 2017 Research Grant. Awarded \$5000 (Role: PI).
- **James Fleming and Dave Taber**: TRANSAFE Rx funded by AHRQ R18HS023754. Awarded \$1,500,000 (Role: JF-Co-I, DT-PI).

Publications

- Ettenger R, Albrecht R, **Alloway R**, Belen O, Cavallé-Coll MW, Chisholm-Burns MA, Dew MA, Fitzsimmons WE, Nickerson P, Thompson G, Vaidya P. Meeting report: FDA public meeting on

patient-focused drug development and medication adherence in solid organ transplant patients. *Am J Transplant* 2018;18:564-73.

- **Alloway RR**. Mounting clinical evidence with tacrolimus generic products. Invited Brief Commentary. *Transplantation* 2017;101:2663-4.
- **Alloway RR**, Vinks AA, Fukuda T, Mizuno T, King EC, Zou Y, Jiang W, Woodle ES, Tremblay S, Klawitter J, Klawitter J, Christians U. Bioequivalence between brand and generic tacrolimus in liver and kidney transplant recipients: a randomized clinical trial. *PLoS Med* 2017;14(11).
- Spaggiari M, Bissing M, **Campara M**, Yeh CC, Tzvetanov I, Jeon H, Benedetti E. Pancreas transplantation from pediatric donors: a UNOS registry analysis. *Transplantation* 2017;101:2484-91.
- Lewis PO, **Covert KL**. Appropriate use of proton pump inhibitors: a double-edged sword. *Am J Med* 2018;131:218-9.
- Sebaaly JC, **Covert KL**. Enoxaparin dosing at extremes of weight: literature review and dosing recommendation. *Ann Pharmacother*. Accepted for publication.
- Vranian SC Jr, **Covert KL**, Mardis CR, et al. Assessment of risk factors for increased resource utilization in kidney transplantation. *J Surg Res* 2018;222:195-202.
- Arms MA, **Fleming J**, Sangani DB, Nadig SN, McGillicuddy JW, **Taber DJ**. Incidence and impact of adverse drug events contributing to hospital readmissions in kidney transplant recipients. *Surgery* 2017.
- **Fleming JN**, Lai JC, Te HS, Said A, Spengler E, Rogal SS. Opioid and opioid substitution therapy in liver transplant candidates: a survey of center policies and practices. *Clin Transplant* 2017.
- **Fleming JN**, McGillicuddy J, Treiber F. Mobile health technology in transplantation. In: Nadig SN, Wertheim JA, eds. *Technological Advances in Organ Transplantation*, 1st ed. Springer, 2017.
- **Fleming JN**, **Taber DJ**, McElligott J, et al. mHealth in solid organ transplant: the time is now. *Am J Transplant* 2017. Accepted for publication.
- **Fleming JN**, **Taber DJ**, **Pilch NA**, Mardis CR, Gilbert RE, Wilson LZ, **Patel N**, Ball S, Mauldin P, Baliga PK. Association of pretransplant opioid use with graft loss or death in liver transplantation patients with Model of End Stage Liver Disease exceptions. *J Am Coll Surg* 2017.

- **Fleming JN, Taber DJ, Pilch NA**, Nadig S, McGillicuddy JW, Bratton CF, Baliga PK, Chavin KD. Valganciclovir followed by CMV hyperimmune globulin compared to valganciclovir for 200 days in abdominal organ transplant recipients at high risk for CMV infection: a prospective, randomized pilot study. *Trans Infect Dis* 2017.
- **Fleming JN**, Treiber F, McGillicuddy J, Gebregziabher M, **Taber DJ**. Improving transplant medication safety through a pharmacist-empowered, patient-centered, mHealth-based intervention: TRANSAFE Rx study protocol. *JMIR Res Prot* 2018;7:e59.
- Spengler EK, O'Leary JG, Te HS, Rogal S, Pillai A, Al-Osaimi A, Desai A, **Fleming JN**, Ganger D, Seetharam A, Tsoulfas G, Montenegro M, Lai JC. Liver transplantation in the obese cirrhotic patient. *Transplantation* 2017.
- Abu Jawdeh BG, Woodle ES, **Leino AD**, Brailey P, **Tremblay S**, Dorst T, Abdallah MH, Govil A, Byczkowski D, Misra H, Abuchowski A, **Alloway RR**. A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. *Clin Transplant* 2018;32(1).
- **Maldonado AQ**, Asempta T, Hudson S, Rebellato LM. Prevalence of CYP3A5 genomic variances and their impact on tacrolimus dosing requirements among kidney transplant recipients in eastern North Carolina. *Pharmacotherapy* 2017;37:1081-8.
- **Maldonado AQ, Bowman LJ, Szempruch KR**. Expanding transplant pharmacist presence in pretransplantation ambulatory care. *Am J Health Syst Pharm* 2017;74:22-5.
- **Maldonado AQ, Johnson D, Trofe-Clark J**. Barriers to vaccination in renal transplant recipients. *Transplant Infect Dis* 2017 Jul 17. [Epub ahead of print]
- **Maldonado AQ**, Summers B, Szempruch KR, Hall J, Harris MT. Early outcomes from de novo weight-based dosing compared with conservative dosing of tacrolimus in kidney transplant recipients: a multi-site perspective. *Ann Pharmacother* 2017;51:518-9.
- Asempta TE, Rebellato LM, Hudson S, Briley K, **Maldonado AQ**. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. *Clin Transplant* 2018;32.
- Everly MJ, Briley KP, Haisch CE, Dieplinger G, Bolin P, Kendrick SA, Morgan C, **Maldonado AQ**, Rebellato LM. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. *Transpl Int* 2017;30:566-78.
- **Potter LM, Maldonado AQ**, Lentine KL, Schnitzler MA, Zhang Z, Hess GP, Garrity E, Kasiske BL, Axelrod DA. Transplant recipients are vulnerable under the Medicare Part D benefit. *Am J Transplant* 2018 Feb 15. [Epub ahead of print]
- West-Thielke P, **Progar K, Campara M**, Jasiak N, Gallon L, Tang I, Spaggiari M, Tzvetanov IG, Benedetti E. Eculizumab for prevention of antibody mediated rejection in blood group incompatible renal transplantation. *Transplant Proc* 2018;50:66-9.
- **Szczepanik A**, Hulbert A, Lee HJ, Benedetti C, Snyder L, Byrns J. Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction. *Clin Transplant* 2018;32(1).
- **Taber DJ, Su Z, Fleming JN**, et al. Tacrolimus trough concentration variability and disparities in African American kidney transplantation. *Transplantation* 2017.
- **Tremblay S, Alloway RR**. Clinical evaluation of modified release and immediate release tacrolimus formulations. *AAPS J* 2017;19:1332-47.
- **Trofe-Clark J**, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate release tacrolimus versus extended release tacrolimus in African American kidney transplant recipients. *Am J Kidney Dis* 2018;71:315-26.
- Varga A, Johnson D, Sawinski DL, Lim MA, Bloom RD, Abt PL, Goral S, Bleicher M, Levine MH, Naji A, Nazarian S, Porrett P, **Trofe-Clark J**. Safety and feasibility of outpatient rabbit antithymocyte globulin induction therapy administration in kidney transplant recipients. *Pharmacotherapy*. Accepted for publication.

Other Notable Achievements

- **James Fleming**: Invited to be on the American College of Clinical Pharmacy Programming Committee, Annual Meeting 2018–2019.
- **Jennifer Trofe-Clark**: Serving as invited member on the American Transplant Congress Planning Committee 2017–2020; Moderator for American College of Clinical Pharmacy Immunology/ Transplantation PRN webinar titled “Tacrolimus Pharmacogenomics – A Practical Approach to the Evidence,” October 2017; Presented remotely on “A Transplant Pharmacist’s Role in Caring for

Solid Organ Transplant and Vascular Composite Allotransplant Recipients” at: Organ Procurement and Transplantation Network/United Network for Organ Sharing Vascular Composite Allograft Committee Meeting; October 2017; Chicago, IL.

Presentations

- **Fleming JN**, Chavin KD, Jonassaint N, Satoskar R, Dubay D. LIVE-C free: early and late treatment of HCV with sofosbuvir/ledipasvir in liver transplant: interim results. International Liver Transplantation Society 2017.
- **Fleming JN, Taber DJ, Pilch NA**, Gilbert RE, Wilson LZ, Mardis CR, Patel N, Baliga PK. Pre-transplant opioid use is significantly associated with graft loss or death in liver transplants with MELD exceptions. Southern Surgical Association Annual Meeting; 2017.
- Asempa T, Hudson S, Rebellato L, **Maldonado AQ**. Prevalence of CYP3A genomic variances and impact on tacrolimus dosing requirements in kidney transplant recipients in eastern North Carolina. Poster presented at: American Transplant Congress; April 2017; Chicago, IL.
- Brooks A, Rebellato L, Briley K, Bolin P, Kendrick S, **Maldonado AQ**, Haisch C, Everly M. De novo DSA positivity is associated with a higher rate of post-transplant bacterial and viral infections. Platform presented at: American Transplant Congress; April 2017; Chicago, IL.
- Elmaasarani Z, Gilbert R, **O'Brien B, Taber DJ**, Mardis CR, **Pilch NA, Patel N**, Ball S, Mauldin P, Baliga P, **Fleming JN**. The impact of opioid use on kidney transplant rejection: different sources provide different answers. ACCP Updates in Therapeutics® 2018; February 2018; Jacksonville, FL.
- Gilbert R, Elmaasarani Z, **O'Brien B, Taber DJ**, Mardis CR, **Pilch NA, Patel N**, Ball S, Mauldin P, Baliga P, **Fleming JN**. Does opioid use impact readmissions after kidney transplant? The source of opioid data matters. ACCP Updates in Therapeutics®; February 2018; Jacksonville, FL.
- **Angela Maldonado**:
Establishing a new service. New Practitioner Council Webinar Series. American College of Clinical Pharmacy. Posted: September 25, 2017.
Online Journal Club. Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype. Am J Transplant 2016;16:2670-5.

Invited Presentations

- **James Fleming:**

mHealth in transplant: the path from potential to reality. American Transplant Congress; June 2018; Seattle, WA (moderator/speaker).

American College of Clinical Pharmacy Immunology/Transplantation PRN New Practitioner's Webinar Series: Tips for writing an abstract and manuscript. November 2017 (speaker).

American College of Clinical Pharmacy Immunology/Transplantation PRN Webinar Series: Impact of opioids in kidney transplantation and prospects for minimization. September 2017 (speaker).

- **Angela Maldonado**: Structuring and sustaining transplant pharmacy services in the pre-transplant setting: optimizing pharmacologic risk assessment of transplant recipients and living donors. American Transplant Congress; April 2017; Chicago, IL (speaker).

- **Jennifer Trofe-Clark:**

Valganciclovir dosing in moderate and high CMV risk SOT recipients (450mg daily vs 900mg daily). American Society of Transplantation, Transplant Pharmacy Community of Practice Live Debate. March 2018 (panelist).

Preconference Course: Non-adherence: patient, payer, and pharmacy considerations. National Kidney Foundation 2018 Spring Clinical Meeting; April 2018; Austin, TX (speaker).

Premeeting Symposium: The immunology of kidney transplantation. American Transplant Congress; June 2018; Seattle, WA (moderator).

Featured Multidisciplinary Transplant Professionals Symposium I: Assessing and addressing medication non-adherence in the “real world” clinical setting. American Transplant Congress; June 2018; Seattle, WA (panelist).

Featured Multidisciplinary Transplant Professionals Symposium I: In clinic tools, tips and theory to mitigate non-adherence after transplant. Assessing and Addressing Medication Non-adherence in the “Real World” Clinical Setting. American Transplant Congress; June 2018; Seattle, WA (speaker)

Poster/Platform Presentations accepted at: American Transplant Congress; June 2018; Seattle, WA:

- **Cross R**, Pollinger H, Tan M, Mulloy M, Ommert T, Ray A, Klein C. Equivalent post-donation eGFR after robotic assisted versus laparoscopic living donor nephrectomy.

- **Fleming JN, Taber DJ**, Gilbert RE, Wilson LZ, Elmaasarani Z, **O'Brien B, Patel N, Pilch NA**, Ball S, Mauldin P, Baliga P. Risk factors for chronic opioid use after kidney transplantation.
- **Fleming JN, Taber DJ, O'Brien B, Patel N, Pilch N**, Gilbert R, Wilson L, Elmaasarani Z, Ball S, Mauldin P, Baliga P. Risk factors for chronic opioid use after liver transplantation.
- **Gylten L**, Mardis C, **Taber D, Meadows H, Perez C**, Elmaasarani Z, **Fleming JN**, Patel N, Baliga P, Rao V, Rohan V, **Pilch N**. Does one size fit all? Implementing a protocolized ambulatory tacrolimus dosing strategy in a predominantly African American renal transplant population.
- Elmaasarani Z, Mardis C, **Gylten L, Fleming JN, Meadows H, Patel N, Perez C, Taber DJ**, Rao V, Rohan V, Baliga P, DuBay D, **Pilch NA**. The providers can't let go! An analysis of an RN driven tacrolimus dose adjustment protocol.
- **Hamel S**, Kuo V, **Johnson D**, Bloom RD, Sawinski D, **Trofe-Clark J**. Use of granulocyte colony-stimulating factor for leukopenia post-renal transplant.
- **Hamel S**, Sawinski D, Weinrieb R, Dave S, **Trofe-Clark J**. Outcomes in renal transplant recipients with bipolar disorder: a large retrospective cohort.
- **Kincaide E**, Hitchman K, **Hall R**, Yamaguchi I, **Crowther B**. Acute antibody mediated rejection treatment impact on class I and class II anti-HLA antibodies in pediatric kidney transplant recipients.
- **Kincaide E**, Hitchman K, **Hall R**, Yamaguchi I, **Crowther B**. Efficacy and safety of acute antibody rejection treatment in pediatric kidney transplant recipients.
- Hardcopf J, **Meadows H, Pilch N, Perez C, Patel N, Fleming J**, Corbo H, Harrison T, **O'Brien B**, DuBay D, Baliga P, **Taber D**. The impact of anticoagulation therapy modifications during the index hospitalization on clinical outcomes in kidney transplant recipients.
- Hardcopf J, **Meadows H, Pilch N, Perez C, Patel N, Fleming J**, Corbo H, Harrison T, **O'Brien B**, DuBay D, Baliga P, **Taber D**. The price of diabetes medication management in kidney transplantation: similar rates of readmissions, but more healthcare utilization.
- **Moorman AF, Todd SB**, Lyon GM, Triemer H. *Clostridium difficile* recurrence in abdominal organ transplant recipients: metronidazole versus oral vancomycin.
- **O'Brien B**, Gilbert R, Elmaasarani Z, **Taber DJ**, Mardis CR, **Pilch NA, Patel N**, Ball S, Maudling

P, Baliga P, **Fleming JN**. The opioid strikes back: pre-transplant opioid exposure is associated with increased readmissions after renal transplant.

- **Patel N, O'Brien B, Taber DJ, Pilch NA**, Baliga P, Elmaasarani Z, Ball S, Mauldin P, Wilson L, Gilbert R, **Fleming JN**. The impact of pre-operative opioid use on delayed graft function in adult kidney transplant recipients.
- Harrison T, **Perez C, Patel N, Meadows H, Fleming JN, Pilch NA, O'Brien B**, Corbo H, Hardcopf H, Baliga P, DuBay D, **Taber DJ**. Assessment and validation of potential predictors of non-adherence in contemporary kidney transplant recipients.
- **Pilch NA**, Mardis C, **Meadows H, Fleming JN, Patel N, Perez C**, Baliga P, DuBay D, Rohan V, Rao V, Taber DJ. "I'll be back": increasing readmission rates in the era of the new kidney allocation system.
- Wilson L, **Taber DJ**, Gilbert RE, Elmaasarani Z, **O'Brien B, Patel N**, Mauldin P, Ball S, Baliga P, **Fleming JN**. The financial impact of the opioid epidemic on kidney transplant readmissions.
- **Trofe-Clark J**, Gbemudu W, Hamel S, Shults J, Neubauer R, Ryan S, Kaminski M, Sawinski D, Goral S, Bleicher M, Lim MA, Bloom RD, Reese PP. Cognitive function and health literacy assessment outcomes in the first months after renal transplant in a diverse single center population.
- Cohen J, Lim MA, Tewksbury C, Torres Landa S, **Trofe-Clark J**, Abt PA, Williams N, Dumon K, Goral S. Bariatric surgery before and after kidney transplantation: long-term weight-loss and allograft outcomes.
- Kaur N, Kamoun M, Kearns J, **Trofe-Clark J**, Abt PL, Levine MH, Goral S. Kidney transplant outcomes in patients with CPRA values > 99% after implementation of the new OPTN/UNOS Kidney Allocation System (KAS): a single center study update.

Infectious Diseases PRN

Introduction

After the ACCP Annual Meeting in Phoenix last fall, the INFD PRN launched a new networking committee and continued to build its more recently established research committee. Be sure to check out the PRN's Social Media Committee (#IDPRN on twitter) for updates on all things ID. Many thanks to the many members who contribute to the PRN's committees and assist its membership. PRN member accomplishments include the following.

Promotions

- **Samuel Aitken:** Residency Program Director, PGY2 Infectious Diseases Pharmacy Residency, University of Texas MD Anderson Cancer Center.
- **Christopher Frei:** Professor (tenured) in the UT Austin College of Pharmacy, effective 9/1/18.

Awards

- **Chris Bland:** 2018 UGA College of Pharmacy Teacher of the Year.
- **Elias Chahine:** 2018 Healthcare Educator Hero in Medicine Award – Palm Beach County Medical Society; 2017 Token of Appreciation – Indian Association of Colleges of Pharmacy/Devaki Amma Memorial College of Pharmacy; 2017 Residency Preceptor of the Year – Florida Society of Health-System Pharmacists.
- **Christopher Frei:** Inaugural Graduate Teaching and Mentoring Award, UT Austin College of Pharmacy, December 2017.
- **Elizabeth Hirsch:** SIDP Young Investigator Award (October 2017).
- **Monica Mahoney:** Highlighted as a “Twitter Rock Star” by ASHP at the 2017 ASHP Midyear Clinical Meeting.

Grants

- **Elias Chahine:**

Assessment of Supplemental Infectious Diseases Instruction Through Social Media. Role: PI. Funding: American College of Clinical Pharmacy Education and Training PRN.

Teaching Enhancement Grant Title: Assessing Knowledge and Attitudes of Long-term Care Residents Regarding Antibiotics and Vaccines Before and After Pharmacy Student-Led Interventions. Role: PI. Funding: Palm Beach Atlantic University Quality Initiative Grant.

- **Chris Destache:**

Combined Antiretroviral Drug and CCR5 Antibody Nanoparticle for HIV-1 Prevention. Role: PI. Nebraska cigarette tax LB629. 2017–2018. \$74,948. Funded.

Integrase Inhibitor Combination Nanomicrobicide for Prevention of HIV Infection. Co-I: 2. R15 AI118550-01 (Shibata A). 02/1/2015 – 01/30/2018 0.06 calendar months. NIAID \$300,000. The goal of this project is to evaluate dolutegravir plus cellulose acetate phthalate for HIV prevention as a vaginal gel.

- **Tom Dilworth:** \$3000 internal Aurora Research Institute grant to study the impact of patient-, treatment- and environmental-level factors on enteric colonization with antibiotic-resistant pathogens.
- **Michelle T. Martin:** Martin MT, Koren D, Teply R, Zuckerman A. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model.

- **Nathan Wiederhold:**

Therapeutics Testing in Murine Models of Fungal Infections – *Candida auris*, *Scedosporium sp.* NIH/ NIAID. HHSN272201000039/HHSN27200003 (Task Order A01).

In Vitro Testing for Antimicrobial Resistant-Related Antibacterial Activity – CARB-X. NIH/ NIAID. HHSN272201100018/HHSN27200014 (Antibacterial – Task Order A32).

New ACCP Fellows

- **Scott Bergman**
- **Kalen Manasco**
- **Michelle T. Martin**
- **Kayla Stover**

Other Notable Achievements

- **John Boreyko:** Series Editor PSAP Infectious Diseases 2017–2018.
- **Dustin Carr:** AAHIVP certification.
- **Monica Mahoney:** Appointed as Section Editor of “In the Literature” on Contagion Live (www.contagionlive.com).
- **Michelle T. Martin:** Editorial Board for the *Journal of the American College of Clinical Pharmacy (JACCP)*.
- **Nathan Wiederhold:** August 2017 – Fellow, Infectious Diseases Society of America.

Publications

- **Aitken SL, Foolad F, McDanel PM.** Should piperacillin-tazobactam be used as definitive therapy against Enterobacteriaceae harboring inducible AmpC β -lactamases? *Antimicrob Agents Chemother* 2017;61(9).
- **Aitken SL, Saunders R, Chemaly RF, Ehninger G.** Letermovir. In: Grayson ML, ed. *Kucers' The Use of Antibiotics*, 7th ed. London: ASM Press, 2017.
- **Altshuler J, Guervil DJ, Ericsson CD, Wanger A, Aitken SL, Ostrosky-Zeichner L.** Clinical outcomes in patients with gram negative infections treated

with optimized cefepime dosing over various minimum inhibitory concentrations. *J Pharm Pract* 2018;31:34-9.

- Shelburne SA, Kim J, Munita JM, Sahasrabhojane P, Shields RK, Press EG, Li X, Arias CA, Cantarel B, Jiang Y, Kim MS, **Aitken SL**, Greenberg DE. Whole-genome sequencing accurately identifies resistance to extended-spectrum β -lactams for major gram-negative bacterial pathogens. *Clin Infect Dis* 2017;65:738-45.
- **Anderson A, McManus D**, Perreault S, Lo Y, Seropian S, Topal J. Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. *Med Mycol Case Rep* 2017;17:11-3.
- **Britt N**, Tirmizi S, Ritchie D, Topal J, **McManus D**, Nizet V, Casabar E, Sakoulas G. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. *J Antimicrob Chemother* 2017 Dec 13.
- **Casapao AM, Jacobs DM**, Bowers DR, Beyda NE, **Dilworth TJ**. Early administration of adjuvant β -lactam therapy in combination with vancomycin among patients with methicillin-resistant *Staphylococcus aureus* bloodstream infection: a retrospective, multicenter analysis. *Pharmacotherapy* 2017;37:1347-56.
- **Chahine EB**. Sexually transmitted diseases, ambulatory care infections, and immunizations. In: **Bland CM, Bookstaver PB, Chahine EB**, et al., eds. *Updates in Therapeutics®: Infectious Diseases Pharmacy Preparatory Review Course*, 2018 ed. Lenexa, KS: ACCP, 2018:155-222.
- **Chahine EB**, Cho JC, Worley MV. Bezlotoxumab for the prevention of *Clostridium difficile* recurrence. *Consult Pharm* 2018;33:89-97.
- **Chahine EB**, Karaoui LR. Lung Abscesses. In Murphy JE, Len MW, eds. *Pharmacotherapy Self-Assessment Program*, 2018 Book 1. Infectious Diseases. Lenexa, KS: ACCP, 2018:161-89.
- **Chahine EB**, Kelley D, Childs-Kean LM. Sofosbuvir/velpatasvir/voxilaprevir: a pan-genotypic direct-acting antiviral combination for hepatitis C. *Ann Pharmacother* 2018;52:352-63.
- Karaoui LR, Mansour H, **Chahine EB**. Elbasvir/grazoprevir: a new direct acting antiviral combination for hepatitis C. *Am J Health Syst Pharm* 2017;74:1533-40.
- **Chastain DB, White BP**, Cretella DA, **Bland CM**. Is it time to rethink the notion of carbapenem sparing therapy against extended-spectrum β -lactamase-producing Enterobacteriaceae bloodstream infections? A critical review. *Ann Pharmacother* 2017 Dec 1.
- Holec A, Mandal S, Prathipati PK, **Destache CJ**. Nucleoside reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. *Curr HIV Res* 2017 Nov 19.
- Mandal S, Khandalavala K, Pham R, Bruck P, Varghese M, Kochvar A, Monaco A, Prathipati P, **Destache C**, Shibata A. Cellulose acetate phthalate and antiretroviral nanoparticle fabrications for HIV pre-exposure prophylaxis. *Polymer* 2017;9(423).
- Pattnaik A, Palermo N, Sahoo BR, Yuan Z, Hu D, Annamalai AS, Vu HLX, Correias I, Prathipati PK, **Destache CJ**, Li Q, Osorio FA, Pattnaik AK, Xiang S. Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening. *Antivir Res* 2017.
- Prathipati PK, **Mandal S**, Pon G, Vivekanandan R, Destache CJ. Pharmacokinetic and tissue distribution profile of long-acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model. *Pharm Res* 2017 Sept 13.
- **Dilworth TJ**, Klein PA, **Mercier RC**, Borrego ME, Jakeman B, Pinkerton SD. Clinical and economic impact of a pharmacist-administered antiretroviral therapy adherence clinic for patients living with HIV. *J Manag Care Pharm* 2018;24:165-72.
- Jones D, **Elshaboury R**, Munson E, **Dilworth TJ**. A retrospective analysis of treatment and clinical outcomes among patients with methicillin-susceptible *Staphylococcus aureus* bloodstream isolates possessing detectable mecA by a commercial PCR assay compared to patients with methicillin-resistant *Staphylococcus aureus* bloodstream isolates. *Antimicrob Agents Chemother* 2017;62(1).
- Lee GC, Dallas SD, Wang Y, Olsen RJ, Lawson KA, Wilson J, **Frei CR**. Emerging multidrug resistance in community-associated *Staphylococcus aureus* involved in skin and soft tissue infections and nasal colonization. *J Antimicrob Chemother* 2017;72:2461-8.
- Srinivasan A, Lee GC, Torres NS, Hernandez K, Dallas SD, Lopez-Ribot J, **Frei CR**, Ramasubramanian AK. High-throughput microarray for antimicrobial susceptibility testing. *Biotechnol Rep (Amst)* 2017;16:44-7.
- **Gross AE**, Johannes RS, Gupta V, Tabak YP, Srinivasan A, Bleasdale SC. The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and *Clostridium difficile* risk in 88 U.S. medical centers. *Clin Infect Dis* 2017;65:613-8.

- **Jacobs DM, Dilworth TJ, Beyda NE, Casapao AM, Bowers DR.** Overtreatment of asymptomatic candiduria among hospitalized patients: a multi-institutional study. *Antimicrob Agents Chemother* 2017;62(1).
- **Jones BM, Hersey RM, Trestman IJ, Bland CM.** Successful treatment of a penicillin-intermediate and ceftriaxone-resistant *Granulicatella adiacens* presumed prosthetic valve endocarditis with vancomycin. 2018. *Int J Antimicrob Agents*. <http://dx.doi.org/10.1016/j.ijantimicag.2017.12.031>.
- Smith EA, Gold HS, **Mahoney MV, Hirsch EB, Giancola SE,** Snyder GM, Marks G, Tran H, Hirai-Yang A, McCoy C. Nasal MRSA screening in patients with pneumonia – a powerful antimicrobial stewardship tool. *Am J Infect Control* 2017;45:1295-6.
- Weins J, Snyder GM, Finlayson S, **Mahoney MV,** Celi LA. Potential adverse effects of broad-spectrum antimicrobial exposure in the intensive care unit. *Open Forum Infect Dis* 2018;5:1-8.
- **Martin MT,** Chen Y, Rosenfeld D, Lee TA, Koppe S. Evaluation of a diverse patient population's sustained virologic response rates after hepatitis C virus treatment at an urban academic medical center with an interdisciplinary team including a clinical pharmacist. Meeting Abstract 1550. *Hepatology* 2017;66:828A.
- **Martin MT,** Deming P. Closing the gap: the challenges of treating genotype 3 hepatitis C virus. *Pharmacotherapy* 2017;37:735-47.
- **Martin MT,** Koppe S. Elbasvir/grazoprevir use in post-liver transplantation patients on hemodialysis. *Transplantation* 2017;101:2088-91.
- **Martin MT,** Rosenfeld D, Lee TA. Comparison of sustained virologic response rates after hepatitis C virus treatment in patients with advanced fibrosis or cirrhosis at an urban academic medical center. Meeting Abstract 215. *Pharmacotherapy* 2017;37:E184-185.
- Isho NY, Kachlic M, Marcelo J, **Martin MT.** Pharmacist-initiated hepatitis C virus screening in an outpatient pharmacy to increase awareness and link to care at the medical center. *J Am Pharm Assoc* 2017;57:S259-S264.
- Molino S, **Martin MT.** Hepatitis C virus resistance testing in genotype 1: the changing role in clinical utility. *Ann Pharmacother* 2017;51:811-6.
- Sapir T, Brau N, Mera J, Martinez AD, Litwin AH, **Martin MT,** Pardo CO, Simone L, Moreo K. Healthcare provider and payer perceptions of optimism, challenges, and strategies for achieving national goals for hepatitis C virus elimination. Meeting Abstract 590. *Hepatology* 2017;66:322A.
- Datta R, **McManus D,** Topal JE, Juthani-Mehta M. Long-acting lipoglycopeptides for gram-positive bacteremia at the end of life to facilitate hospice care: a report of 3 cases. *Open Forum Infect Dis* 2018;5:ofx277.
- Zapolskaya T, Perreault S, **McManus D,** Topal JE. Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies. *Support Care Cancer* 2018 Jan 10.
- **Nesbitt WJ,** Aronoff DA. Amikacin. In: Grayson ML, ed. *Kucers' The Use of Antibiotics*, 7th ed. London: ASM Press, 2017.
- **Reveles KR,** Backo JL, Corvino FA, Zivkovic M, Broderick KC. Fidaxomicin versus vancomycin as first-line treatment for *Clostridium difficile*-associated diarrhea (CDAD) in specific patient populations: a pharmacoeconomic evaluation. *Pharmacotherapy* 2017;37:1489-97.
- **Reveles KR,** Cosimi RA, Ryan CN, Chan LS, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. *Gut* 2017. [Epub ahead of print]
- **Reveles KR,** Lawson KA, Mortensen EM, Pugh MV, Koeller JM, Argamany JR, **Frei CR.** National epidemiology of initial and recurrent *Clostridium difficile* infection in the Veterans Health Administration from 2003 to 2014. *PLoS One* 2017;12:e0189227.
- **Reveles KR,** Mortensen EM, Koeller JM, Lawson KA, Pugh MV, Rumbellow SA, Argamany JR, **Frei CR.** Derivation and validation of a *Clostridium difficile* infection recurrence prediction rule in a national cohort of veterans. *Pharmacotherapy* 2018.
- **Reveles KR,** Pugh MV, Lawson KA, Mortensen EM, Koeller JM, Argamany JR, **Frei CR.** Shift to community-onset *Clostridium difficile* infection in the national Veterans Health Administration, 2003 to 2014. *Am J Infect Control* 2017. [Epub ahead of print]
- **Santarossa M, Aitken SL,** Nagel JL. Improving antimicrobial stewardship in oncology patients through implementation of guidelines. *Curr Treat Options Infect Dis* 2017;9:333-46.
- Freeman T, Eschenauer G, Patel TS, Gandhi T, Petty L, Chenoweth C, **Santarossa M,** Nagel JL. Evaluating the need for antibiotic stewardship prospective audit and feedback on weekends. *Infect Control Hosp Epidemiol* 2017;38:1262-3.

- **Stover K**, Kenney RM, **King ST**, **Gross AE**. Evaluation of the use of novel biomarkers to augment antimicrobial stewardship program activities. *Pharmacotherapy* 2018;38:271-83.
- **Wiederhold NP**. The antifungal arsenal: alternative drugs and future targets. *Int J Antimicrob Agents* 2017. In press.
- **Wiederhold NP**. Antifungal resistance: current trends and future strategies. *Infect Drug Resist* 2017;10:249-59.
- **Wiederhold NP**, Najvar LK, Jaramillo R, Olivo M, Catano O, Pizzini J, Patterson TF. The oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by wild-type and echinocandin resistant *Candida glabrata*. *J Antimicrob Chemother* 2018;73:448-51.
- **Wiederhold NP**, Patterson H, Tran BH, Yates C, Schotzinger RJ, Garvey EP. The fungal specific CYP51 inhibitor VT-1598 demonstrates in vitro activity against *Candida* and *Cryptococcus* species, endemic fungi, including *Coccidioides* species, *Aspergillus* species, and *Rhizopus arrhizus*. *J Antimicrob Chemother* 2018;73:404-8.
- **Wiederhold NP**, Shubitz LF, Najvar LK, Jaramillo R, Olivo M, Catano G, Trinh HT, Yates CM, Schotzinger RJ, Garvey EP, Patterson TF. The novel fungal CYP51 inhibitor VT-1598 is efficacious in experimental models of central nervous system Coccidioidomycosis caused by *Coccidioides posadasii* and *Coccidioides immitis*. *Antimicrob Agents Chemother* 2018. In press.
- Autmizguine J, Tan S, Cohen-Wolkowicz, Cotten CM, **Wiederhold NP**, Goldberg RN, Adams-Chapman I, Stoll B, Smith PB, Benjamin DK. Antifungal susceptibility and clinical outcome in neonatal candidiasis. *Pediatr Infect Dis J* 2018. In press.
- Desoubeaux G, Debourgogne A, **Wiederhold NP**, Zaffino M, Sutton D, Burns RE, Frasca S, Hyatt MW, Cray C. Multi-locus sequence typing provides epidemiological insights for diseased sharks infected with fungi belonging to the *Fusarium solani* species complex. *Med Mycol* 2017. In press.
- Perlin DS, **Wiederhold NP**. Culture-independent molecular methods for antifungal resistance mechanisms and fungal identification. *J Infect Dis (Suppl)* 2017;216(suppl 3):S458-S465.
- Schwartz IS, Sanche E, **Wiederhold NP**, Patterson TF, Sigler L. *Emergomyces canadensis* is a new cause of fatal systemic disease in humans in North America. *Emerg Infect Dis* 2018. In press.
- Siqueira JPZ, Sutton D, Gene J, Garcia D, **Wiederhold NP**, Guarro J. Species of *Aspergillus* section *Aspergillus* from clinical samples in USA. *Med Mycol* 2017. In press.
- Spitzer M, **Wiederhold NP**. Reduced antifungal susceptibility of vulvovaginal *Candida* species at normal vaginal pH levels. *JLGTD* 2018. In press.
- Stchigel AM, Sutton DA, Cano-Lira JF, **Wiederhold NP**, Guarro J. New additions to the genus *Spiromastigoides* (Eurotiomycetes, Ascomycota). *Mycopathologia* 2017;182:967-78.
- Valenzuela-Lopez N, Cano-Lira JF, Guarro J, Sutton DA, **Wiederhold NP**, Crous PW, Stchigel AM. *Coelomycetous dothideomycetes* with emphasis on the families Cucurbitariaceae and Didymellaceae. *Stud Mycol* 2017;90:1-69.
- Vipulanandan G, Herrera M, **Wiederhold NP**, Li X, Mintz J, Wickes BL, Kadosh D. Dynamics of mixed *Candida* species biofilms in response to antifungals. *J Dental Res* 2018;97:91-8.
- Seyedmojtaba S, Bosco S, de Hoog GS, Ebel F, Elad D, Gomes R, Jacobsen ID, Martel A, Mignon B, Pasmán S, Piekova E, Rodrigues AM, Singh K, Vicente V, Wibbelt G, **Wiederhold NP**, Guillot J. Fungal infections in animals: a patchwork of different situations. *Med Mycol* 2017. In press.

Nephrology PRN

Awards

- **Rachel Flurie**: Virginia Society of Health-System Pharmacists, 2017 New Practitioner Award.

Grants

- **Calvin J. Meaney**: Personalized Erythropoiesis in Hemodialysis Patients: The Novel PREDHICT Tool. AACP New Investigator Award.

Publications

- Medina-Moreno S, **Dowling TC**, Zapata JC, Le NM, Sausville E, Bryant J, Redfield RR, Heredia A. Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. *PLoS One* 2017;12(8).
- Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, **Dowling TC**, Weir MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM. Cystatin C is a gender-neutral glomerular filtration rate biomarker in patients with cirrhosis. *Dig Dis Sci* 2018;63:665-75.

- Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, **Dowling TC**, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C. Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. *Transl Res* 2017 Dec 12.
- **El Nekidy WS**, Mooty MY, Attallah N, et al. Successful treatment of multidrug resistant *Klebsiella pneumoniae* using dual carbapenem regimen in immunocompromised patient. *IDCases* 2017;9:53-5.
- **Flurie RW**, Brophy DF. Chronic hyperkalemia: evolving options for a common problem. Powerpak.com. <https://www.powerpak.com/course/pre-ambly/115972>. Published December 29, 2017.
- Gravatt LAH, **Flurie RW**, Lajthia E, Dixon DL. Clinical guidance for managing statin and antimicrobial drug-drug interactions. *Curr Atheroscler Rep* 2017;19(46).
- **Maxson R**. Medications in kidney disease. *J Nurse Pract* 2017;13:687-92.
- Fusco NM, Francisconi R, **Meaney CJ**, Duman D, Frederick CA, Prescott WA. Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis. *J Pediatr Infect Dis Soc* 2017;6:e103-e108.
- Holsen MR, **Meaney CJ**, Hassinger AB, Fusco NM. Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin/tazobactam. *Pediatr Crit Care Med* 2017;18:e585-e591.
- Heung M, **Mueller BA**. Prevention of hypophosphatemia during continuous renal replacement therapy – an overlooked problem. *Semin Dial* 2018 Feb 5.
- Scoville BA, Vulaj V, **Mueller BA**, Annich GM, Wagner DS. Acetaminophen clearance during ex vivo continuous renal replacement therapies. *J Artif Organs* 2017 Oct 23.
- Shaw AR, **Mueller BA**. Antibiotic dosing in continuous renal replacement therapy. *Adv Chronic Kidney Dis* 2017;24:219-27.
- **Nguyen T**. Penicillin allergy: a revisit for nurse practitioners. *J Nurse Pract (JNP)* 2018;13:211-2.
- **Nguyen T**, Shoukhardin I, Gouse A. Duloxetine uses in patients with kidney disease: different recommendations from the United States versus Europe and Canada. *Am J Ther* 2018 Feb 5.

Poster Presentations

- **El Nekidy WS**, et al. Efficacy of alteplase (tPA) 1 mg versus 2 mg in restoring hemodialysis catheter function: a randomized double-blind controlled study. American Society of Nephrology Annual Meeting; November 2017.

Pain and Palliative Care PRN

Promotions

- **Sandy DiScala**: Affiliate Assistant Professor of the University of Miami, Miller School of Medicine at the West Palm Beach VA Medical Center.

Awards

- **Chris Herndon**: Received the 2018 Distinguished Service Award from the American Pain Society. The Distinguished Service Award recognizes outstanding and dedicated service to APS.
- **Mary Lynn McPherson**: Selected as one of 30 Hospice and Palliative Medicine Visionaries by the American Academy of Hospice and Palliative Medicine.

Grants

- **Michael Smith**: For: 2017–2018 Physician-Pharmacist Collaborative to Enhance Safe Opioid and Buprenorphine Prescribing. From Blue Cross Blue Shield of Michigan Foundation. \$75,000 total direct costs, 10% effort. Co-I. For: 2017–2018 “Exploring the Pharmacogenomics of Methadone Rotation in Palliative Care Patients” from Michigan Institute for Clinical and Health Research, University of Michigan. \$5000 total direct costs, 10% effort. PI

Publications

- Blackburn LM, **Abel S**, Green L, Johnson K, Panda S. The Use of Comfort Kits to Optimize Adult Cancer Pain Management. *Pain Manag Nurs* 2018 Feb 28. [Epub ahead of print]
- Tran N, **DiScala SL**, Forbes H, Brooks A, Melendez-Benabe J, Cuevas-Tristan R. Pilot inpatient pain pharmacist consult service at the West Palm Beach VA Medical Center. *Fed Pract* 2018;35:38-46.
- **Fudin J**, Raouf M, Wegrzyn EL, Schatman ME. Safety concerns with the Centers for Disease Control opioid calculator. *J Pain Res* 2018;11:1.
- Dragic LL, Wegrzyn EL, Schatman ME, **Fudin J**. Pharmacogenetic guidance: testing results in

enhanced pain outcomes. *J Pain Res* 2017;10. In press. Available at https://www.dovepress.com/articles.php?article_id=36141.

- **Fudin J**, Bettinger JJ, Raouf M. Expanding the pharmacist's role in preventing opioid abuse: understanding abuse-deterrent formulations and identifying risks. Power-Pak CE, continuing education for pharmacists. December 22, 2017. Available at <https://www.powerpak.com/course/preamble/115940>.
- **Fudin J**, Bettinger JJ, Wegrzyn WL. Ask the expert: would morphine offer a viable pain management option for patients who do not respond to oxycodone or codeine? *Pract Pain Manage* 2017;17:13-5.
- **Fudin J**, Raouf M, Wegrzyn WL. Pharmacological considerations regarding equianalgesic dosing. A white paper from the Academy of Integrative Pain Management. September 2017.
- **Fudin J**, Raouf M, Wegrzyn WL. Opioid drug policy: pharmacological considerations regarding equianalgesic dosing. *Pain Pract* 2017;27:19-22.
- **Fudin J**, Raouf M, Wegrzyn EL, Schatman ME. Safety concerns with the Centers for Disease Control opioid calculator. *J Pain Res* 2018;11:1.
- Argoff CE, Alford DP, **Fudin J**, Adler JA, Bair MJ, Dart RC, Gandolfi R, McCarberg BH, Stanos SP, Gudim JA, Polomano RC. Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. *Pain Med* 2017 Dec 1.
- Cleary J, Brennan M, **Fudin J**. Opioid rotation from Opana ER following FDA call for removal. *Pract Pain Manage* 2017;17:50-7.
- Dragic L, **Fudin J**. Alcohol screen recommended to reduce opioid-induced depression overdose. *Pract Pain Manage* 2017;17:45-9.
- Dragic L, Raouf M, **Fudin J**. Ask the expert: what type of withdrawal symptoms from tramadol might a patient experience? *Pract Pain Manage* 2017. In print. Available at <https://www.practicalpainmanagement.com/treatments/what-type-withdrawal-symptoms-tramadol-might-patient-experience>.
- Gruber MR, **Fudin J**. Opioid abuse-deterrent formulations: what clinicians need to know. CME Zone, Applied Clinical Education. November 8, 2017. Available at <https://www.cmezone.com/activities/mm177/2450/>.
- Mahatme S, Atkinson TJ, Spallone A, **Fudin J**. The preliminary impact of pain management integration into an HIV specialty clinic. *Scientific Pages Anesth Pain Manage* 2017;1:7-12.

- Wegrzyn EL, Chaghtai A, Argoff C, **Fudin J**. The CDC opioid guideline: proponent interpretation has led to misinformation. *Clin Pharmacol Ther* 2018. In press.
- **Lockman K**, Haines ST, McPherson ML. Improved learning outcomes after flipping a therapeutics module: results of a controlled trial. *Acad Med* 2017;92:1786-93.
- Sunilkumar MM, **Lockman K**. Practical pharmacology of methadone: a long-acting opioid. *Indian J Palliat Care* 2018;24:10-4.

Poster Presentations

- Bettinger JJ, Wegrzyn EL, **Fudin J**. A retrospective drug utilization review to assess the safety and efficacy of buprenorphine for chronic pain in a veteran population. Poster: (1-257). ASHP Midyear Clinical Meeting and Exhibition; 2016; Orlando, FL.
- Coisson KL, Persico AL, Wegrzyn EL, Strassels SA, **Fudin J**. Assessing pharmacist compensation per state: does the number of pharmacy schools, their location, cost of living, or increasing prevalence play a role? Poster: (2-158). ASHP Midyear Clinical Meeting and Exhibition; 2016; Orlando, FL.
- Dragic LL, **Fudin J**. Quality assurance alcohol monitoring by urine ethyl glucuronide screen in patients receiving chronic opioid therapy. Poster 54. PainWeek 2017 at the Cosmopolitan Hotel; September 7, 2017; Las Vegas, NV.

Professional Service

- **Stephanie Abel**: 2018 Chair of the Nominations Committee for the Society of Palliative Care Pharmacists.
- **Sandy DiScala**: 2018 Treasurer for the Society of Palliative Care Pharmacists.
- **Jeffrey Fudin**:
Consultant for the FDA Drug Safety and Risk Management Advisory Committee Office of Surveillance and Epidemiology in the FDA Center for Drug Evaluation and Research
National Coalition for Hospice and Palliative Care
Co-Chair Advocacy Committee, Society for Palliative Care Pharmacists
- **Chris Herndon**: 2018 Chair-Elect for the Society of Palliative Care Pharmacists.
- **Jason Kimbrel**: Pharmacist Section Leader for the National Hospice and Palliative Care Organization.
- **Kasey Malotte**: 2018 Secretary for the Society of Palliative Care Pharmacists.

Other:

- New blogs and posts at <http://paindr.com/blog/> and www.pharmacytimes.com/contributor/jeffrey-fudin.

Pediatrics PRN

Introduction

Several PEDI PRN subcommittees have been developing new programming and opportunities for its members. Highlights are as follows:

PEDI PRN resident and fellow journal clubs have been presented by Drs. Anna Cosnahan, Keito Hoshitsuki, and Sana Said. The final journal club for the academic year was presented Tuesday, April 17, at 3 p.m. (EST) by Dr. Brittany Logston. Please keep your eye on the PRN's e-mail list and Facebook page for more information.

The PEDI PRN Education Committee has submitted a PEDI PRN focus session for this year's ACCP Global Conference. The proposal is an update in pediatric pain management.

The PEDI PRN Research Committee continues to support PRN members in their research and scholarly endeavors. The committee is developing a formal mission statement for the PRN and will continue to be involved with review for scholarships and travel awards. Committee members are also organizing pediatric poster rounds at the Global Conference.

The PEDI PRN Travel Awards Committee will provide two awards again this year, one for students and one for residents.

The Social Media Committee continues to post on Facebook and update the PRN website.

The Nominations Committee will solicit nominations for the chair-elect and secretary/treasurer positions in May. More information on how to apply/nominate an active PRN member will be e-mailed to PRN members, together with descriptions of the respective offices in April. To continue to recognize the PRN members' work, the PRN is also excited to continue the PEDI PRN awards for outstanding practitioner and PRN achievement. Please consider nominating deserving colleagues for each of these awards. Nominations and materials will be due early August, so look for award and deadline information in early summer. All awards will be presented at the PEDI PRN business meeting at the ACCP Global Conference on Clinical Pharmacy this October.

Promotions

- **Chasity M. Shelton:** Promoted to Associate Professor, Department of Clinical Pharmacy and Translational Science, the University of Tennessee Health Science Center.

Awards

- **Katherine H. Chessman:** American College of Clinical Pharmacy Pediatrics PRN Outstanding Practitioner Award.
- **Elizabeth Goswami,** Elys Bhatia, Emma Sexton, Erica Lander, Alicia Neu, Jeffrey Fadrowski: Maryland Patient Safety Center Minogue Award for Patient Safety Innovation Circle of Honor Winner; Jeff Fadrowski, **Elizabeth Goswami,** Elys Bhatia, Emma Sexton, Alicia Neu: E. Robert Feroli Award for Excellence in Medication Safety. The Johns Hopkins Armstrong Institute for Patient Safety and Quality.
- **Joseph M. LaRochelle:** Chair's Award, American College of Clinical Pharmacy Pediatrics PRN.
- **Chasity M. Shelton:** 2017 Tennessee Society of Health-System Pharmacists Health-System Pharmacist of the Year.
- **Trey Smith:** American College of Clinical Pharmacy Pediatrics PRN Resident Travel Award.
- **Charlotte Wagner:** American College of Clinical Pharmacy Pediatrics PRN Student Travel Award.

Publications

- **Johnson PN.** Prevalence of unrounded medication doses and associated factors among hospitalized pediatric patients. *J Pediatr Pharmacol Ther* 2017;22:286-92.
- **Johnson PN,** Gildon GL, Condren M, Miller JL, Hagemann TM, Lewis TV, John B, Farmer KC. Description of a pediatric degree option program in a doctorate of pharmacy curriculum and its impact on pediatric-focused advanced pharmacy practice experience rotations and faculty scholarly productivity. *Curr Pharm Teach Learn*.
- **Johnson PN,** Skrepnek G, Golding CL, Owora AH, Thomas AN, Miller JL. Relationship between rate of fentanyl infusion and time to achieve sedation in nonobese and obese critically ill children. *Am J Health Syst Pharm* 2017;74:1174-83.
- Jones AN, Miller JL, Neely SB, Ibach BW, Hagemann TM, Golding CL, Lewis TV, Peek L, Miller JL, **Johnson PN,** Harkey K, Siatkowski RM. Sedation protocol during bevacizumab intravitreal injection in preterm infants with retinopathy of prematurity. *J Pediatr Pharmacol Ther* 2018;23:34-40.
- Miller JL, Lepa TM, Ranallo C, Chaaban H, Skrepnek GH, **Johnson PN.** Detectable concentrations of inhaled tobramycin in critically ill children without cystic fibrosis: should routine monitoring be recommended? *Pediatr Crit Care Med* 2017;18:e615-20.

- **LaRochelle JM**, Jack K, Kitto BA, Kosmidis A, Creel AM. Comparative analysis of clinical pharmacy interventions in a pediatric intensive care unit. Crit Care Shock 2018;21:20-7.
- **Pettit RS**, Peters SJ, McDade EJ, Kreilein K, Patel R, Epps K, Kittell F, Duval MA, Zobell JT. Vancomycin dosing and monitoring in the treatment of cystic fibrosis: results of a national practice survey. J Pediatr Pharmacol Ther 2018;22:406-11.
- Deschamp AR, **Pettit RS**, Donaldson JA, Slaven JE, Davis SD. Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis. SAGE Open Med 2017;16:eCollection2017.
- **Sharpless B**, Hilmas E, Molle-Rios Z, DelRosario F. Utilization of electronic medical record tools to facilitate and audit infliximab prescribing. J Pediatr Pharmacol Ther 2018;23:18-25.
- Mathew S, Kussin ML, Liu D, Pozotrigo M, Seyboth B, **Thackray J**, Yan SQ, Hsu M, Cohen N, Seo S. Retrospective analysis of posaconazole suspension dosing strategies in a pediatric oncology population: single-center experience. J Pediatr Infect Dis Soc 2017;6:e149-e151.
- Chang JS*, Chiou PY, **Yao SH**, Chou IC, Lin CY. Regression of neonatal cardiac rhabdomyoma in two months through low-dose everolimus therapy: a report of three cases. Pediatr Cardiol 2017;38:1478-84.

New ACCP Fellows

- Robert Kuhn
- Joseph M. LaRochelle
- Kalen Manasco
- Emma Tillman

Other Notable Achievements

- **Jama Huntley**: Successful operation of the Pharmacy Department at a new stand-alone children's hospital in Springdale, Arkansas, February 2018.
- **Peter Johnson**: Fellow of the American College of Critical Care Medicine (FCCM); San Antonio, Texas, February 2018.

Perioperative Care PRN

Introduction

Under the leadership of Chair-Elect Marian Gaviola, the PERI PRN is actively engaged in creating its 2018 focus session on perioperative emergencies for the ACCP

Global Conference on Clinical Pharmacy in Seattle. In addition, Gourang Patel at Rush, Sara Jordan Hyland at Grant, and Jenna Lovely at Mayo are leading the PRN's first opinion paper, tentatively titled "Perioperative Clinical Pharmacy: Collaborative Practice to Optimize Patient Outcomes." Other members of the PRN's Writing Committee include Kara Birrer, Stacey Bortlik-Hodgson, Russell Dixon, Elizabeth Farrington, Marian Gaviola, Amanda Giancarelli, Eric Johnson, Nikki Milne, Richard Parrish, Carole Richardson, April Smith, William Vincent, Rachel Wolfe, and Megan Young. The group expects to complete the first draft of the paper by the 2018 ACCP Global Conference.

PRN Webinar Schedule Announced

The PERI PRN is pleased to announce its 2018 webinar schedule. All webinars will begin at 1 p.m. (EST) and last 45 minutes. Invites with conference call/webinar details will be distributed 1 week before the meeting. In addition to all PRN members, the webinar is open to all student, resident, and fellow members of the College.

Date	Topic	Presenter and Contact Information
March 22	CDC guidelines on antimicrobial prophylaxis – debate	Eric Johnson and Sara Jordan Hyland
May 21	Perioperative glycemic management	Rachel Wolfe
July 23	Antimicrobial stewardship in the OR and beyond	Jenna Lovely

Students, Residents, and Fellows

Have you ever considered a career that cares for patients undergoing a surgical procedure? Would you like to learn what clinical pharmacists are doing in this cutting-edge practice area? The PERI PRN was established in October 2014 to provide education and resources related to the overall treatment of perioperative patients, address the regulatory requirements imposed by accrediting bodies, and provide a place for members to discuss complicated perioperative patients and seek input and recommendations on care. The PRN strives to address common concerns associated with pre-, inter-, and postoperative phases of care as they relate to patient-specific parameters (age, sex, and comorbid conditions) and medical severity. The scope of this network includes addressing underlying disease processes and progression, successfully managing sedation and pain, identifying alterations in

drug disposition (administration, absorption, distribution, metabolism, and excretion), and using evidence-based medicine to evaluate and minimize surgical complications. The goal of this network is to incorporate interdisciplinary collaboration through academia, research, and practice development while ensuring the safe and effective perioperative management of all patient populations. **The PRN supports student and resident travel and provides opportunities for presenting projects and research at webinars and annual meetings.** For more information, please contact Richard Parrish, PRN chair, at Richard.Parrish@tenethealth.com.

Publications

- Howard ML, **Gaviola ML**. Progressive disclosure cases: the design and evaluation of use in multiple therapeutics courses. *Curr Pharm Teach Learn* 2018. In press.
- **Johnson EG**, Oyler DR. Introduction to surgical and perioperative clinical pharmacy for third-year pharmacy students: a pilot study of an elective course. *Curr Pharm Teach Learn* 2018. In press.
- Dornfeld M, **Lovely JK**, Huebner M, Larson DW. Surgical site infection in colorectal surgery: a study in antibiotic duration. *Dis Colon Rectum* 2017;60:971-8.
- Dowdy SC, **Lovely JK**, Bakkum-Gamez JN. Venous thromboembolism: an unrecognized crisis in gynecologic oncology reply [letter]. *Obstet Gynecol* 2017;130:914-5.
- Larson DW, **Lovely JK**, Welsh J, Annaberdyev S, Coffey C, Corning C, Murray B, Rose D, Prabhakar L, Torgenson M, Dankbar E, Larson MV. A collaborative for implementation of an evidence-based clinical pathway for enhanced recovery in colon and rectal surgery in an affiliated network of healthcare organizations. *Jt Comm J Qual Patient Saf* 2018.
- Strong A, Muneeruddin S, **Parrish R**, Lui D, Conley SB. Isosorbide dinitrate in nephronophthisis treatment. *Am J Med Genet Part A* 2018;176:1023-6.

Pharmaceutical Industry PRN

On Tuesday, April 17, at 1 p.m. (EST), members of the Pharmaceutical Industry PRN held a Pharmaceutical Industry Career Panel webinar for students. Panelists discussed their current positions and how they entered into the industry and provided insight to students on how to learn more about this unique career path.

Promotions

- **Sandra L. Chase**: Region Director of the Nephrology Midwest and North team.

- **Kay M. Uttech**: Vice President of Consulting in Life Sciences at Scientific Commercialization, LLC.

Publications

- **Roth SW**. Innate immune signaling in *Drosophila* blocks insulin signaling by uncoupling PI(3,4,5,) P3 production and AKT activation. *Cell Rep* 2018;22:2550-6.

Poster Presentations

- **Soliman SR**, Kanmaz T. Overview of medical affairs education at colleges and schools of pharmacy. *ACCP Updates in Therapeutics*® 2018; February 2018; Jacksonville, FL.

Pharmacokinetics/Pharmacodynamics/ Pharmacogenomics PRN

Introduction

The PK/PD PRN is spearheading a multi-PRN opinion paper titled “What Is Precision Medicine?” Kelly Caudle, Pharm.D., Ph.D., current PK/PD PRN chair, is leading this effort. Members from 18 PRNs are contributing their PRN’s perspective on precision medicine. This project aligns with ACCP President Jill Kolesar’s theme for the year that focuses on precision pharmacotherapy. This paper will complement the efforts of the 2017–2018 ACCP Clinical Practice Affairs Committee, which is tasked with writing an ACCP white paper that articulates real-world clinical applications of precision medicine to today’s clinical pharmacist’s practice. The PK/PD PRN is also excited to collaborate with the Geriatrics PRN in developing a focus session for the 2018 ACCP Annual Meeting. In addition, PK/PD PRN members recently compiled a shared online database of available postgraduate training options in pharmacokinetics, pharmacodynamics, and pharmacogenomics, which will serve as a valuable resource for members interested in pursuing additional training in these fields.

Awards

- **Mary H.H. Ensom**: Highest honor of the Canadian Society of Hospital Pharmacists (CSHP), the Distinguished Service Award (<https://cshp.ca/distinguished-service-award>); Honorary Membership to the CSHP, bestowed on only 21 other individuals in the organization’s history, “on recognition of outstanding career contributions to hospital pharmacy or some related field of healthcare” (<https://cshp.ca/honorary-membership>).
- **Jasmine Luzum**: AACP New Investigator Award.
- **D. Max Smith**: American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Presidential Trainee Award for submission of an abstract titled “Outpatient *CYP2D6* Genotype-Supported Opioid Therapy: A Prospective Trial.”

Publications

- Mangal N, Hamadeh IS, **Arwood MJ**, Cavallari LH, Samant TS, Klinker KP, Bulitta J, Schmidt S. Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults. *Clin Pharmacol Ther* 2018 Jan 9. [Epub ahead of print]
- Singh S, McDonough CW, Gong Y, Alghamdi WA, **Arwood MJ**, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome wide association study identifies the HMGCS2 locus to be associated with chlorthalidone induced glucose increase in hypertensive patients. *J Am Heart Assoc* 2018;7(6).
- Bank P, **Caudle KE**, Swen JJ, **Gammal RS**, Whirl-Carrillo M, Klein TE, Relling MV, Guchelaar HJ. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. *Clin Pharmacol Ther* 2018;103:599-618.
- Rybak JM, Dickens CM, Parker JE, **Caudle KE**, Manigaba K, Whaley SG, Nishimoto AT, Luna-Tapia A, Roy S, Zhang Q, Barker KS, Palmer GE, Sutter TR, Homavouni R, Wiederhold NP, Kelly SL, Rogers PD. Loss of C-5 sterol desaturase activity results in increased resistance to azole and echinocandin antifungals in a clinical isolate of *Candida parapsilosis*. *Antimicrob Agents Chemother* 2017;61(9).
- Walsh TJ, Moriyama B, Penzak SR, Klein TE, **Caudle KE**. Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights into the Contribution of CYP3A4*22 to Metabolism of Voriconazole.” *Clin Pharmacol Ther* 2018;103:187.
- Phillips EJ, Sukasem C, Whirl-Carrillo M, Muller DJ, **Dunnenberger HM**, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Mushiroda T, Klein T, **Gammal RS**, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. *Clin Pharmacol Ther* 2018;103:574-81.
- Beach J, Perrott J, Turgeon R, **Ensom MHH**. Penetration of vancomycin into the cerebrospinal fluid: a systematic review. *Clin Pharmacokinet* 2017;56:1479-90.
- Ng JCY, Leung M, Wright AJ, Ensom MHH. Clinical pharmacokinetic monitoring of leflunomide in renal transplant recipients with BK virus reactivation – a review of the literature. *Clin Pharmacokinet* 2017;56:1015-31.
- Shah K, Turgeon R, Gooterham PA, **Ensom MHH**. Prevention and treatment of hyponatremia in patients with subarachnoid hemorrhage: a systematic review. *World Neurosurg* 2018;109:222-9.
- Tkachuk S, Collins K, **Ensom MHH**. The relationship between vancomycin trough concentrations and AUC/MIC ratios in pediatric patients: a qualitative systematic review. *Paediatr Drugs* 2018;20:153-64.
- **Gammal RS**, **Hoffman JM**. Leveraging precision medicine to mitigate medication safety challenges. *Am J Health Syst Pharm* 2017;74:2031-2.
- Bime C, Pouladi N, Sammani S, Batai K, Casanova N, Zhou T, Kempf CL, Sun X, Camp SM, Wang T, Kittles RA, Lussier YA, Jones TK, Reilly JP, Meyer NJ, Christie JD, **Karnes JH**, Gonzalez-Garay M, Christiani DC, Yates CR, Wurfel MM, Meduri GU, Garcia JGN. Genome wide association study in African Americans with acute respiratory distress syndrome identifies the selectin P ligand gene as a risk factor. *Am J Respir Crit Care Med* 2018. In press.
- **Kiang TKL**, **Ensom MHH**. Population pharmacokinetics of mycophenolic acid: an update. *Clin Pharmacokinet* 2017 Aug 31. [Epub ahead of print]
- **Kiang TKL**, Ranamukhaarachchi SA, **Ensom MHH**. Revolutionizing therapeutic drug monitoring with the use of interstitial fluid and microneedles technology. *Pharmaceutics* 2017;9(4).
- Wilson DM, **Kiang TKL**, **Ensom MHH**. Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: a pilot study. *Am J Health Syst Pharm* 2018;75:351-8.
- Allyn-Feuer A, Ade A, **Luzum JA**, Higgins GA, Athey BD. The pharmacoeogenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants. *Pharmacogenomics* 2018 Feb 5. [Epub ahead of print]
- Mukherjee C, Sweet KM, **Luzum JA**, Abdel-Rasoul M, Christman MF, Kitzmiller JP. Clinical pharmacogenomics: patient perspectives of pharmacogenomics testing and the incidence of actionable test results in a chronic disease cohort. *Per Med* 2017;14:383-8.

- Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, **McLeod HL**, **Caudle KE**, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. *Clin Pharmacol Ther* 2018;103:210-6.
- Goetz MP, Sangkhul K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, **McLeod HL**, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, **Caudle KE**, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2D6* and tamoxifen therapy. *Clin Pharmacol Ther* 2018 Jan 31. [Epub ahead of print]
- **Pasternak AL**, Ward KM, **Luzum JA**, Ellingrod VL, **Hertz DL**. Germline genetic variants with implications for disease risk and therapeutic outcomes. *Physiol Genomics* 2017;49:567-81.
- **Smith DM**, **Weitzel KW**, Cavallari LH, Eelsey AR, Schmidt SO. Clinical application of pharmacogenetics in pain management. *Per Med* 2018 Jan 31.
- **Weitzel KW**, **Smith DM**, **Eelsey AR**, **Duong BQ**, Burkley B, Clare-Salzler MJ, Gong Y, Higgins TA, Kong B, Langae T, McDonough CW, Staley BT, **Vo TT**, **Wake DT**, Cavallari LH, Johnson JA. Development and implementation of standardized clinical processes for TPMT testing in a diverse multidisciplinary population: unique challenges and lessons learned. *Clin Transl Sci* 2018 Jan 19. [Epub ahead of print]

Other Notable Achievements

- **Meghan Arwood**: “Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges,” published in *Clinical and Translational Science*, was one of the journal’s top 10 most downloaded papers (as of year-end 2017, it had received 2875 downloads).
- **Mary H.H. Ensom**: Professor Emerita, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (as of January 15, 2018).

Pulmonary PRN

Publications

- **Boylan PM**, Joseph T, Hale GM, Moreau C, Seamon M, Jones R. Development of chronic obstructive pulmonary disease and heart failure self-management kits for outpatient transitions of care. *Consult Pharm* 2018;33:145-51.

- **Boylan P**, Trinh K, Helms J, Ghoubrial-Waibel R, Mege J. Integration of transitions of care pharmacist services within an accredited pulmonary rehabilitation clinic. *Pharmacotherapy* 2017;37:e214.
- Cheng J, Moore CA, Iasella CJ, Glanville AR, Morrell MR, Smith RB, McDyer JF, **Ensor CR**. Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplantation. *Clin Transplant* 2018. [Epub ahead of print]
- **Ensor CR**, Iasella CJ, Harrigan KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. *Am J Transplant* 2018. [Epub ahead of print]
- Hayanga JWA, Shigemura N, Aboagye JK, **Ensor C**, Dew MA, Hayanga HK, Esper SA, Joubert K, Morrell MR, Ensor CR, D’Cunha J. ECMO support in lung transplantation: a contemporary analysis of hospital charges in the US. *Ann Thorac Surg* 2017. [Epub ahead of print]
- Iasella CJ, Winstead RJ, Moore CA, Morrell MR, Hayanga JA, Lendermon EA, Johnson BA, Zeevi A, McDyer JF, **Ensor CR**. Successful maintenance belatacept-based immunosuppression in lung transplant recipients who failed calcineurin inhibitors. *Transplantation* 2018. [Epub ahead of print]
- Rivosecchi RM, Clancy CJ, Shields RK, **Ensor CR**, Shullo MA, Falcione BA, Venkataramanan R, Nguyen MH. Effects of isavuconazole on the plasma concentrations of tacrolimus among solid organ transplant patients. *Antimicrob Agents Chemother* 2017. [Epub ahead of print]
- **Murphy JA**, Schroeder MN, Rarus RE, Yakubu I, McKee SOP, Martin SJ. Implementation of a cardiac transitions of care pilot program: a prospective study of inpatient and outpatient clinical pharmacy services for patients with heart failure exacerbation or acute myocardial infarction. *J Pharm Pract* 2018 Jan 1. [Epub ahead of print]
- **Murphy JA**, Sheridan EA. Evidence based review of pharmacotherapy for opioid-induced constipation in noncancer pain. *Ann Pharmacother* 2017. [Epub ahead of print]
- **Wieruszewski PM**, Kashani KB, Rabinstein AA, Frazee E. Levetiracetam pharmacokinetics in a critically ill anephric patient on intermittent hemodialysis. *Neurocrit Care* 2017. [Epub ahead of print]
- **Wieruszewski PM**, Nei SD, Maltais S, Schaff HV, Wittwer ED. Vitamin C for vasoplegia after cardiopulmonary bypass: a case series. *A A Pract* 2018. [Epub ahead of print]

- **Wieruszewski PM**, Vijayvargiya P, Wilhelm MP, Razonable RR. Cytomegaloviraemia clearance with foscarnet during renal replacement therapy. *J Antimicrob Chemother* 2018;73:548-9.

Presentations

- **Ensor CR**. Medication management for solid organ transplantation survivorship. American College of Clinical Pharmacy; October 2017; Phoenix, AZ.
- **Ensor CR**, Potter LM. Antibody mediated rejection: are we really making progress? A spirited debate. American College of Clinical Pharmacy; October 2017; Phoenix, AZ.
- **Santibanez M**. Safety and efficacy of 4F-PCC for warfarin and non-warfarin major bleeding and emergent surgery. SCCM 47th Annual Congress; February 2018; San Antonio, TX.
- **Wieruszewski PM**, Frazee E, Barreto JN, Daniels CE, Tosh PK, Mara KC, Dierkhising RA, Limper AH. Preadmission corticosteroids and risk for respiratory failure in non-HIV pneumocystis pneumonia. *Crit Care Med* 2018;46:495.
- **Wieruszewski PM**, Personett HA, Peters SG, Gajic O, Hogan WJ, Dierkhising RA, Alkhateeb H, Yadav H. The peri-engraftment respiratory distress syndrome following autologous hematopoietic cell transplant. American Thoracic Society International Conference 2018; May 22, 2018; San Diego, CA.

Other Noteworthy Achievements

- **Murphy J**: Best Poster, American College of Clinical Pharmacy Education and Training PRN, October 2017.

Women's Health PRN

Publications

- **Alicia Forinash**: American College of Clinical Pharmacy Women's Health PRN Vital Contributions to Women's Health Award.

Grants

- **Sally Rafie** and **Jennifer McIntosh**: American College of Clinical Pharmacy Women's Health PRN Mini-Grant.

Other Notable Achievements

- **Borgelt L**, **EI-Ibiary S**, **Raney E**. Contraception. Resource page: iForumRx – the evidence that informs ambulatory care practice. Available at www.iforumrx.org. December 2017.
- Anderson L, **Borgelt LM***, Clark P, Moore, G. Encouraging comprehensive and consistent

pharmacist education for provision of contraception. *J Am Pharm Assoc* 2018;58:113-6.

- **Griffin B**, **Stone R**, **EI-Ibiary S**, **Westberg S**, **Shealy S**, **Forinash A**, **Yancey A**, **Vest K**, **Karaoui L**, **Rafie S**, **Horlen C**, **Stack N**, **Cieri-Hutcherson N**, **McBane S**, **Simonyan A**. Guide for drug selection during pregnancy and lactation: what pharmacists need to know for current practice. *Ann Pharmacother* 2018. In press.
- **Batra P**, **Rafie S**, Zhang Z, Singh AV, Bird CE, Sridhar A, Sullivan JG. An evaluation of the implementation of pharmacist-prescribed hormonal contraceptives in California. *Obstet Gynecol* 2018.
- **Schnock KO**, **Dykes PC**, **Albert J**, **Ariosto D**, **Cameron C**, **Carroll DL**, **Donahue M**, **Drucker AG**, **Duncan R**, **Fang L**, **Husch M**, **McDonald N**, **Maddox RR**, **McGuire J**, **Rafie S**, **Robertson E**, **Sawyer M**, **Wade E**, **Yoon CS**, **Lipsitz S**, **Bates DW**. A multi-hospital before-after observational study using a point-prevalence approach with an infusion safety intervention bundle to reduce intravenous medication administration errors. *Drug Saf* 2018.
- **Vu K**, **Rafie S**, **Grindlay K**, **Gutierrez H**, **Grossman D**. Pharmacist intentions to prescribe hormonal contraception following new legislative authority in California. *J Pharm Pract* 2017. [Epub ahead of print]
- **Wilkinson T**, **Miller C**, **Rafie S**, **Landau SC**, **Rafie S**. Older teen attitudes towards birth control access in pharmacies: a qualitative study. *Contraception* 2017;97:249-55.
- **Wilkinson T**, **Rafie S**, **Clark P**, **Carroll A**, **Miller E**. Evaluating community pharmacy responses about levonorgestrel emergency contraception by mystery caller characteristics. *J Adolesc Health* 2017. [Epub ahead of print]
- **Skaer TL**. Current issues regarding the care of the fibromyalgia patient. *Fibrom Open Access* 2017;2:120.
- **Skaer TL**, **Kwong J**. Illness perceptions and burden of disease in fibromyalgia. *Exp Rev Pharmacoecon Outcomes Res* 2017;17:9-15.
- **Lederhos-Smith C**, **Skaer TL**, **Orr M**, **Barbosa-Leiker C**, **Howell DN**, **Dyck DG**. Development of a multi-family group and mindfulness treatment for chronic pain: preliminary outcomes. *J Musculoskel Disord Treat* 2017;3(4):open access.
- **Stone RH**, **Anguiano R**, **Falk K**, **Bobowski C**, **Alvarez P**, **Mastrogiannis D**. Latency of 17OHP delivery from prescription to first dose in patients receiving compound vs commercial product and patient outcomes. *J Reprod Med* 2018. In press.

- **Stone RH**, Bobowski C, Milikhiker N, Anguiano R, Mastrogiannis D. Prevention of preterm labor with hydroxyprogesterone caproate (17OHP): are there differences in adverse reaction rates between the compounded and commercial formulation? *Am J Perinatol* 2017;34:1436-41.


ARTICLE 5 – RESEARCH GRANTS OPEN



2018 Futures Grants Request for Applications Is Open

- The ACCP Research Institute Futures Grants program invites *student, trainee, and early-career ACCP members* to apply for developmental research grants. The amount of Futures Grants may range from \$5000 to \$40,000, depending on applicant eligibility and the proposal's requisite budget. Up to \$100,000 in mentored, developmental research awards will be granted through the Futures Grants program in 2018.
- Before completing an application, all applicants must complete the eligibility assessment. This assessment will guide each qualified applicant to either the Fellow/Junior Investigator or the Student/Resident application. Completed applications are due by June 1, 2018. To access detailed instructions and complete the online eligibility assessment and application, visit www.accpri.org/futuresapp. For all other questions, contact Jessie Culley, Project Coordinator (jculley@accp.com).

ARTICLE 6 – RI PARTNERSHIP: META-ANALYSIS PROGRAM



Learn to Design, Conduct, and Publish Meta-Analyses

ACCP and the Research Institute have partnered with the Center for Health Outcomes & PharmacoEconomic Research at the University of Arizona College of Pharmacy (the HOPE Center) to make the center's

recognized hands-on training program in meta-analysis available to ACCP members at a significantly reduced registration rate.

By integrating in-depth instruction and action-oriented workshops, this program will teach participants to design protocols, perform effective searches for data sets, screen studies and extract data, and conduct and interpret meta-analysis and meta-regression. The 3-day curriculum is designed for professionals and trainees with entry to intermediate levels of prior knowledge in meta-analysis.

To further encourage members to publish meta-analyses pertinent to clinical pharmacy practice and research, in addition to reducing their registration rate, ACCP will competitively award up to three \$500 scholarships on the basis of applicants' meta-analysis projects and commitment to present and submit their work for publication. These scholarships can be used for lodging, travel, meals, and any other expenses associated with attending the June 18–20, 2018, training program. For more information on the scholarships or to apply for one, visit www.accp.com/we39r2.

To view the detailed meta-analysis program agenda and registration information, visit https://www.accp.com/docs/misc/Meta-Analysis_2018_eBrochure.pdf

ARTICLE 7 – WASHINGTON UPDATE

Washington Update

ACCP's Washington office is fully focused on the College's advocacy initiative to achieve full integration of a coordinated comprehensive medication management (CMM) service for Medicare beneficiaries delivered by qualified clinical pharmacists practicing as part of interprofessional health care teams.

Despite the well-documented political dysfunction gripping Capitol Hill, it is encouraging that moderate legislators remain willing to work in a bipartisan manner to address several important health care issues, including efforts to improve chronic care. In addition, ACCP is expanding its focus to explore regulatory opportunities to advance the College's initiative, particularly within the context of evolving Medicare alternative payment models (APMs) that have been embraced by the Centers for Medicare & Medicaid Services (CMS). The leadership of key CMS staff as part of ACCP's recent Patient-Centered Team-Based Practice Forum in Jacksonville, Florida, demonstrates that the agency is increasingly prioritizing the issue of improving medication use among America's seniors.

The following are just some of the activities ACCP was engaged in throughout the first quarter of 2018.

HHS Secretary Alex Azar Responds to ACCP's Medication Management Questions

On January 29, 2018, Alex Azar, a former drug industry executive, was sworn in by Vice President Mike Pence as the secretary of the Department of Health and Human Services (HHS). Azar will serve as the Trump administration's second HHS leader. His predecessor, Tom Price, resigned following widespread criticism of his use of expensive private charter planes for official business travel at taxpayers' expense.

With an annual budget of over \$1 trillion, HHS is the largest department within the federal government and has jurisdiction over the Centers for Medicare & Medicaid Services (CMS) as well as agencies such as the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH).

Azar previously served under President George W. Bush as HHS general counsel in 2001–2005 and later as deputy secretary. However, Azar's nomination was controversial to many Democrats, given his background in the pharmaceutical industry as president of Indianapolis-based Lilly USA and his public opposition to the Affordable Care Act (ACA). His nomination was eventually confirmed in the Senate by a vote of 55-43. Seven Democrats voted for Azar's confirmation, and one Republican, Senator Rand Paul (KY), opposed him.

As part of the Senate nomination hearing, Senator Tom Carper (D-DE) introduced the following questions on behalf of ACCP to Azar related to his positions on policy approaches to improving medication use among Medicare beneficiaries:

Question: You served at the Department of Health and Human Services during the initial implementation of the Medicare Part D program. That program has been successful in ensuring that seniors have coverage for the medications their doctors prescribe. In addition to covering the cost of drugs for seniors, the Part D law included medication therapy management services to help seniors take their medications correctly and to obtain the greatest health care benefit. Unfortunately, that part of the program has not been as successful as we had hoped. A recent report by the Medicare Payment Advisory Commission indicated that the medication therapy management programs are "falling short" of their goal to reduce unnecessary expenditures and improve quality. The report also indicated that physicians might be reluctant to accept recommendations on medication management from Part D drug plans. Given that MTM in the Part D program isn't meeting its intended goals, what more should we do to help seniors use their medications effectively? Do you

think we should do more to make sure proven medication adherence programs such as comprehensive medication management and medication synchronization are available to seniors in Medicare? How can we make sure that doctors and clinical pharmacists are collaborating to help Medicare beneficiaries take the right drugs in the right ways at the right times?

Response: As I indicated in my opening statement, one of my top four priorities as Secretary, if confirmed, will be to use the power of Medicare to drive transformation of our health care system from a procedure-based system that pays for sickness to a value-based system that pays for quality and outcomes. The Center for Medicare & Medicaid Innovation (CMMI) will be a critical part of these efforts. I understand that CMMI currently has an ongoing model, the Part D Enhanced MTM Model, which offers an opportunity and financial incentives for basic stand-alone Part D prescription drug plans (PDPs) in selected regions to offer innovative MTM programs in lieu of the standard CMS MTM model, aimed at improving the quality of care while reducing costs. I believe CMS is also testing changes to the Part D program that aim to achieve better alignment of PDP sponsor and government financial interests while creating incentives for robust investment and innovation in MTM targeting and interventions. If confirmed, I look forward to coordinating with CMS as they work toward their goal of fostering an affordable, accessible health care system that puts patients first.

Azar also testified that his broad priorities as secretary would include working to make health care more affordable, altering Medicare to reward providers for promoting good health, and tackling the opioid epidemic.

Carper has established himself as a leading voice in the Senate on issues related to medication use. As part of the negotiations related to the Bipartisan Budget Act of 2018, Carper – together with his Republican colleague from Kansas, Senator Pat Roberts – introduced an amendment requiring the Secretary of HHS to establish a process, beginning in plan year 2020, by which a Medicare Part D plan sponsor may submit a request to HHS for claims data under Medicare Parts A and B.

ACCP Submits Comments to Senate Finance Committee on how to Improve Medicare and Medicaid Responses to the Opioid Epidemic

Following the October 2017 announcement by the Trump administration directing the Department of Health and Human Services (HHS) to declare the ongoing opioid crisis a public health emergency, health policy leaders on Capitol Hill have worked to develop legislation that would

impose new rules to restrict access to opioid painkillers and open up access for opioid addiction treatment.

As part of this process, in February 2018, Senate Finance Committee Chairman Orrin Hatch (R-UT) and Ranking Member Ron Wyden (D-OR) issued a request for feedback from health care stakeholders across the country on how to improve Medicare, Medicaid, and human services program responses to the opioid epidemic.

Citing alarming data that indicate opioid prescriptions made up \$4 billion in Medicare Part D spending in 2016 and services and care for those with opioid use disorders amounted to \$9 billion in Medicaid spending in 2015, Hatch and Wyden called for “policy recommendations along the continuum that spans from addressing the root causes that lead to, or fail to prevent, opioid use disorder and other substance use disorders to improving access to and quality of treatment.”

In response to this request, ACCP submitted comments to the Senate Finance Committee, calling on Congress to include reforms to the Medicare program that provide for coverage of comprehensive medication management (CMM) services provided by qualified clinical pharmacists as members of the patient’s health care team.

Specifically, ACCP’s comments focused on how pharmacists providing CMM identify appropriate goals for opioid therapy in individual patients, recommend alternatives if these goals are not met, and monitor adverse effects of opioids to mitigate the risks of oversedation and overdose. The comments also described how clinical pharmacists help:

- Ensure that patients reach medication-related clinical goals that are established through shared decision-making with all members of the health care team.
- Address opioid use and/or misuse, when applicable.
- Educate patients and health care providers about acute and chronic pain therapeutics.
- Evaluate and implement clinical pathways and systems to optimize use of opioids and other controlled substances for therapeutic use.

In addition, the comments recommended increased use of clinical pharmacists to administer naloxone and provide appropriate education on its use in patients experiencing an opioid overdose, and ensure that patients identified as having opioid use disorder are appropriately referred to treatment centers to address their addiction.

On February 27, a bipartisan group of senators introduced legislation that would establish a 3-day initial prescribing limit on opioids for acute pain, increase the availability of treatment, and improve services to promote

recovery. The Senate bill authorizes \$1 billion in additional funding that includes:

- \$10 million to fund a national education campaign on opioids.
- \$300 million to increase training for first responders and their access to opioid overdose reversal drugs.
- \$300 million to expand medication-assisted treatment.
- \$200 million to help build more recovery support services.

On the House side, the Energy and Commerce Committee is working on legislation aimed at combating the opioid epidemic. Chairman Greg Walden (R-OR) indicated that he hopes to pass the measures out of the House by the Memorial Day weekend.

[Click here](#) to read ACCP’s comments in full.

[Click here](#) for more information on the Senate effort to reauthorize and expand the Comprehensive Addiction and Recovery Act of 2016.

ACCP is the Voice of Clinical Pharmacy in Washington, DC: Introducing the ACCP-PAC Governing Council

A well-funded Political Action Committee (PAC) provides ACCP with important financial resources to support its friends on Capitol Hill. ACCP-PAC is the only political action committee dedicated to electing members of Congress who are committed to advancing the College’s Medicare Initiative.

As with many of ACCP’s initiatives, ACCP-PAC is member-driven, and strategic policy decisions – including those related to which candidates to support – are made by the PAC Governing Council. The current ACCP-PAC Governing Council consists of the following ACCP members:

President

- Sara Brouse, ACCP Regent.

Treasurer

- Gary Matzke, ACCP Past President.

Secretary

- Michael Maddux (supported by ACCP staff member John McGlew).

Members

- Brad Phillips, University of Georgia.
- Daniel Nam, America’s Health Insurance Plans (AHIP) and former Congressional Fellow.
- Tracey Hagemann, ACCP Regent.

All decisions regarding financial contributions to candidates are made by the PAC Governing Council on the basis of certain established criteria:

- Position on key health care committees in Congress.
- Proven support for pharmacy and health care-related issues.
- Previous health care experience.

Contributions from ACCP-PAC to members of Congress help raise the College's profile on Capitol Hill, improve its standing among key lawmakers, and provide unique opportunities to discuss the College's initiative with potential congressional champions. ACCP-PAC will also help ensure that elected officials who support the initiative remain in office to advance the goals of the proposal in the future.

Only ACCP members are eligible to contribute to the PAC and allow the College to make these vital political contributions. With its almost 18,000 ACCP members, ACCP is in a position to become one of the most prominent pharmacy PACs in Washington. To do this, the widespread support of ACCP membership is needed.

If each ACCP member contributed just \$25, ACCP-PAC would raise over \$350,000. All ACCP members should consider donating at least \$25 to ACCP-PAC. [CLICK HERE](#) to support your PAC today!

Now Accepting Applications – ACCP/ASHP/VCU Pharmacy Policy Fellow Program

The Congressional Healthcare Policy Fellow Program is a collaborative effort of ACCP, the School of Pharmacy at the Medical College of Virginia/Virginia Commonwealth University, and the American Society of Health-System Pharmacists.

The program provides a unique health care policy learning experience designed to demonstrate the value of pharmacy-government interaction and to facilitate practical contributions to the effective use of scientific and pharmaceutical knowledge in government policy development. Fellows spend the first 2 months of the program with each of the professional organizations as members of their respective government and professional affairs staff. In September of the fellow year, the Fellow begins working in a legislative environment requiring health care input on the staff of an individual senator or representative or a relevant congressional committee.

The program is an enriching opportunity for the Fellow to develop legislative evaluation and policy development skills, improve research and writing skills, and integrate practical policy experience with theory. The Fellow will be expected to undertake a wide array of responsibilities, including researching and preparing briefs on health care issues; assisting with policy decisions; drafting memoranda; and planning, organizing, and carrying out program and management objectives.

Fellows typically seek congressional office placement with one of the committees that predominantly deal with health issues such as the Senate Health, Education, Labor, and Pensions (HELP) Committee and Senate Finance Committee or the House Ways and Means or Energy and Commerce committee. **Interested candidates should visit the [Pharmacy Healthcare Policy Fellow](#) program's website for more information and instruction on submitting and application.**

Contact Us! For more information on any of ACCP's advocacy efforts, please contact the ACCP Government and Professional Affairs team:

John K. McGlew

Director, Government Affairs
jmcglew@accp.com

Daniel S. Aistrope, Pharm.D., BCACP

Director, Clinical Practice Advancement
daistrope@accp.com

Katherine Pham, Pharm.D., BCPPS

Director of Policy and Professional Affairs
kpham@accp.com

American College of Clinical Pharmacy

1455 Pennsylvania Ave. Northwest
Suite 400
Washington, DC 20004-1017
(202) 621-1820
jmcglew@accp.com

ARTICLE 8 – SAVE THE DATE GLOBAL CONFERENCE



Registration Now Open. Please [click here](#) for detailed meeting information and to register online.

ARTICLE 9 – CALL FOR ABSTRACTS – GLOBAL CONFERENCE

Call for Abstracts: 2018 ACCP Global Conference on Clinical Pharmacy

Important Dates:

- **Regular Decision** (accept/decline notification by August 15, 2018)
 - June 15, 2018: Regular decision submission deadline for Original Research, Systematic Reviews, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts.
 - July 15, 2018: Regular decision submission deadline for Research-in-Progress abstracts (Students and Residents and Fellows).

To review the complete submission instructions, guidelines, and review criteria or to submit an abstract, visit the [ACCP website](#).

All abstracts accepted for presentation, except for “Encore” and “Research-in-Progress” presentations, will be published online in an official ACCP journal. Only the abstract title, authors, and original citation will be published for “Encore” presentations. All accepted abstracts will be provided full-text in the ACCP Meeting App.

The ACCP Global Conference on Clinical Pharmacy is the premier gathering for clinical pharmacists from around the world to exchange new knowledge and experiences in research, practice, education, and training. The Global Conference will be held at the Washington State Conference Center in Seattle, Washington, October 20–23, 2018.

ARTICLE 10 – STUDENT INITIATIVES UPDATE

2018 ACCP Student Chapter Awards – Applications Due June 30

ACCP recognizes two awards for Student Chapter members: the Outstanding Student Chapter and the Outstanding Student Chapter Member. These honors will be awarded annually. Application for each award is submitted as part of the Annual Chapter Report and is due June 30, 2018. A description of each award follows.

Outstanding Student Chapter Award

This award recognizes the ACCP student chapter that has exemplified strength in leadership, dedication in patient care, and passion for professional development through its activities and membership. The chapter’s activities should address ACCP’s core values of extending the frontiers of clinical pharmacy and promoting dedication to excellence in patient care, research, and education. A key component of all the core values is the clinical pharmacist’s ability to work collaboratively within the health care environment. Each chapter must demonstrate its ability to work with other health disciplines.

An announcement will be featured on the ACCP website, and an article highlighting the winning chapter’s accomplishments will be published in *StuNews* and the *ACCP Report*. A commemorative plaque and \$1000 cash will be awarded to the winning chapter. The faculty liaison/adviser and one appointed student liaison from the winning chapter will receive complimentary full Annual Meeting registrations, and each will receive a \$250 travel stipend to attend.

Members of student chapters who wish to apply for the award will complete an application form as part of their end-of-the-year report, due June 30. As part of the application process, each chapter is required to submit a rationale statement (250 words or less) outlining the plan for using the \$1000 award funds, should said chapter be selected as the winner.

Outstanding Student Chapter Member

This award recognizes a student who has enhanced student involvement from his or her ACCP chapter at the local, state, or national level and who has expanded the presence of ACCP through community engagement, education promotion, research opportunities, and/or professional stewardship. The activities of the selected student should address ACCP’s core values of extending the frontiers of clinical pharmacy and promoting dedication to excellence in patient care, research, and education.

Each chapter award recipient will receive a certificate suitable for framing and recognition in an *ACCP Report* article, a *StuNews* article, and the *Annual Meeting News*. In addition, student award winners attending the award-year Annual Meeting will be recognized during the Clinical Pharmacy Challenge semifinal round of competition.

Each recognized student chapter will select its recipient for Outstanding Student Chapter annually and submit the winner's name to the ACCP national office as part of its year-end report, due June 30.

ACCP SNAC Now Accepting Applications for 2018–2019

Initiated as a working group in 2006, the National Student Network Advisory (SNAC) group became a standing committee of the College in 2007 whose members are appointed by the ACCP president-elect. The present committee serves in an advisory capacity to the ACCP Board of Regents and staff, providing feedback and assistance in developing new programs and services for students. Student members who are interested in serving on the ACCP SNAC, either as a member-at-large or in a leadership role, may apply for appointment. All applicants must submit a CV, a personal essay, and a letter of recommendation from a professor, a preceptor, or an academic dean or his or her designee. Application for appointment to the 2018–2019 SNAC is available online. Applications are due June 15, 2018.

ARTICLE 11 – POSTGRADUATE TRAINEE UPDATE

Residents, Fellows, and Graduate Students

All resident, fellow, and graduate student members of ACCP currently receive a monthly electronic newsletter titled *Experts in Training*. The readers would like to thank all the PRNs, residency programs, and clinical pharmacists who have contributed to the publication. You may view archives through the link above. For topics you'd like to see covered in future editions, submit your ideas to ksims@accp.com.

PRNs can also engage resident, fellow, and graduate students through Twitter. Follow or tag @ACCPpostgrads to engage in dialogue on professional development and clinical topics.

ACCP will offer resident/fellow-specific educational programming at the 2018 Global Conference on Clinical Pharmacy. Residents and fellows will also be able to speak to recruiters and preview early practitioner positions in the Professional Placement Forum. Consider representing your institution's residency, fellowship, or new practitioner position at the ACCP Global Conference 2018 Professional Placement Forum this fall in Seattle.

ACCP resident and fellow members continue to benefit from the mentoring program. Mentors are ACCP members who have at least 5 years of professional experience and have volunteered to participate in the program. Mentor/mentee pairs are encouraged to correspond at least monthly and are provided with timely topics of discussion. A call for mentors goes out each year in August.

The College is currently accepting applications for all positions on the 2019 Resident Advisory Committee. The committee is a working group composed of residents, fellows, and graduate student members of ACCP. Applications for chair, vice chair, and member-at-large positions are due by June 15, 2018. Some exciting new resources for postgraduate trainees will be unveiled in the fall, thanks to the 2018 Resident Advisory Committee.

ARTICLE 12 – PRN MEMBERSHIP TOTALS

Ambulatory Care PRN (AMBU)	1086
Adult Medicine PRN (AMED)	1943
Cardiology PRN (CARD)	1192
Central Nervous System PRN (CNSY)	233
Clinical Administration PRN (CADM)	463
Critical Care PRN (CRIT)	2165
Drug Information PRN (DINF)	294
Education and Training PRN (EDTR)	591
Emergency Medicine PRN (EMED)	997
Endocrine and Metabolism PRN (ENDO)	282
Geriatrics PRN (GERI)	331
GI/Liver/Nutrition PRN (GILN)	201
Global Health PRN (GLBL)	161
Health Outcomes PRN (OCEC)	192
Hematology/Oncology PRN (HMON)	783
HIV PRN (HIV)	228
Immunology/Transplantation PRN (IMTR)	523
Infectious Diseases PRN (INFD)	2111
Nephrology PRN (NEPH)	203
Pain and Palliative Care PRN (PAIN)	347
Pediatrics PRN (PEDI)	918
Perioperative Care PRN (PERI)	103
Pharmaceutical Industry PRN (INDU)	264
Pharmacokinetics/Pharmacodynamics/Pharmacogenomics PRN (PKPD)	302
Pulmonary PRN (PULM)	57
Women's Health PRN (WOMN)	199
TOTAL:	16,169

ARTICLE 13 – PRN CONTACT INFORMATION

For more information about a specific PRN, please contact the PRN's incoming chair identified as follows.

PNR TITLE	PNR CONTACT
Adult Medicine	<u>Leigh Anne H. Gravatt</u>
Ambulatory Care	<u>Kelly Cochran, Pharm.D., BCPS</u>
Cardiology	<u>Craig J. Beavers, Pharm.D., BCPS, CACP</u>
Central Nervous System	<u>Jeannine M. Conway, Pharm.D., BCPS</u>
Clinical Administration	<u>Elizabeth L. Michalets, Pharm.D., FCCP, BCPS</u>
Critical Care	<u>Drayton A. Hammond, Pharm.D., BCPS, BCCCP</u>
Drug Information	<u>Janine S. Douglas, Pharm.D., BCPS</u>
Education and Training	<u>Eliza A. Dy-Boarman, Pharm.D.</u>
Emergency Medicine	<u>Nadia I. Awad, Pharm.D., BCPS</u>
Endocrine and Metabolism	<u>Christie A. Schumacher, Pharm.D., BCPS, BCACP</u>
Geriatrics	<u>Emily P. Peron, Pharm.D., M.S.</u>
GI/Liver/Nutrition	<u>Johnathan Voss, Pharm.D.</u>
Global Health	<u>Jodie V. Malhotra, Pharm.D.</u>
Health Outcomes	<u>Diana M. Sobieraj, Pharm.D.</u>
Hematology/Oncology	<u>Larry W. Buie, Pharm.D., FASHP, BCOP</u>
HIV	<u>Neha S. Pandit, Pharm.D., BCPS, AAHIVP</u>
Immunology/Transplantation	<u>James N. Fleming, Pharm.D., BCPS</u>
Infectious Diseases	<u>Elias B. Chahine, Pharm.D., FCCP, BCPS-AQ ID</u>
Nephrology	<u>Rachel F. Eyler, Pharm.D.</u>
Pain and Palliative Care	<u>Jennifer Pruskowski, Pharm.D., BCPS, CGP</u>
Pediatrics	<u>Rebecca S. Pettit, Pharm.D., MBA, BCPS</u>
Perioperative Care	<u>Richard H. Parrish II, Ph.D., FCCP, BCPS</u>
Pharmaceutical Industry	<u>Carmelina Staino, Pharm.D.</u>
Pharmacokinetics/Pharmacodynamics/Pharmacogenetics	<u>Kelly E. Caudle, Pharm.D., Ph.D.</u>
Women's Health	<u>Rebecca H. Stone, Pharm.D., BCPS, BCACP</u>